HOX gene expression in ovarian cancer. by Kelly, Zoe L.
  
 
 
HOX gene expression in ovarian 
cancer 
 
 
 
by 
 
 
Zoё Louise Kelly BSc (Hons) 
 
 
 
 
 
Submitted to the University of Surrey 
for the degree of Doctorate of Philosophy 
 
 
 
Faculty of Health and Medical Science 
University of Surrey 
 
 
November 2014 
  
2 
 
DECLARATION 
I hereby declare that the work embodied in this thesis is the result of my own 
independent investigations except where specifically stated. This work has not 
already been accepted for any degree, and is not concurrently submitted in 
candidature for any other degree 
 
 
…………………………………………………………. 
 
Zoe Louise Kelly 
November 2014 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgements 
Firstly, I would like to thank my supervisor Dr Agnieszka Michael for her continued 
support, motivation and encouragement throughout my PhD. I would like to thank 
Dr Richard Morgan for his immense knowledge and guidance, and I would also like to 
thank Professor Hardev Pandha for the opportunity to work in his laboratory and for 
his continued support, motivation and enthusiasm towards my research. I would like 
to say a big thank you to Dr Carla Moller-Levet for her invaluable knowledge of 
statistics and for constructing heat maps of my data. I also thank Francesca 
Launchbury for teaching me immunohistochemistry techniques and Mick Denyer for 
his help in flow cytometry. My sincere thanks goes to the charity GRACE and their 
supporters for funding my research. A special thanks goes to my family for their 
patience, constant support and encouragement. And finally, to all I have worked with 
in the Oncology department of the Leggett Building, thank you for your support and 
guidance, both inside and outside the lab. 
 
 
  
 
 
 
 
4 
 
Abstract 
Ovarian cancer is the leading cause of cancer death among all gynaecological cancers. 
Its aggressive nature is partly due to genetic heterogeneity and the lack of effective 
treatments strategies. Standard treatment involves cytoreductive surgery followed 
by chemotherapy using a platinum-based agent. Although initially, patients response 
well to this treatment, the majority will relapse and develop recurrent disease, 
predominantly due to the emergence of platinum resistance. Further understanding 
of the molecular changes which occur during ovarian ontogenesis and in the 
development of platinum resistance is essential to design new targeted drugs to 
improve patient prognosis. HOX gene are a family of homeodomain-containing 
transcription factors that determine cell and tissue identity in the early embryo and 
are found to be aberrantly expressed in cancer. HOX gene expression in ovarian 
cancer of different histological subtypes and in primary ovarian tumours were 
evaluated here. This is the first comprehensive study of HOX gene expression in a 
cohort of primary ovarian tumours, including statistical analysis of HOX gene 
expression profiles along with clinic-pathological data of each patient. HOX genes 
were found to be profoundly dysregulated in ovarian cancer cell lines and primary 
ovarian tumours, with very little to no expression found in normal ovarian and 
fallopian tube tissue. A 5-HOX gene signature which predicts poor overall survival in 
ovarian cancer patients was identified. Platinum resistant disease displayed an 
overall higher level of HOX gene expression, significantly HOXB4 and HOXB9. This 
dysregulated HOX expression reported could therefore act as a set of targets for 
therapeutic intervention. The novel peptide, HXR9, has been developed to block the 
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interaction between HOX proteins and their co-factor, PBX, and therefore 
subsequent target gene expression. The efficacy of HXR9 treatment of ovarian cancer 
cells was explored. HXR9 treatment was shown to induce cell death via apoptosis in 
ovarian cancer cells shown by an increase in apoptotic cells identified by flow 
cytometric analysis, and increase in caspase-3 activity and the upregulation of pro-
apoptotic gene cFos. Enhanced cell cytotoxicity was observed when combining HXR9 
with cisplatin to treat platinum resistant cells, revealing a new therapeutic option for 
drug resistant disease that should be explored further for potential clinical trial 
investigation.  
A limiting factor towards the development of new treatment strategies is the lack of 
a reliable animal model of ovarian cancer. Common methods used to test new drugs 
involve in vitro investigation and the use of engineered animal models. However, 
these models do not represent the true heterogeneity and complexity of human 
ovarian tumours. Therefore, the use of the chicken choriallontoic membrane (CAM) 
as a model of ovarian cancer for the testing of anti-cancer drugs was assessed. Cell 
lines grafted onto the CAM successfully and developing into micro-tumours. Cell 
cultured from ascites samples of ovarian cancer patients also grafted, but with a less 
success rate. Morphological and tumour retardation was detected after treatment 
with HXR9. This demonstrated the potential of this model to be developed for future 
personalised drug screening.  
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1.1 Ovarian cancer  
1.1.1 Incidence of ovarian cancer 
Worldwide, ovarian cancer is the seventh most common malignancy in women and 
claims just over 151, 000 lives per year making it the eighth leading cause of cancer 
death among women (Figure 1.1) (Ferlay J, 2013). In the UK ovarian cancer mortality 
is even higher, being  the fifth deadliest malignancy among woman with an estimated 
4040 deaths per year in 2012 (Ferlay J, 2013). This high mortality is primarily due to 
difficulties in diagnosing early stage disease. The majority of women (75%) are 
diagnosed at an advanced stage (stage III or IV) for which the 5-year survival rate is 
only 20-30%. However, if caught early (stage I) the survival rate increases to 73% 
(Jemal et al., 2008). Despite the development of new therapeutic approaches these 
figures have remained unchanged for the last three decades (Heintz et al., 2006). The 
late diagnosis is mainly due to the fact that ovaries are not palpable and the 
symptoms usually occur when patients develop metastatic spread. Symptoms can 
include abdominal pain, bloating, nausea and urinary urgency, but these are often 
mistaken for gastrointestinal problems (Goff et al., 2000). This is why ovarian cancer 
is often referred to as the ‘silent killer’.  
The major risk factors for ovarian cancer is advancing age, number of ovulatory 
cycles, and a positive family history of ovarian, breast, uterine or colon cancer with 
germ line mutations of the BRCA1, BRCA2 mismatch repair genes, or TP53. The 
majority of ovarian cancer cases are sporadic and occur in women with no known 
predisposing factors, giving a low overall risk in the general population of 2-5%. A 
31 
 
small percentage (5-10%) of patients have a genetic predisposition with 90% of these 
patients being carriers of the mutated BRCA1 and/or BRCA2 gene, tumour suppressor 
genes which normally regulate cellular proliferation and DNA repair (Antoniou et al., 
2003).  
 
Figure 1.1. Cancer incidence and mortality numbers in women worldwide in 2012 
(Ferlay J, 2013).  
 
 
1.1.2 Biology of ovarian cancer  
The ovaries develop from the gonadal ridge and partly from the mesonephros and 
are the site of ovum (egg) production and the main source of the hormones 
oestrogen and progesterone in premenopausal women. The ovary is composed of 
three major cell types: 1) germ cells derived from the endoderm that migrate to the 
32 
 
gonadal ridge to proliferate and differentiate into oocytes, 2) endocrine and 
interstitial cells that produce oestrogen and progesterone, and 3) epithelial cells 
derived from the Müllerian duct which cover the ovary and line inclusion cysts 
immediately beneath the ovarian surface. All three tissue types can give rise to 
ovarian tumours, the most common accounting for about 90% of ovarian cancers are 
epithelial carcinomas thought to arise from the ovarian surface epithelium (OSE). Sex-
cord-stromal tumours arise from the ovarian connective tissue and often secrete 
hormones. They occur in women of all ages, comprising approximately 6% of all 
ovarian malignancies and germ cell tumours account for 4% of ovarian cancers 
(Holschneider and Berek, 2000). Tumours are further divided into benign, borderline 
or malignant depending of the degree of cellular proliferation, atypical nuclear, and 
the presence or absence of stromal invasion. Borderline tumours of low-malignant 
potential contain morphologically and molecularly partially transformed epithelial 
cells however, they do not invade the underlying stroma, making their prognosis 
better than that of carcinomas (Tavassoli F. A and Devilee, 2003).  
 
1.1.2.1 Histological subtypes of epithelial ovarian cancer (EOC) 
Some of the challenges in the diagnosis and treatment of ovarian cancer are due to 
its heterogeneous nature resulting in differing clinico-pathological features and 
behaviour. Ovarian cancer is not a single disease but rather referred to as a diverse 
group of malignancies affecting the ovary. The distinct tumour types are classified 
according to their histological appearance. Current clinical guidelines set by the 
World Health Organisation (WHO) classified eight tumour subtypes: serous, 
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endometrioid, mucinous, clear cell, transitional cell, squamous cell, mixed epithelial 
and undifferentiated (Tavassoli F. A and Devilee, 2003). The three most common 
tumour types – serous, endometrioid and mucinous- are characterised by their 
resemblance to the specialised epithelia of the female reproductive tract, with serous 
tumours resembling the fallopian tube epithelia, endometrioid tumours resembling 
endometrial glands and mucinous tumours resembling endocervical epithelium 
(Figure 1.2) (Auersperg et al., 2001). 
 
Figure 1.2. Major histological subtypes of epithelial ovarian cancer. Three major 
subtypes of epithelial ovarian cancer: serous, endometrioid and mucinous, resemble 
the specialised epithelia of the fallopian tube, endometrial glands and endocervix, 
respectively. Images show representative ovarian tumour sections stained with 
haematoxylin and eosin. The shaded circle represents the anatomical location of 
which ovarian carcinomas are thought to arise. Figure adapted from Karst and 
Drapkin (2010) (Karst and Drapkin, 2010).  
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Based on the clinico-pathological and molecular data, a dualistic model of epithelial 
EOC has been proposed (Shih and Kurman, 2004) which categorises EOCs into two 
major groups designated Type I and Type II. Type I cancers tend to be confined to the 
ovary, usually present at a low stage (I-II), are clinically indolent and resist 
conventional chemotherapy. Their invasion occurs in a stepwise sequence of events 
from benign cystic and borderline forms to invasive carcinomas. They are genetically 
relatively stable, sharing several genetic alterations which are not found in Type II 
tumours. Type I tumours include low-grade serous, low-grade endometrioid 
carcinomas, clear cell and mucinous carcinomas. Type II tumours are more prevalent 
and highly aggressive which often present at an advanced stage (III-IV). They are 
genetically highly unstable, characteristically harbouring TP53 mutations and 
respond better to conventional chemotherapy. These include high-grade serous 
(HGS), high-grade endometrioid carcinoma, mixed malignant mesodermal tumour 
(MMMT) and undifferentiated carcinoma.  
 
1.1.2.2 Molecular heterogeneity of EOC   
It is the differences in the genetic features between Type I and Type II tumours which 
account for the distinct morphological differences. Each histological subtype of the 
Type I tumours display specific mutations. KRAS, BRAF, and ERBB2 mutations are 
frequent in low-grade serous carcinomas, whereas these tumours tend to have a 
normal karyotype and wild-type TP53 and BRCA1/2 (Hsu et al., 2004). Low-grade 
endometrioid carcinomas exhibit aberrations in the Wnt signalling pathway involving 
somatic mutations of CTNNB1 (gene encoding β-catenin), inactivating mutations and 
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epigenetic silencing of Phosphatase and tensin homolog (PTEN)  and activating 
mutations of hosphatidylinositol-3-kinase catalytic subunit α (PIK3CA) resulting in an 
upregulation of PI3K signalling (Cho and Shih, 2009). Low-grade endometrioid 
carcinomas share a similar gene expression profile to clear cell carcinomas, with the 
expression of chemo-resistant genes, ANXA4 and UGT1A1 (Zorn et al., 2005). 
Inactivating mutations of ARID1A, a chromatin-remodelling gene, are found in 49% 
of clear cell and 30% of low-grade endometrioid carcinomas (Jones et al., 2010, 
Wiegand et al., 2010). Mutations of the cancer associated gene, protein phosphatase 
2 regulatory protein-1A (PPP2R1A) is found in approximately 10% of endometrioid 
and clear cell carcinomas (McConechy et al., 2011, Shih et al., 2011) and mucinous 
carcinomas frequently exhibit KRAS mutations (Pieretti et al., 2002).  
Type II high-grade cancers are driven by copy number abnormalities and have distinct 
genomic instability. Most ovarian cancers with BRCA1 or BRCA2 mutations are type II 
high-grade tumours. In addition to germline mutations of BRAC1/2 downregulation 
of BRCA function can occur through somatic mutations of BRCA1 /2,  or methylation 
of BRAC1 and other members of the pathway which produces ‘BRCAness’ or 
homologous DNA repair deficiency (Geisler et al., 2002, Hilton et al., 2002). The 
Cancer Genome Atlas (TCGA) project recently carried out an extensive genomic and 
proteomic characterisation of ovarian cancer where 489 HGS carcinomas were 
analysed and amplification of more than 30 growth-stimulatory genes was detected. 
Ninety-six percent of HGS cancers had mutations of the TP53 gene and 20% of 
samples had germline or somatic mutations of BRCA1/2. Other statistically 
recurrently mutated genes found were RB1, NF1, FAT3, CSMD3, GABRA6, and CDK12. 
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Less than 1% of cases had mutations of BRAF, PI3KCA, KRAS or NRAS found in Type I 
cancers (TCGA, 2011).  
The TCGA also revealed that HGS ovarian cancer can be divided into 4 subtypes based 
on mRNA expression, being termed as ‘immunoreactive’, ‘differentiated’, 
‘proliferative’ and ‘mesenchymal’. The immunoreactive subtype being characterised 
by the high expression of T-cell chemokine ligands CXCL11 and CXCL10 and the 
receptor CXCR3. High expression of the transcription factors HMGA2 and SOX11 and 
proliferation markers MCM2 and PCNA and low expression of ovarian cancer markers 
MUC1 and MUC16 defined the proliferative subtype. Whereas the differentiated 
subtype was characterised by high expression of ovarian cancer markers MUC1 and 
MUC16, as well as the secretory fallopian tube marker SLPI. High expression of 
homeobox (HOX) genes and markers of stromal components were associated with 
the mesenchymal subtype (TCGA, 2011). This heterogeneity seen within ovarian 
carcinomas suggest the different types of ovarian cancers develop along different 
molecular pathways. 
Despite the high degree of variability both phenotypically and genetically, HGS 
ovarian cancer patients are virtually treated identically: cytoreductive surgery 
followed by platinum-based chemotherapy. Despite the large amount of research 
and advances in surgical techniques and chemotherapy regimens to treat ovarian 
cancer, the 5-year survival rate has only improved by 7% since 1975 (Siegel et al., 
2012). It is therefore highly justified to focus on targeted therapies to exploit 
molecular and genetic characteristics of individual tumour subtypes.  
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1.1.2.3 Origin of EOC 
The cell of origin and mechanisms by which EOC develops has long been the subject 
of debate. Unlike most tissues which become less differentiated with neoplastic 
progression, EOCs differentiate into distinct histotypes resembling the specialised 
and more architecturally complex epithelia of the female reproductive tract that 
derived from the embryological Müllerian ducts. The normal cellular constituents of 
the proposed precursor cells, the OSE, is a single layer of mesodermal derived cells 
which have an ‘uncommitted’ phenotype, however the epithelia of ovarian tumours 
have a more committed phenotype do not resemble the cell types seen in the ovary, 
hence the dilemma regarding the origin of EOC (Feeley and Wells, 2001).  
 
The traditional view is that the OSE is the cell of origin for EOC. During ovulation, 
physical trauma is inflicted upon the ovarian surface due to follicular rupture and 
oocyte release. This damage must be repaired and over the course of a woman’s 
reproductive life this process is repeated many times. This repetitive rupture of 
follicles coupled with postovulatory wound repair has been proposed to be a cause 
of EOC, known as the incessant evolutionary theory (Fathalla, 1971). The 
inflammation and stimulation of OSE cell proliferation caused by ovulation month 
after month provides an opportunity for genetic abnormalities. In addition, during 
ovulation OSE cells become trapped beneath the OSE in a favourable 
microenvironment for tumour cell growth consisting of aberrant autocrine/paracrine 
stimulation from hormones, phospholipids and vascular endothelial growth factor 
(VEGF) (Ozols et al., 2004). 
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Due to this constant cycle of damage and repair the OSE exhibits a high level of 
plasticity to facilitate tissue remodelling, expressing both epithelial and mesenchymal 
markers and transitioning from an epithelial to a mesenchymal phenotype, a 
phenomenon known as epithelial-to-mesenchymal transition (EMT). This 
mesenchymal phenotype aids the ovulatory process because these cells have 
increased motility, an altered proliferative response and the ability to remodel the 
extracellular matrix (ECM) (Ahmed et al., 2006). This process of EMT has been 
implicated in the development of cancer (Craene and Berx, 2013) and it is thought 
ovarian cancer may represent unregulated EMT. Furthermore, the ovarian surface 
develops numerous invaginations into the cortical stroma as women age. Frequently, 
these invaginations pinch off and become entrapped in the stroma forming circular 
OSE-lined structures termed ‘cortical inclusion cysts’ (CICs) (Karst and Drapkin, 2010). 
Inside the ovary these epithelial cells are exposed to a new hormone-rich 
environment which is thought to induce differentiation into epithelium resembling 
that of the Müllerian duct derived organs (Drapkin et al., 2004, Karst and Drapkin, 
2010). This Müllerian differentiation suggests differentiation-regulatory factors may 
contribute to the progression of EOC. It has been suggested that the mechanism by 
which ovarian cancers differentiate may involve HOX genes (Naora et al., 2001a) as 
these genes play an important role in tissue differentiation during embryonic 
development and in adult tissues. Expression of the HOXA9, HOXA10 and HOXA11  
genes which regulate normal gynaecological differentiation have been linked to 
ovarian cancer histotypes (Cheng et al., 2005) (discussed later in more detail in 
section 1.2.4.1).  
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An alternate theory is that tumours with a Müllerian phenotype (serous, 
endometrioid and clear cell) are derived from Müllerian-type tissue, as the normal 
ovaries develop from the urogenital ridge separate from the Müllerian ducts where 
the fallopian tubes, endometrium and cervix derive from (the epithelia that these 
tumours resemble). According to this theory ovarian cancer arises from cysts located 
in paratubal and paraovarian locations which are lined with Müllerian-type tissue. As 
the tumour grows it compressed and obliterates the ovarian tissue, resulting in an 
adnexal tumour of the ovary (Dubeau, 2008). 
More recently, it has been suggested that HGS tumours arise from serous tubal 
intraepithelial carcinomas (STIC) of the fallopian tube which then spreads to the 
ovary. It has been reported that in over 70% of sporadic ovarian and peritoneal HGS 
cancers show mucosal tubal involvement including STICs (Kindelberger et al., 2007), 
however, it can be argued that this tubal involvement is a result of secondary spread 
from an ovarian carcinoma. It has also been argued that the formation of an inclusion 
cyst may derive from the dislodgement of normal tubal epithelia from the fimbria 
which then implants on the site of rupture where ovulation occurs. These cells then 
undergo malignant transformation. It is also thought endometrioid and clear cell EOC 
may not arise from the ovary but develop from endometriosis.  It is generally believed 
that endometriosis results from retrograde menstruation (Bulun, 2009) therefore the 
implantation of endometrioid tissue on the ovarian surface forms an endometrioid 
cyst from which low grade or clear cell carcinomas can develop (Figure 1.3) (Kurman 
and Shih, 2010).  
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Figure 1.3. Development models of low –grade (LGS) and high-grade serous (HGS) 
carcinoma. Schematic representation of mechanisms of development of ovarian 
cancer. Normal tubal epithelium is shed from the fimbria which implants on the ovary 
forming an inclusion cyst which can develop into a HGS or LGS carcinoma depending 
on whether there is a TP53 or KRAS/BRAF/ERRB2 mutation respectively. A serous 
borderline tumour (SBT) can arise from a serous cystadenoma, which often develops 
into a LGS carcinoma. Another mechanism shown is the direct dissemination of 
malignant cells from a serous tubal intraepithelial carcinoma (STIC) which implant on 
the ovarian surface.  
 
 
1.1.3 Staging and grading 
The staging of ovarian cancer is determined surgically by examining the extent of 
metastasis (Table 1.1). Metastasis of ovarian cancer spreads by direct extension from 
the ovaries to neighbouring organs or the sloughing of tumour cells into the 
peritoneal cavity. These exfoliated cells float in the peritoneal fluid and can bind to 
the wall of the peritoneal cavity to form additional lesions. Tumour cells will also 
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disseminate via lymphatic spread (Tsumura et al., 1998). Stage I EOC is confined to 
the ovaries, stage II affects other pelvic structures and stage III is when the disease 
has spread beyond the pelvis into the upper abdominal cavity or lymph nodes. Stage 
IV disease has spread beyond the peritoneal cavity and invades other organs, most 
commonly this includes parenchymal liver lesions or malignant pleural effusions 
(Benedet et al., 2000).  
 
Ovarian cancers are also graded and several grading systems are currently in use but 
the most commonly used system is of the International Federation of Gynaecology 
and Obstetrics (FIGO), whereby tumours are graded depending on their ratio of 
glandular or papillary structures to solid tumour (Table 1.2). The grade of carcinoma 
does not add any prognostic value in cases where the histological type has been 
carefully assessed using the WHO diagnostic criteria and is mainly used for 
determining between high and low grade serous carcinomas.  
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Table 1.1. FIGO (International Federation of Gynaecology and Obstetrics) staging of 
ovarian cancer.  
Stage Description 
I Tumour confined to ovaries: 
IA 
Tumour limited to one ovary, capsule intact, no tumour present on 
surface. 
IB Tumour involves both ovaries, otherwise like IA. 
IC Limited to one or both ovaries: 
IC1 Surgical spill. 
IC2 Capsule rupture before surgery or tumour on ovarian surface. 
IC3 Malignant cells in the ascites or peritoneal washings. 
II 
Tumour involves one or both ovaries with pelvic extension (below the pelvic 
brim) or primary peritoneal cancer. 
IIA Extension and/or implant on uterus and/or Fallopian tube. 
IIB Extension to other pelvic intraperitoneal tissues. 
III 
Tumour involving one or both ovaries with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and/or metastasis to 
the retroperitoneal lymph nodes. 
IIIA 
Positive retroperitoneal lymph nodes and/or microscopic metastasis 
beyond the pelvis. 
 Positive retroperitoneal lymph nodes only: 
   IIIA(i) Metastasis ≤ 10mm. 
IIIA(ii) Metastasis ≥ 10mm. 
IIIA2 
Microscopic, extrapelvic peritoneal involvement ± positive 
retroperitoneal lymph nodes. 
IIIB 
Macroscopic, extrapelvic, peritoneal metastasis ≤ 2cm ± positive 
retroperitoneal lymph nodes. Includes extension to capsule of 
liver/spleen. 
IIIC Macroscopic, extrapelvic, peritoneal metastasis ≥ 2cm ± positive. 
IV Distant metastasis excluding peritoneal metastasis. 
IVA Pleural effusion with positive cytology. 
IVB 
Hepatic and/or splenic parenchymal metastasis to extra-abdominal 
organs. 
(Prat, 2014) 
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Table 1.2: FIGO (International Federation of Gynaecology and Obstetrics) grading 
of ovarian cancer. 
Grade Description 
1 < 5% solid tumour growth 
2 5-50% solid tumour growth 
3 > 50% solid tumour growth 
(Prat, 2014) 
 
1.1.4 Current clinical management of ovarian cancer  
During surgical staging of EOC the surgeon will attempt to remove all visible tumours 
from within the peritoneal cavity and wash several times to remove as many tumour 
cells as possible. This procedure is termed cytoreductive surgery or tumour debulking 
(Gallup and Hoskins, 1997).  
The standard treatment of ovarian cancer is based on a combination of cytoreductive 
surgery and chemotherapy (usually 6 cycles of carboplatin and paclitaxel). 
Carboplatin is an alkylating by creating cross-links in DNA by forming intrastrand and 
interstrand covalent bonds with DNA bases preventing DNA transcription. Paclitaxel 
binds non-covalently with microtubules increasing their stability which interferes 
with mitotic spindle formation. The surgery can be done either upfront or following 
primary chemotherapy (usually 3 cycles).The surgery will include hysterectomy, 
bilateral oophorectomy (removal of both fallopian tubes), omentectomy (removal of 
the omentum), and pelvic and aortic lymph node dissection as well as resection of all 
visible tumour deposits. Younger patients who want to preserve fertility and present 
at an early stage can opt to have only the affect ovary removed. Chemotherapy after 
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surgery (adjuvant chemotherapy) is dependent upon the grade and stage of the 
tumour. Vast majority of patients present at an advanced stage and those who are 
staged Ic and above are considered high risk and offered adjuvant chemotherapy. 
The exception here is patients with low grade and borderline tumours.  While 70% to 
80% of patients will initially respond to this traditional therapy, more than 60% will 
relapse after treatment and 70% to 90% of these women will ultimately die of their 
disease (Cannistra, 2004). Patients who show disease recurrence within 6 months 
following an initial response to platinum-based therapy are classified  as having 
platinum-resistant ovarian cancer (Ushijima, 2010).  The time to relapse and 
sensitivity to platinum-based chemotherapy is the main prognostic factor. Patients 
who are platinum-resistant have a poor prognosis with survival of 12- 18 months 
(Colombo et al., 2012), and those who relapse a year of more after first line treatment 
usually have a better survival (Hogberg et al., 2001). Platinum resistance is a major 
problem in the current treatment of ovarian cancer. It is therefore essential for the 
development of innovative and effective therapeutic strategies for the management 
of advanced EOC to improve patient outcome. Second-line chemotherapy is given to 
patients with recurrent disease. Although not curable, combinations of drugs can 
prolong survival. In platinum-sensitive disease retreatment with carboplatin with 
paclitaxel (Gonzalez-Martin et al., 2005), gemcitabine (Pfisterer et al., 2006) or 
liposomal doxorubicin (Pujade-Lauraine et al., 2010) has shown to be superior to 
carboplatin alone (Bast and Markman, 2010), with carboplatin and paxclitaxel 
showing a 20-50% response rate (Romero and Bast, 2012). For platinum-resistant 
patients, response rates are much less ranging from 10-30% from treatment with 
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liposomal doxorubicin (Gordon et al., 2004), weekly paclitaxel (Markman et al., 2006), 
and topotecan (Ten Bokkel Huinink et al., 1997). 
High recurrence rates following surgery and chemotherapy are related to the nature 
of metastasis and immunosuppressive effects tumour cells exert. Metastasis is easily 
facilitated due to the anatomical location of the ovaries within the peritoneal cavity. 
Tumour cells can spread by sloughing off the main tumour and binding to other sites 
in the vicinity, including the peritoneal cavity surface and omentum which is highly 
vascular (Tan et al., 2006). This makes it impossible to remove all cancer cells during 
cytoreductive surgery. The build-up of peritoneal fluid (ascites) in patients aids 
metastasis by increasing the flow of tumour cells within the cavity. This process 
means that unlike other common epithelial cancers, ovarian cancers do not have to 
undergo vascular invasion for metastasis (Tan et al., 2006). In addition, the ascites 
contains a tumour-friendly microenvironment promotes tumour cell growth and 
motility (Ahmed et al., 2003, Ahmed et al., 2005) and inhibits the response of 
chemotherapy (Lane et al., 2007). The ascites also contains factors secreted from 
tumour cells which suppress the patient’s immune system (Giuntoli et al., 2009), 
further complicating treatment.  
 
1.2 HOX genes 
HOX genes constitute a family of transcription factors, organised into evolutionary 
conserved clusters in the genome of all bilateral animals (Garcia-Fernandez, 2004). 
These genes have emerged as important master regulators of development. They are 
expressed during embryonic development in a highly co-ordinated manner along the 
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anterior-posterior (AP) axis, to assign distinct morphology to various body segments 
(McGinnis and Krumlauf, 1992). They were first discovered following striking 
mutations of the fruit fly, Drosophila melanogaster, which lead to drastic changes in 
body morphology whereby one specific body segment or structure transformed into 
the likeness of another. For example, a gain-of-function mutation of the 
Antennapedia (Antp) gene resulted in the fly antennae being replaced by legs (Figure 
1.4). These changes were describes as homeotic transformations, and the term 
‘homeotic selector gene’ was devised by Drosophila geneticists to encompass the 
concept that the development of each segment of the fly could be controlled by a 
master regulatory gene. Further investigation of the Drosophila identified a cluster of 
genes consisting of the bithorax complex with three homeobox genes (Ubx, Abd-A, 
and Abd-B) and the antennapedia complex with five homeobox genes (Lab, Pb, Dfd, 
Scr and Antp). Collectively these genes are referred to as the Homeotic complex 
(HOM-C) (Lewis, 1978).  
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Figure 1.4. Scanning electron micrograph. (a) Wild-type Antennapedia (antp) and 
antp gain-of-function mutant (b). Ectopic expression of antp in the antenna 
primordium transforms them into leg-like structures (Parrish et al., 2009).  
  
The vertebrate equivalents of the bithorax/antennapedia spilt cluster are found in 
four clusters due to two genome duplication events occurring during vertebrate 
evolution. In mammals, the four HOX gene clusters (A-D) are located on different 
chromosomes at 7p15, 17q21.2, 12q13, and 2q31 (Lappin et al., 2006). The loss of 
individual HOX genes in each cluster also occurred during mammalian evolution, 
resulting in a total of 39 genes across the four clusters. Each cluster consists of 13 
paralogue groups with nine to eleven members assigned to each on the basis of 
sequence similarity and relative position within the cluster (Figure 1.5) (Garcia-
Fernandez, 2005).  
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Figure 1.5. HOX organisation and conservation between the HOM-C and HOX gene 
clusters. A schematic representation of the comparison between the four 
mammalian HOX clusters and the single homologous Drosophila HOM-C. Colours 
correspond to paralogue groups.  
 
The 3’ to 5’ order of HOX genes along a chromosome corresponds to the order of 
their expression and function along the AP axis. This HOX colinearity is crucial in 
mammalian embryogenesis, resulting in the combinational expression of subsets of 
HOX genes in specific areas along the axes that are translated into a regional identity. 
Genes at the 3’ end of the cluster (paralogue group 1) are expressed in and pattern 
the anterior part of the body, whereas genes at the 5' end (paralogue group 13) 
pattern the posterior end of the body (McGinnis and Krumlauf, 1992). In addition to 
this spatial colinearity, HOX clusters also show temporal colinearity, which refers to 
the timing of gene expression during embryogenesis with anterior genes being 
express earlier than posterior genes of the cluster (Duboule and Morata, 1994). 
Posterior prevalence exists within the clusters, with the products of more posterior 
genes being functionally dominant over those of anteriorly expressed genes (Duboule 
and Morata, 1994). Functional redundancy exists between paralogous genes and 
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genes that are adjacent to each other in the same cluster as they have overlapping 
domains of expression (Kmita et al., 2005). This explains why in vertebrates with 
multiple HOX clusters, mutations in HOX genes do not always result in such drastic 
phenotypic changes which have been seen in the Drosophila. For example, in 
mammals a mutation in a single gene can be compensated for by a paralogue (Hunt 
et al., 1991).  
 
The function of HOX genes in mammalian development have been elucidated 
through gene inactivation studies and transgenic animals models with altered HOX 
expression domains. In some cases where HOX information was completely 
eliminated or significantly reduced, cells were unable to mature resulting in the 
absence of whole structures or lineages. This suggests their role in stem cell 
differentiation and expansion during embryonic development. The combined loss-of-
function of the Drosophila labial homologous Hoxa1 and Hoxb1 in the developing 
hindbrain, rhombomere 4 (r4) in particular, demonstrates this concept. Hoxb2 
expression in r4 is dependent upon Hoxb1 function in the same region (Maconochie 
et al., 1997), therefore this genetic combination essentially resulted in the triple 
knock out leaving only Hoxa2 expression in the r4 region. Although the territory was 
not completely lost, there was a cell autonomous defect in r4 neural crest cell 
generation (Gavalas et al., 2001), which consequently resulted in the early involution 
of the second pharyngeal arch and loss of its derivative skeletal elements (Gavalas et 
al., 1998). Other cell lineages in this territory were generated, such as motor 
neurones, however they harboured identity changes and displayed atypical 
behaviour (Gavalas et al., 1998). In another study, targeted disruption of Hoxa3 
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resulted in the complete loss of the thymus. The thymus derives through the 
mesenchymal neural crest of the third pharyngeal arch and in these mutants the 
neural crest is generated and migrates correctly but fails to differentiate and properly 
interact with the surrounding tissue to generate the thymus (Manley and Capecchi, 
1995). These cases demonstrate that patterning, lineage specification and cellular 
growth are linked, with HOX genes playing a central role in these processes. Thus, for 
proper AP specification a specific HOX code is necessary for stem and progenitor cells 
to expand and differentiate appropriately to signals.  
 
1.2.1 Regulation of HOX gene expression 
The precise and restricted localised expression of each HOX gene is essential for the 
correct patterning of tissues during embryonic development. It is therefore crucial to 
have a tight transcriptional regulatory mechanism in place. Three phases of 
vertebrate HOX gene expression have been suggested: initiation, establishment and 
maintenance (Deschamps et al., 1999). First is the initial transcription of the 3’ HOX 
genes in the primitive streak with the sequential activation of progressively more 5’ 
genes in the posterior embryo. After initiation, HOX genes are activated to form well 
established expression domains, which are then maintained through epigenetic 
mechanisms once the appropriate expression boundaries are reached. 
a) Initiation: 
The HOX genes have no ascribed role in early zygotic cleavage, it is after 
differentiation of the three germ layers (gastrulation), that AP axis determination is 
initiated by HOX gene expression. The exact mechanism of this initial HOX gene 
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transcription is not fully understood. Among the potential HOX inducers are Wnt, 
retinoic acid (RA), fibroblast growth factors (FGF), Krox-20 and Kreisler (Deschamps 
and van Nes, 2005). RA is the most extensively studied regulator of HOX gene 
expression. Retinoids act as ligands to directly activate two families of nuclear 
receptors, the RA receptors (RARα, β and γ), and the retinoid X receptors (RXRα, β 
and γ). These receptors interact to form RAR-RAR or RAR-RXR homo- or 
heterodimers, respectively, and bind to cis-acting DNA sequences called retinoic 
response elements (RAREs) (Gronemeyer and Miturski, 2001). RAREs have been 
found in the 3’ regulatory region of a number of HOX genes (Oosterveen et al., 2003b, 
Oosterveen et al., 2003a, Kobrossy et al., 2006). The CDX proteins, targets of the Wnt, 
RA and FGF signalling pathways, have also been found as important upstream 
regulators (Bel-Vialar et al., 2002, Lohnes, 2003), with clusters of CDX-binding sites 
(TTTATG) found upstream of HOX genes (Gaunt et al., 2004, Tabaries et al., 2005). 
The sex steroids are among the regulators of HOX genes at the 5’ end of the cluster, 
determining posterior development, including the development of the reproductive 
tract (Taylor et al., 1998, Taylor et al., 1999, Goodman, 2002, Cermik et al., 2001, Ma 
et al., 1998). Oestrogen is necessary for the development of the reproductive tract 
and is thought to mediate segmental HOX genes expression in posterior structures. 
Developmental abnormalities and abnormal Hox gene spatial expression was 
observed in the reproductive tracts of animals exposed in utero to synthetic 
nonsteroidal oestrogen diethylstilbestrol (DES) (Daftary and Taylor, 2006).  
It has been postulated that HOX gene clusters undergo a change in chromatin 
structure which regulate their transcription (Chambeyron and Bickmore, 2004). 
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According to this two-step model, histone modifications and chromatin 
decondensation induces a progressive change in chromatin structure 3’-5’. This 
allows programmed expression of genes along their cluster, preventing posterior 
genes from being expressed too early. As the sequential opening of chromatin moves 
successively towards the 5’ end, the 3’ end genes become silenced, allowing for the 
expression of more 5’ genes (Roelen et al., 2002, Kmita and Duboule, 2003, Duboule 
and Deschamps, 2004).   
Regulators of HOX genes are also protein complexes, interacting with each other to 
initiate a cascade of regulatory pathways. Sonic Hedgehog (shh) expression has been 
shown to activate HOX genes for AP patterning in the mesoderm (Riddle et al., 1993). 
Shh is a member of the Hedgehog (Hh) family of genes and is a secreted glycoprotein 
released from notochord and floor plate during embryonic development and acts 
through the shh pathway to regulate for the correct patterning of various organs 
systems (Martinez-Frias et al., 2001, Ramalho-Santos et al., 2000). 
b) Establishment: 
After initial HOX expression in the posterior streak region, HOX expression domains 
spread anteriorly in and along the streak, extending rostrally to reach their anterior-
most position. Therefore, tissue restriction and the boundaries of these expression 
domains need to be set. Chromosomes are divided into a series of separate higher-
order chromatin domains, each having their own transcription units. These chromatin 
domains can be delimited by cis-acting elements called boundaries or insulators 
(West et al., 2002, Felsenfeld et al., 2004, Zhou and Berger, 2004). These work to 
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block the activation of neighbouring genes beyond the chromatin domain (Kondo et 
al., 1998, Kmita et al., 2000).  
Establishment of domains is also thought to be controlled by morphogens, such as 
RA and CDX proteins, with these proteins serving as an instructional gradient (Faiella 
et al., 1994, Maves and Kimmel, 2005). In this model, HOX genes are regulated in a 
dose-dependent manner, for example, CDX protein concentration establishes 
temporal colinearity by regulating the rate and extent of sequential HOX expression 
(Gaunt et al., 2004).  
c) Maintenance:  
The polycomb group (PcG) and Trithorax group (TrxG) genes have been recognised 
as important regulatory factors involved in the maintenance of cell identity. These 
proteins form multimeric complexes which bind to chromatin to PcG or TrxGr 
response elements (PRE/TRE), found in regulatory regions of HOX genes. Here they 
target chromatin structure and accessibility by catalysing post-translational histone 
modifications, dividing the genome into transcriptionally active and silent areas. The 
PcG protein complexes maintain HOX boundaries by repressing transcription outside 
the normal expression domains, and the TrxG proteins maintain the spatial HOX 
expression domains by sustaining gene activation within their established 
transcription domains (Gould, 1997, Pirrotta, 1997a, Pirrotta, 1997b, Pirrotta, 1998, 
Schumacher and Magnuson, 1997).  
 
 
54 
 
1.2.1.1 Translational control of HOX gene expression 
In addition to the transcriptional control of Hox genes during early embryonic 
development, translational control of tissue patterning also exists through a 
regulatory role played by ribosomes. This translational regulation was discovered 
through research carried out on Tail short (Ts) mice who exhibit pronounced skeletal 
patterning defects. In addition to a shorter tail than WT mice, Ts/+ mice possess 
defects such as the presence of 14 ribs instead of 13. This defect strongly suggests 
that the first lumbar vertebra that normally does not possess a rib anlage has been 
transformed anteriorly into a thoracic vertebra (Morgan, 1950, Deol, 1961). 
Complete analysis of the skeletal patterning in Ts/+ mice revealed A-P directed 
homeotic transformations along the entire axial skeleton, suggesting the gene 
mutated in Ts mice is an important regulator of A-P skeletal patterning. The mutated 
gene shown to be causing this phenotype was RPL38, a ribosomal protein 
(Kondrashov et al., 2011). Hox gene expression boundaries and transcript levels were 
analysed to revel no changes in the Ts/+ embryos compared to WT, however, a 
decrease in protein levels of a HOXA5, A11 and B13 were observed in Ts/+ embryos 
compared to WT embryos. Protein levels of these Hox genes are restored to normal 
levels in Ts/+; PCAGGS-Rpl38 transgenic mice, and no longer displayed the Ts 
phenotype. In addition, a decrease in protein levels similar to those seen in Ts/+ 
embryos were observed upon a stable knockdown of Rpl38 in a multipotent 
mesenchymal stem cell line, further demonstrating a post-translation control of Hox 
transcripts (Kondrashov et al., 2011).  
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Ribosome-mediated control of HOX gene expression has been shown to be enabled 
by RNA regulons embedded in the homeobox 5’ untranslated regions (UTR) (Xue et 
al., 2015). These structured RNA elements resemble viral internal ribosome entry 
sites (IRESs) located in viral mRNAs to provide an alternative mechanism for the 
recruitment of ribosomes to promote translation of mRNAs which are not capped 
(Sonenberg and Hinnebusch, 2009, Plank and Kieft, 2012). All eukaryote mRNAs are 
capped and cap-dependent translation is the predominant means for translation for 
the majority of transcripts in the mammalian genome (Livingstone et al., 2010, 
Sonenberg and Hinnebusch, 2009). However, IRES elements have been found in a 
number of cellular mRNAs, acting as a ‘fail safe’ mechanism to promote translation 
in periods of stress when cap-dependent translation is down-regulated, such as 
apoptosis and hypoxia (Pyronnet et al., 2001, Holcik et al., 2000). These IRES elements 
have been found in the 5’ UTR of the subset of specific Hox genes regulated by RPL38, 
with RPL38 showing to be critical in their IRES dependent translation (Xue et al., 
2015).  This ribosome-mediated control of gene expression adds an addition level of 
regulatory control, critical for mammalian development.  
 
1.2.2 HOX proteins 
For the regulation of gene transcription, specific interactions between transcription 
factors and their target genes are needed. This binding is sequence specific therefore 
DNA-binding domains with characteristic structural motifs are found within such 
regulatory proteins. The products of the HOX genes, HOX proteins, are able to bind 
DNA through the conserved homeodomain, a 60 amino acid polypeptide, encoded by 
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the homeobox (Gehring et al., 1994). The homeodomain consists of three helices and 
an N-terminal arm which is unstructured in unbound proteins. Site-specific binding 
to DNA is facilitated through interactions of the third helix with the major groove of 
DNA and the flexible N-terminal arm with the minor groove, mainly through binding 
to the TAAT core motif in DNA (Gehring et al., 1994).  
 
The HOX proteins can function as monomers or homodimers, although their target 
DNA binding affinities and specificities are enhanced by functioning as heterodimers 
or heterotrimers with cofactors PBX (pre-B-cell transformation-related gene) (Chang 
et al., 1995, Lu et al., 1995, Neuteboom et al., 1995, Phelan et al., 1995, Popperl et 
al., 1995) and MEIS (Moskow et al., 1995, Shen et al., 1997), members of the three-
amino acid loop extension (TALE) family of homeodomain proteins. The binding 
between HOX proteins and PBX is facilitated through a highly conserved hexapeptide, 
also known as the YPWM motif (Figure 1.6) and is located N-terminal to the 
homeodomain of HOX genes from paralogue groups 1-8 (Gehring et al., 1994, Mavilio 
et al., 1986). The hexapeptide is connected to the homeodomain by a non-conserved 
flexible linker, which varies in length and sequence between HOX proteins (Knoepfler 
and Kamps, 1995). The YPWM motif of HOX proteins contacts the residues located 
within and immediately following the homeodomain in PBX (Chang et al., 1995, 
Chang et al., 1997, Lu et al., 1995). HOX proteins from the abdominal-B (Abd-B) class 
(paralogous groups 9–10) do not contain this hexapeptide but are able to form 
cooperative complexes with PBX through conserved tryptophan residues (Chang et 
al., 1996, Shen et al., 1997). HOX proteins from paralogue groups 9 and 10 are also 
able to form complexes with co-factor MEIS (Shen et al., 1997).  
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Figure 1.6. Conserved hexapeptide region of Hox paralogue groups (1-8). Capital 
letters denote the conserved amino acids between paralogue groups (based on the 
standard IUB codes). The amino acids in green are those that define the hexapeptide. 
‘f’ denotes either phenylalanine (F) or tyrosine (Y) and ‘r’ denotes either arginine (R) 
or lysine (K). ‘h’ is a hydrophobic amino acid. ‘x’ indicates that the amino acid at that 
position is not conserved, although the spacing is (Morgan et al., 2000).  
 
1.2.2.1 Function of HOX proteins in adults 
Although well characterised for their role in embryogenesis and AP axis specification, 
HOX genes are expressed in adult tissues, having various roles in cellular proliferation, 
cell adhesion, apoptosis and cell migration, cell-cell and cell-ECM interactions (Taylor 
et al., 1997, Carrio et al., 2005, Rhoads et al., 2005) (Srebrow et al., 1998). They also 
enable a level of developmental plasticity to be retained, allowing certain tissues to 
undergo rapid developmental changes, such as the reproductive tract and the 
haematopoietic system which exhibit a high cyclic turnover. Organogenesis is a 
complex process which is regulated by HOX genes, from the early development stages 
through to the formation of adult organs and their homeostatic regulation. Each adult 
organ displays a characteristic HOX expression profile (Cillo et al., 1992, De Vita et al., 
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1993) due to differing cell phenotypes, structure and positioning along the AP axis 
(Cillo et al., 2001). Other essential processes which they are involved in are: 
angiogenesis, hair follicle morphogenesis and skin repair (Awgulewitsch, 2003, Mack 
et al., 2003), contributing to positional identity and the generation of the correct skin 
type of that location (Rinn et al., 2008, Scott and Goldsmith, 1993). Spatially 
colinearity of HOX genes has partially remained in adult tissues, with posterior tissues 
expressing more HOX genes than anterior tissues (Chang et al., 2002, Rinn et al., 
2006, Takeda et al., 2001, Yamamoto et al., 2003). Considering tissues of common 
embryonic origin, such as the female reproductive tract, the conservation of 
developmental gene expression is even more evident.  
 
1.2.2.2 The reproductive tract 
In mammals the female reproductive system develops from the Müllerian ducts, 
initially being morphologically undifferentiated and homologous in appearance. At 
this early stage (embryonic day 15.5 through to 19) a uniform pattern of HOX gene 
expression is observed, including Hoxa9, Hoxa10, Hoxa11 and Hoxa13 (Taylor et al., 
1997). At the postnatal age of 2 weeks, a Hox gene axis is established along the 
Müllerian duct, where the uniformly expressed Hox genes now become spatially 
restricted. Hoxa9 is expressed in the oviducts, Hoxa10 in the uterus followed by 
Hoxa11 in the cervix and finally Hoxa13 in the vagina and vulva (Figure 1.7) (Du and 
Taylor, 2004). This restricted expression pattern remains in the adult reproductive 
tract  of mammals and humans, and is needed for a functional reproductive system 
(Taylor et al., 1997).  
59 
 
During the menstrual cycle, the endometrium undergoes cyclic regeneration, 
involving proliferation and differentiation of multiple cell lineages, including 
epithelium, stroma and endothelium, allowing for a receptive state for embryo 
implantation. Dynamic temporal patterns of expression of HOXA10 and HOXA11 are 
seen in accordance to this (Taylor et al., 1998, Taylor et al., 1999). Significantly higher 
levels of expression are seen during the mid- and late-secretory phases (Taylor et al., 
1998, Taylor et al., 1999) which coincides with the time of embryo implantation and 
high systemic levels of oestrogen and progesterone, which are regulators of these 
genes (Eda Akbas et al., 2004, Taylor et al., 1998). If implantation is unsuccessful, 
apoptosis and degradation of the endometrium occurs, followed by another cycle of 
programmed development.  
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Figure 1.7. HOX control of Müllerian differentiation. The Müllerian ducts 
differentiate to form the fallopian tubes, uterus, cervix and vagina. HOX gene 
expression becomes spatially restricted to these regions with the expression of 
HOXA9, HOXA10, HOXA11 and HOXA13, restricted to the fallopian tubes, uterus, 
cervix and vagina, respectively (Taylor et al., 1997).  
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1.2.3 HOX genes and hematopoietic stem cells 
HOX genes also function in the adult haematopoietic system playing an extremely 
complex role in mediating haematopoietic stem cell (HSC) expansion, differentiation 
and lineage commitment. The mixed populations of cells found in human blood 
originate from bone marrow stem cells which have undergone proliferation and 
differentiation along a number of distinct lines. HOXB4 has been implicated in 
mediating HSC specification, expansion and self-renewal, by having the ability to 
engraft and confer definitive long-term multi-lineage haematopoiesis in irradiated 
mice. Also, retroviral transduction of Hoxb4 promoted yolk sac cells to switch to a 
HSC phenotype (Kyba et al., 2002). In vivo, ectopic expression of HOXB4 in mouse and 
human bone marrow stem cells increased self-renewal of HSC (Amsellem et al., 
2003), and ex vivo HOXB4 induced rapid expansion of transduced HSCs (Antonchuk 
et al., 2002). Functional studies have provided evidence that HOX proteins influence 
lineage commitment of haematopoietic stem and progenitor cells, with each 
haematopoietic line expressing a distinct set of HOX genes from the A, B and C 
clusters (Sauvageau et al., 1994). As well as lineage- specific, HOX gene expression is 
also stage- specific with the genes located at the 3’ end of the cluster being expressed 
in the most primitive HSCs, for example HOXB3, HOXB4 and HOXB5 (Sauvageau et al., 
1994, Kawagoe et al., 1999), and those located at the 5’ end being expressed in later 
stages of differentiation, such as the myeloid and erythroid lineage commitment 
(Sauvageau et al., 1994, Giampaolo et al., 1995). The differences in HOX gene 
expression in the different lineages and stages reflect their distinct functions.  
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Overexpression of HOX genes involved in haematopoiesis has been linked to 
leukaemogenesis. This has been shown for HOXA9 and HOXA10 which are widely 
expressed in acute myeloid leukaemia (AML) (Lawrence et al., 1995, Thorsteinsdottir 
et al., 1997, Lawrence et al., 1999, Kroon et al., 1998).  The discovery of cancer stem 
cells (CSCs) was first demonstrated in AML where leukemic cancer cells were found 
to retain many features or normal HSCs (Lapidot et al., 1994, Bonnet and Dick, 1997). 
CSCs have been identified in solid tumours such as breast, brain and ovary (Al-Hajj et 
al., 2003, Singh et al., 2004, Bapat et al., 2005), where it is thought that these tumours 
either arise from a subpopulation of stem cells or differentiated cells acquire stem 
cell-like properties upon mutational transformation. The properties of CSCs include 
tumorigenic or self-renewal capacity, the potential for multi-lineage differentiation, 
able to participate in serial passages and express unique surface markers, CD133, 
CD44 and CD177 (Clarke et al., 2006). As HOX genes have been implicated in 
regulating self-renewal and expansion of stem cells and progenitor cells in normal 
organs and the haematopoietic system, it is likely they may play a similar role in 
tumourgenesis.  
 
1.2.3.1 HOX genes and cancer stem cells 
The process of normal embryogenesis and neoplasia share many of the same 
pathways, with tumour development being referred to as an aberrant form of 
organogenesis. Early models of carcinogenesis stipulate that uncontrolled 
proliferation arises due to serial acquisition of genetic lesions that lift normal 
restrictions, upregulate proliferative responses and abrogate programmed cell death. 
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The more recent stem cell model for carcinogenesis suggests that a key event would 
be the regulatory disruption of genes involved in the regulation of stem cell renewal. 
For example, the Wnt, Hedgehog, Polycomb and Notch signalling pathways which 
control pattern formation and maintenance and self-renewal of stem cells are 
deregulated in many cancers  and have emerged as the driving forces behind 
tumourgenesis [reviewed in (Taipale and Beachy, 2001, Reya and Clevers, 2005)]. 
Such cancers include basal cell carcinoma (Xie et al., 1998), gastrointestinal 
malignancies (Huang et al., 2006, Berman et al., 2003, Qualtrough et al., 2004, Kinzler 
and Vogelstein, 1996) and ovarian cancers (Chen et al., 2007b). HOX genes interact 
with these signalling pathways (Briscoe et al., 1999, Yun et al., 2002, Daikoku et al., 
2004, Zakany et al., 2004) and are regulated by Polycomb genes (vanderLugt et al., 
1996, Bel-Vialar et al., 2000, Kajiume et al., 2004). With the role HOX genes are known 
to play in normal stem cell differentiation and expansion during embryonic 
development, it could be suggested that these genes are playing a similar role in 
cancer stem cell activity. Increasing research is finding aberrant expression of HOX 
genes in cancerous tissues including lung, prostate, breast, colon, bladder and thyroid 
(Calvo et al., 2000, Miller et al., 2003, Raman et al., 2000, Vider et al., 1997, Cantile 
et al., 2003) compared to their normal tissue counterpart, supporting their role in 
oncogenesis.  
Changes found in malignant tissues include 1) temporospatial deregulation where 
HOX gene expression in a tumour of a specific tissue is temporospatially different 
from the expression seen in the normal tissue counterpart. 2) Gene dominance 
showing an increase in the expression of HOX genes which are usually expressed at 
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lower levels in the normal tissue; and 3) epigenetic deregulation which can result in 
the down-regulation or silencing of certain HOX genes which normally function as 
tumour suppressors. Understanding their functions in oncogenesis may provide 
important diagnostic tools and means to control carcinogenesis. 
 
 
1.2.4 HOX gene function in cancer 
Aberrant HOX gene expression affects various pathways that promote tumourgenesis 
and metastasis. This can happen through a number of mechanisms that are listed 
below. 
a) Differentiation: 
The expression of HOX genes involved in terminal differentiation of normal tissues is 
altered in malignant tissues, resulting in a failure of cellular differentiation and 
therefore cells maintain an embryonic state. For example, HOXC8 is not normally 
expressed in prostate tissues but is upregulated in prostate cancer (Miller et al., 
2003), and overexpression in prostate cancer cell lines and primary cancer specimens 
correlated with a loss of differentiation (Waltregny et al., 2002).  
b) Apoptosis: 
Another way in which aberrant HOX gene expression contributes to tumourgenesis is 
through activating anti-apoptotic pathways. This was first described in breast cancer 
where deficient p53 expression in breast cancer cell lines and primary tumours 
correlated with methylation of the HOXA5 promoter and loss of HOXA5 expression. 
HOXA5 binding sites were found in the promoter region of the TP53 tumour 
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suppressor gene, and transient transfection of HOXA5 activated the p53 expression 
in the breast cancer cell lines, MCF-7 and ZR75.1, which led to increased rates of 
apoptosis (Raman et al., 2000). HOXA5 can also induce apoptosis independently of 
p53 pathways through activation of caspase-2 and caspase-8 mediated apoptosis 
(Chen et al., 2004a). HOXA10 was also found to have a similar role to HOXA5 by 
activating p53 expression in breast cancer cells. This is likely to happen through 
oestrogen-HOX signalling as oestrogen can upregulate the expression of HOXA10 in 
these ER+ breast cancer cells (Chu et al., 2004).  
c) Proliferation: 
HOX genes can also induce cellular proliferation of cancer cells. In human mammary 
carcinoma cells, increased expression of human growth hormone (hGH) increases the 
expression of HOXA1 which results in a decreased apoptotic response, increased 
proliferation and metastatic potential (Zhang et al., 2003). HOX activity seems to 
show tissue specificity, for example, downregulation of HOXD10 in breast cancer 
(Carrio et al., 2005) and HOXB13 in colorectal cancer (Jung et al., 2005) increases 
proliferation, whereas upregulation of HOXC9 and HOXD10 in lung cancer is 
associated with increased proliferation (Plowright et al., 2009).  
d) Invasion and EMT: 
HOX genes have also been implicated as causal factors of the invasive properties of 
cancer cells. HOXB7 is found overexpressed in bone metastases and primary breast 
tumours, and cells transfected with HOXB7 gained many features of EMT. This 
included the loss of adhesion molecules and changes in cell morphology and 
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cytoskeleton arrangement (Wu et al., 2006). EMT is a biological process of the 
morphogenesis of various tissues during embryogenesis where polarized epithelial 
cells undergo multiple biochemical changes that enable them to assume a 
mesenchymal cell phenotype to facilitate migration through the ECM. It is 
hypothesised that cancer cells undergo an EMT-like process in order to promote ECM 
invasion and distant metastasis (Thiery, 2009). In breast cancer cells, HOXB9 was 
shown to transactivate the production of transforming growth factor- β (TGF-β), ErbB 
ligands and several angiogenic factors leading to EMT, invasion, and angiogenesis 
(Hayashida et al., 2010). 
 
1.2.4.1 Ovarian Cancer Stem Cells (CSCs) 
The most widely accepted hypothesis of carcinogenesis is that cancers are driven by 
a subset of highly tumorigenic cells with stem-cell like properties known as CSC which 
have the acquired property of sustaining growth from the neoplastic clone. As 
mentioned previously (1.2.3), CSC possess the properties of normal stem cells, like 
self-renewal and multi-lineage differentiation, but also possess properties such as 
high motility, increased proliferative rate and drug resistance. Like normal stem cells, 
CSCs attain their capacity for self-renewal and differentiation through symmetric and 
asymmetric division. Symmetric division yields a cell which has the ability to 
proliferate indefinitely, and is therefore responsible for tumour maintenance. 
Asymmetric division however yields a progenitor cell that differentiates into the 
ultimate tumour phenotype after mitotic divisions. It is these cells which constitute 
the bulk of the tumour and due to their fast growing nature are readily affected by 
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chemotherapy. However, the CSCs are able to escape the effects of chemotherapy 
due to molecular pathways which protect the CSC from apoptosis. Due to the 
expression of membrane efflux transporters of CSCs, standard chemotherapy fails to 
target these tumour progenitors, they therefore remain in the G0 phase and lay 
dormant in their microenvironment – the stem cell ‘niche’. This can explain tumour 
relapse after chemotherapy. Drug resistance is a major obstacle in the treatment of 
ovarian cancer, initially advance ovarian cancer is generally responsive to 
chemotherapy agents (carboplatin and Paclitaxel), however very often this is 
followed by tumour recurrence with a drug-resistant phenotype.  
 
EMT has been tightly linked to the biology of stem-like cells with a series of studies 
showing that induction of EMT can generate cells with stem cell properties (Mani et 
al., 2008, Gupta et al., 2009). EMT has been associated with the early progression of 
cancer as cells gain an increased migration capacity and invasiveness (Thiery, 2002), 
resulting in tumour metastasis (Hollier et al., 2009), and drug resistance (Wang et al., 
2010). As mentioned previously (1.2.4d), HOX genes have been implicated in the 
induction of EMT. The known signals for inducing EMT are multiple and diverse and 
some of which are also regulators of HOX gene expression, including FGF, β TGF-β, 
oestrogens, Wnt and Snail signalling (Thiery, 2009). In ovarian cancer cells it has been 
shown that TFG-β induces tissue transglutaminase 2 (TG2)-regulated EMT resulting 
in the induction of metastasis (Cao et al., 2012). Therefore, with drug resistance being 
a major problem in the treatment of ovarian cancer, further understanding of ovarian 
cancer stem cells is needed. With HOX genes being implicated in EMT and normal 
stem cell expansion and differentiation, along with the growing evidence of aberrant 
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expression of HOX genes in cancerous tissue, it is logical to suggest that they are also 
playing a role in the regulation of CSC.  
 
1.2.4.2 HOX genes and Ovarian Cancer 
As discussed previously (section 1.2.2.2), four HOX genes, HOXA9, HOXA10, HOXA11, 
and HOXA13 are expressed along the Müllerian duct axis of the female reproductive 
system. These tandemly arranged HOX genes are expressed uniformly in early 
embryonic development however in adults their expression becomes spatially 
restricted to particular organs, important for preserving a high level of developmental 
plasticity of the female reproductive system due to the dramatic structural and 
functional changes which occur during the oestrous cycle and pregnancy (Taylor et 
al., 1997). It is thought that inappropriate expression of these genes is an early step 
in EOC and induces the aberrant epithelial differentiation observed. A study by Cheng 
et al. (Cheng et al., 2005) used immunohistochemical analysis of biopsied tissue to 
show that the HOX genes which normally regulate Müllerian duct differentiation 
were not expressed in normal OSE but were expressed in EOCs. The HOX expression 
pattern appears to determine the histological identity of EOCs with serous papillary, 
endometrioid and mucinous tumours showing overexpression of HOXA9, HOXA10 
and HOXA11, respectively (Cheng et al., 2005). Another HOX gene, HOXA7, was 
reported to be aberrantly expressed both at the RNA level and at the protein level in 
ovarian cancer tissues which display Müllerian-like characteristics, however little or 
no expression was found in undifferentiated ovarian carcinomas and normal OSE  
(Naora et al., 2001a). When expressed ectopically in an undifferentiated ovarian 
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mouse tumour, HOXA7 was shown to promote the ability of HOXA9, HOXA10 and 
HOXA11 to induce Müllerian differentiation rather than induce lineage specificity 
itself (Naora et al., 2001a, Cheng et al., 2005). These results suggest HOXA7 plays a 
role in epithelial differentiation of OSE in EOCs, although Ota et al. (2007) found 
HOXA7 overexpression in all ovarian carcinomas tested, including undifferentiated 
subtypes. This could suggest that HOXA7 is associated with Müllerian differentiation 
but is not sufficient to maintain it. 
 
Several other studies have reported altered HOX gene expression in ovarian 
carcinomas when comparing to normal OSE (Naora et al., 2001a, Yamashita et al., 
2006, Ota et al., 2007) however, there are some discrepancies. Naora et al. (2001) 
(Naora et al., 2001b) found HOXB7 was expressed at higher levels in ovarian 
carcinomas compared to normal OSE. This was supported by a later study by 
Yamashita et al. (2006) (Yamashita et al., 2006) who created an expression profile of 
HOX genes in ovarian-derived samples. In this study overexpression of sixteen HOX 
genes in ovarian cancer cell lines were found, the most common being HOXB7, 
HOXA13 and HOXB13. Overexpression varied between cell lines but of these sixteen 
genes, HOXA10, A13, B4, B7, B13 and C13 showed little or no expression in normal 
tissue (Table 1.3).  
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Table 1.3. Study of the overexpression of HOX genes in ovarian cancer cell lines by 
quantitative real time RT-PCR 
 Cell line 
HOX gene SKOV-3 CaOV3 JHOC-6 SMOV2 ES-2 
A3 - - - 2.0 - 
A4 - - - - 2.0 
A7 - 2.1 - - - 
A10 12.1 13.3 3.5 - 12.6 
A13 >300 >300 >300 >300 >300 
B2 9.2 - - - 4.1 
B3 6.6 - - - - 
B4 267 44.9 - 141.8 91.8 
B5 14.9 - - - - 
B6 9.4 - - - - 
B7 >300 >300 >300 >300 >300 
B8 47.6 - 3.2 - - 
B9 6.1 3.1 3.0  5.6 
B13 >300 >300 >300 >300 >300 
C13 - 3.3 - - - 
D13 3.6 - - - - 
Note: Numbers indicate folds of expression level of each HOX gene in cancer cells 
compared with the expression in normal samples. 
(Yamashita et al., 2006). 
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Slightly different results were found in a more recent study by Hong et al. (2010) 
(Hong et al., 2010). In this study the expression of thirty-six HOX genes in ovarian 
cancer cell lines and tissues were compared to normal ovarian tissue, revealing a 
difference in expression of eleven HOX genes (HOXA7, B3, B4, B6, C10, C11, D1, D3, 
D10, D11 and D13). Of these eleven genes, HOXB4 was the only HOX gene showing 
significantly higher levels of expression in ovarian cancer cell lines than in normal 
ovarian tissue (p=0.029). Its expression was confirmed at protein level by Western 
blot analysis, with exclusive expression in all four ovarian cancer cell lines and all 
seven ovarian cancer tissue samples and not in the normal ovarian tissues. HOXB4 
has also been implicated as a cancer-related gene in other malignancies including 
breast cancer, leukaemia, osteosarcoma and lung cancer (Bodey et al., 2000b, Zhang 
et al., 2008, Bodey et al., 2000c, Bodey et al., 2000a). The main limitations of these 
studies are the use of ovarian cancer cell lines only, or a very limited number of 
carcinoma tissues used. Furthermore, some studies have only focused on selected 
HOX genes, missing valuable data on the whole HOX gene network.  
 
The recent genomic analysis of HGS ovarian cancer (HGS-OvCa) by TCGA found a 
number of somatic copy number alterations, and among the focally amplified regions 
found included three members of the HOXB family HOXB2, B5 and B8. The group 
divided HGS-OvCa into four expression subtypes ‘immunoreactive’, ‘differentiated’, 
‘proliferative’ and ‘mesenchymal’ on the basis of gene content, and high expression 
of HOX genes were characteristic of the mesenchymal subtype (TCGA, 2011). These 
HOXB genes were among those found overexpressed in HGS tumour samples in this 
study, supporting an oncogenic role of HOXB genes in ovarian cancer. 
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1.2.4.2.1 Function of HOX genes in ovarian cancer  
In addition to phenotypic determination, the functions of a number of HOX genes in 
ovarian cancer have been investigated.  
a) Tumour Growth 
In addition to phenotypic determination, HOX genes are thought to play a role in the 
oncogenesis of ovarian cancer. HOXB7 overexpression in immortalised OSE cells was 
shown to upregulate basic fibroblast growth factor (bFGF). bFGF is a potent mitogenic 
and angiogenic factor, although in this study it should be noted that the majority 
(95%) of bFGF protein was intracellular and a relatively limited amount may therefore 
be available for cell to cell signalling (Naora et al., 2001b). HOXB13 has also been 
shown to enhance the proliferation of the ovarian cancer cell lines SKOV-3 and 
OVCAR5 in vivo, and to promote the growth of a mouse ovarian cancer cell line in vivo 
and in vitro (Miao et al., 2007a). This oncogenic function of HOXB13 is thought to 
require activated ras, as HOXB13 promoted tumourgenesis in ovarian cancer cell lines 
containing genetic alterations in p53, myc and K-ras but not in cell lines containing 
genetic alterations in p53, myc and Akt. In this ras activated cell line, HOXB13 also 
conferred resistance to tamoxifen-mediated apoptosis suggesting a pro-survival role 
in ovarian cancer.  
 
HOXA10 is also strongly expressed in ovarian clear cell adenocarcinomas (OCCA) (Li 
et al., 2009, Cheng et al., 2005) but not expressed in normal ovarian epithelia, ovarian 
serous adenocarcinomas, or endometrial cysts (Li et al., 2009). HOXA10 has been 
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shown to promote proliferation, migration and invasion of ovarian clear cell 
adenocarcinoma cells (Li et al., 2009).  
As well as a proposed determinant of histological subtype in ovarian cancer HOXA9 
overexpression has been linked to promoting EOC growth. HOXA9 promoted tumour 
growth in vivo, but did not stimulate ovarian cancer cell growth in vitro. Instead 
HOXA9 induced normal peritoneal fibroblasts to express markers of cancer-
associated fibroblasts (CAFs) which in turn stimulated EOC and endothelial cell 
growth. Similarly, expression of HOXA9 in EOC cells induced normal adipose- and 
bone marrow–derived mesenchymal stem cells (MSCs) to acquire features of CAFs. 
These effects of HOXA9 were due in part to its transcriptional activation of the gene 
encoding TGF-β2 that acted in a paracrine manner on peritoneal fibroblasts and MSCs 
to induce CXCL12, IL-6, and VEGF-A expression. These results indicate that HOXA9 
expression in EOC cells promotes a microenvironment needed for tumour growth (Ko 
et al., 2012).  
b) Cell motility and spreading  
In addition to promoting proliferation, HOXB7 and HOXB13 are also thought to be 
associated with the invasive characteristics of ovarian cancer cells. This invasive 
ability was investigated in a study by Yamashita et al. (2006) using the invasive cancer 
cell line SKOV-3, which overexpresses HOXB7 and HOXB13. Antisense HOXB7 and 
HOXB13 fragments were introduced into SKOV-3 cells which resulted in an 85% and 
50% reduction of motility, respectively, suggesting a role in cancer cell invasion. 
However, as invasion was not completely suppressed, the function of these HOX 
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genes may be redundant and complemented by closely related genes such as 
HOXA13, which was also overexpressed in this cell line.  
Invasive EOC cell lines also show overexpression of HOXA4 compared to non-invasive 
cell lines, suggesting a possible role for HOXA4 in promoting migration and invasion. 
However a number of studies have indicated that the role of HOXA4 could be 
invasion-suppressive as siRNA-mediated knockdown of HOXA4 enhanced cellular 
motility in normal OSE cells treated with epithelial growth factor (EGF) (Ota et al., 
2009), although it had no effect on the basal levels of migration in the absence of 
EGF.  This finding was supported in part by Klausen et al. (2009) where knockdown of 
HOXA4 in OVCAR-3 and OVCAR-8 cells increased migration (although not Matrigel 
invasion). HOXA4 knockdown also reduced cell-cell adhesion and β1-integrin protein 
level within cell colonies, suggesting β1-integrin has a role in mediating these 
changes. Intriguingly, these changes in protein level are not reflected at the RNA 
level, indicating that the effect of HOXA4 on β1-integrin and hence cell motility may 
be through an indirect mechanism.  Taken together these findings suggest that 
HOXA4 is indeed primarily a suppressor of invasion, and it is possible then that the 
increased HOXA4 expression observed in invasive cell lines may be linked to a 
tumour-suppressive response. 
 
c) DNA Repair 
HOXB7 is one of the HOX genes which shows a markedly higher expression in ovarian 
cancer cell lines compared to normal ovarian epithelia (Naora et al., 2001b) and 
promotes growth in ovarian epithelial cells (Cheng et al., 2005).It also plays a novel 
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role in DNA double strand break repair through interacting with proteins that act as 
genomic caretakers, including members of the DNA-dependent protein kinase 
haloenzyme, Ku70, Ku80 and DNA-PKcs (Rubin et al., 2007). Binding of HOXB7 to such 
haloenzymes endogenously and exogenously increased DNA repair through 
poly(ADP) ribose polymerase (PARP) activity. Different HOXB7 expressing breast 
cancer cell lines exposed to ionising radiation (IR) showed enhanced end-joining 
product formation and enhanced double-strand break repair whereas non-malignant 
cell lines that were transfected with a HOXB7 expression vector developed increased 
resistance to killing by IR.  Correspondingly, chromosomal damage was reduced 
following IR and less residual damage was seen in cells expressing HOXB7, an effect 
which could be reversed by HOXB7 silencing. These findings suggest that HOXB7 
could be a potential target for therapies that enhance IR cell killing.  
 
1.2.4.3 HOX genes as potential biomarkers and prognostic markers 
Circulating autologous antibodies to tumour antigens have a potential of acting as 
diagnostic biomarkers for the detection of early stage cancers. The search for an 
ovarian tumour antigen has been researched by Naora et al (2001). In this study, the 
SEREX methodology (serological identification of antigens by recombinant expression 
cloning) was used to screen tumour cDNA expression libraries using ovarian cancer 
patient serum. HOXB7 was one of the HOX genes found in this screen, with significant 
serological reactivity to HOXB7 in thirteen of the thirty-nine ovarian cancer patients 
and in one healthy female, suggesting the detection of anti-HOXB7 antibodies could 
act as a possible diagnostic tool (Naora et al., 2001b, Yamashita et al., 2006). 
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However, further research using larger sample number sizes and correlation studies 
of titre of anti-HOXB7 with disease stage is needed. Similar methodology applied to 
the serum of patients with serous ovarian carcinomas identified the HOXA7 gene as 
a potential biomarker of this disease (Naora et al., 2001a). A promising prognostic 
marker for OCCA is HOXA10 overexpression as this is strongly correlated with poor 
survival and not expressed in normal OSE (Li et al., 2009).  
 
HOX genes showing markedly higher expression in ovarian cancer cell lines and 
cancer tissue specimens compared to the normal ovaries also have the potential of 
acting as prognostic markers, these include HOXB4 (Hong et al., 2010) and HOXB7 
(Rubin et al., 2007). In microarray analysis of ovarian tissues, HOXA5 and HOXA9 were 
both shown to be overexpressed (Bahrani-Mostafavi et al., 2008). HOXA5 has been 
found to act as a tumour suppressor in breast tissue by transactivating the p53 gene 
(Raman et al., 2000) to induce apoptosis by p53-dependent and p53-independent 
mechanisms (Chen et al., 2004b). A possible tumour-suppressor role for HOXA5 is 
also supported by low HOXA5 expression in breast (Raman et al., 2000) and lung 
(Shiraishi et al., 2002) cancer tissues which is thought to be mediated by methylation 
of the CpG island located on the 5’ end of the HOXA5 gene (Raman et al., 2000). As 
HOXA5 was found overexpressed in ovarian cancer samples this may suggest a tissue-
specific role of HOXA5 or a result of the cells attempt to disrupt the transformation 
process by initiating an apoptotic cascade.  
 
In addition to expression profiling, epigenetic alterations associated with ovarian 
carcinogenesis have been studied (Teodoridis et al., 2005, Muller et al., 2004, Wei et 
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al., 2006). The most common molecular alteration in human neoplasia is DNA 
methylation (Laird, 2003) and this  could possibly act as prognostic marker. Fiegl et 
al. (2008) analysed the DNA methylation of 71 genes in 22 ovarian cancers and 18 
non-neoplastic samples and identified the best discriminators between cancer and 
non-neoplastic tissue being HOXA10 and HOXA11. In particular HOXA11 methylation 
was strongly associated with poor outcome, suggesting a role for DNA methylation 
as a prognostic marker in ovarian cancer. A more recent study has shown that 
increased expression of HOXA10 is present in ovarian carcinomas as a result of 
promoter hypomethylation of HOXA10 (Cheng et al., 2010). This could also act as a 
prognostic factor in ovarian cancer as well as a possible therapeutic target, for 
example by using drugs that can reverse epigenetic changes. 
 
1.2.4.3.1 Clinical relevance 
 
Research into the clinical role of HOX genes in ovarian cancer is limited. Nuclear 
HOXA7 protein expression was related to longer disease-specific survival in an 
analysis of 512 ovarian carcinomas of different histological type (Ota et al., 2007). 
HOXA10 protein overexpression was related to poor survival in analysis of twenty-
nine clear cell carcinomas (Li et al., 2009). HOXA9 overexpression has been linked to 
poor outcomes in patients with EOC and in mouse xenograft models of EOC (Ko et al., 
2012). HOXA11 gene hypermethylation was strongly associated with higher volume 
of residual disease and poor relapse-free survival, being an indicator of poor overall 
survival (Fiegl et al., 2008). One study has analysed the protein expression and clinical 
relevance of HOXB5 and HOXB8 in malignant effusions from 286 patients with 
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advanced-stage serous ovarian cancer (Stavnes et al., 2013). Findings show HOXB5 
expression was higher in effusions compared to solid lesions, as well as in post-
chemotherapy disease recurrence effusions compared to pre-chemotherapy 
effusions. This suggests an involvement of this HOXB5 in metastasis to effusions and 
disease progression in serous ovarian cancer. A study by Wu et al., (Wu et al., 2003) 
found that HOXB5 acts as a potential transcriptional regulator of flk-1, a receptor for 
VEGF, indicating a role for HOXB5 in early angiogenesis which would support its 
potential role in metastatic development in serous ovarian cancers. HOXB8 
expression was higher in primary carcinomas and solid metastases compared to 
effusions, and associated with poorer outcome (Stavnes et al., 2013).  
 
 
1.2.4.4 Targeting the HOX/PBX interaction 
 
The high level of HOX gene dysregulation makes these potential targets for 
therapeutic intervention. Targeting specific HOX genes is problematic due to the 
functional redundancy between proteins. However, targeting the HOX/PBX dimer is 
a more effective way to impact the function of multiple HOX genes.  One possible 
method is a use of a peptide that disrupts the interaction between HOX proteins and 
co-factor PBX, in order to block the function of PBX-dependent HOX functions. HXR9 
is a small peptide designed to mimic the hexapeptide sequence found in HOX proteins 
of paralogue groups 1- 8 (Phelan et al., 1994, Chang et al., 1995, Shanmugam et al., 
1997, Piper et al., 1999, Morgan et al., 2000, Medina-Martínez and Ramírez-Solis, 
2003), therefore acting as a specific competitive inhibitor of the HOX/PBX interaction. 
This prevents the formation of HOX/PBX dimers and subsequent binding to target 
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DNA sequences, in effect inhibiting the transcription of target genes (Figure 1.8). To 
enable HXR9 to enter cells, a polyarginine (R9) sequence is linked to the hexapeptide 
which has previously been shown as an effective delivery system (Jiang et al., 2004). 
Previous studies have shown that HXR9 is capable of blocking this interaction in vitro 
and in vivo (Morgan et al., 2007, Plowright et al., 2009, Morgan et al., 2010) and 
antagonising the HOX/PBX interaction induces apoptosis (Morgan et al., 2007, Shears 
et al., 2008, Plowright et al., 2009, Morgan et al., 2010, Morgan et al., 2012). 
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Figure 1.8. Blocking HOX/PBX dimerisation with the small peptide HXR9.  HXR9 is a 
small peptide which mimics the hexapeptide sequence of HOX proteins, acting as a 
competitive inhibitor of HOX/PBX binding. This hexapeptide sequence is linked to 
nine arginine residues to allow cell membrane penetration.  
 
Changes in gene transcription after HXR9 treatment of melanoma cells was 
investigated by microarray analysis to reveal twenty-two genes that had a significant 
increase in transcription (p < 0.05). This increase was confirmed by quantitative PCR 
and the upregulated genes were oncogenes Fos and Jun (Morgan et al., 2007). These 
are members of the bZIP superfamily of transcription factors, characterised by a basic 
DNA-binding domain combined with a leucine zipper region (Hess et al., 2004). JUN 
proteins can form homodimers or heterodimers with FOS proteins to make the 
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activating protein (AP-1) transcription factor. AP-1 mediates the regulation of genes 
controlling a number of physiological functions including cell proliferation and 
differentiation, apoptosis and neoplastic transformation (Ameyar et al., 2003, Eferl 
and Wagner, 2003, Jochum et al., 2001, Shaulian and Karin, 2001, Shaulian and Karin, 
2002). Upregulation of Fos expression is a key event in HXR9-mediated apoptosis. 
Cells treated with antisense oligonucleotides that were complementary to Fos prior 
to HXR9 treatment (which would lead to ablation of Fos RNA), showed a decreased 
level of apoptosis compared to cells treated with a non-targeting oligo control 
(Morgan et al., 2007). The exact mechanism of AP-1 mediated apoptosis is unclear, 
however, AP-1 complexes containing JUN promote the transcription of Fas ligand 
(FasL) which promotes cell death through the FasL/Fas receptor pathway in lymphoid, 
fibroblast and neuronal cells (Eichhorst et al., 2000, Kasibhatla et al., 1998a, Kolbus 
et al., 2000, Le-Niculescu et al., 1999, Matsui et al., 2000). In prostate cancer cells, 
JUN and FOS heterodimerisation has shown to repress the transcription of cellular-
FLICE-inhibitory protein long isoform [c-FLIP(L)], an anti-apoptotic molecule, which 
resulted in the sensitisation of resistant prostate cancer cells to tumour necrosis 
factor–related apoptosis-inducing ligand (TRAIL) induced apoptosis (Li et al., 2007, 
Zhang et al., 2007). Overexpression of Fos in hepatocytes induces apoptosis (Mikula 
et al., 2003) and in hepatoma cells is required for Myc-induced cell death (Kalra and 
Kumar, 2004). Fos re-expression in a number of established tumour cell lines show 
the activation of pro-apoptotic genes which uses a different mechanism that does 
not involve Jun (Fleischmann et al., 2003). In prostate cancer cells, in addition to Fos 
and Jun, other genes were upregulated in response to HXR9 treatment, these being 
82 
 
Dusp1, Aft3, Transcription factor Krüppel-like factor 4 (KLF4), Mad and Drak2. Dusp1 
encodes dual specificity phosphate 1 which dephosphorylates serine, threonine and 
tyrosine residues from a wide range of substrates, such as mitogen-activated protein 
kinases (MAPKs), which play essential roles in the MAPK signalling pathway that 
regulate cell division and cell growth. Dephosphorylation of these kinases leads to 
inactivation of this pathway (Ducruet et al., 2005). 
 
Aft3 is a member of the activating transcription factor/cyclic AMP-response element 
binding protein family of transcription factors, which are known for roles in stress 
response, including DNA damage. Aft3 has shown to promote tumour suppressor 
functions by stabilising p53 through the prevention of ubiquitination, inducing cell 
cycle arrest and apoptosis in response to stress, and blocks ras-mediated 
transformation (Yan et al., 2005, Yan and Boyd, 2006, Lu et al., 2006). KLF4 is a tumour 
suppressor gene known to be downregulated in colorectal cancers and has been 
shown to interact with β-catenin and inhibit oncogenic activity. Expression prevented 
xenograft tumour growth in athymic nude mice (Zhang et al., 2006a). Mad, an 
inhibitor of another oncogenic transcription factor myc, also has a role in blocking 
cellular proliferation (reviewed in (Rottmann and Luscher, 2006)). And finally 
upregulation of Drak2 was also seen. This is a serine/threonine kinase which has a 
high degree of sequence and function homology with the death-associated kinases 
involved in apoptosis and has shown to induce apoptosis when overexpressed in the 
fibroblast cell line NIH 3T3 (Sanjo et al., 1998).  
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As the expression of tumour suppressor and pro-apoptotic genes increases after 
HXR9 treatment in malignant cells, this suggests that some of the overexpressed HOX 
genes found in these cells may function to inhibit intrinsic tumour suppressing 
pathways and create a pro-tumour environment. Targeting the HOX/PBX interaction 
is therefore an important target in cancer therapy, and further investigation into the 
extent of HOX deregulation in ovarian cancer cancers is needed to determine 
whether HXR9 is a potential treatment option.   
 
1.3 Chorioallantoic membrane (CAM) model 
 
One of the major obstacles in ovarian cancer research is the lack of reliable ovarian 
cancer models. New drugs are usually tested in cell lines and engineered animal 
models that often do not represent the true heterogeneity and complexity of human 
ovarian tumours. The most commonly used animal model to study ovarian cancer is 
subcutaneous or intraperitoneal injection (ip) of tumour cells into nude mice, but this 
model has its limitations. A less commonly used model for the study of cancers is the 
chick CAM model. This model was first introduced to study the behaviour of 
mammalian tumours by Murphy a century ago (Murphy, 1913). It involves the 
grafting of cancer cells on to the CAM of a fertilized chick egg for short-term 
investigations. It represents an intermediate state between in vivo and in vitro 
systems and addresses some of the limitations faced with previously used animal 
models.  
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1.3.1 Chick embryo and the CAM 
 
Chick embryo development lasts 21 days before hatching. The first day of incubation 
is considered as day 1 of embryonic development, termed as embryonic day (ED). 
Three extra-embryonic membranes which protect and nourish the embryo are 
formed during development: the yolk sac membrane, the amnion, and the CAM. The 
CAM is formed during ED4 to 5 by the fusion of the mesodermal layers of both the 
allantois and the chorion, which results in a transparent and highly vascularised 
membrane, composed of arteries, veins, and an intricate capillary network (Ribatti et 
al., 2001, Samkoe and Cramb, 2003). Capillary proliferation continues rapidly until 
ED11, when the mitotic index dramatically decreases and growth rate is minimal. The 
vascular system of the chick embryo attains its final arrangement on ED18. The main 
function of the CAM is to serve as the respiratory organ for the embryo, mediating 
the exchange of gas and nutrients until hatching. The CAM is connected to the 
embryonic circulation by the allantoic arteries and veins (Ribatti et al., 2001). The 
chick embryo immune system does not start to develop until ED11 where the 
presence of T cells are first detected. Prior to this, the embryo is not fully 
immunocompetent, lacking both B and T cell-mediated immune functions. By ED12 
B-cells are detected, mononuclear phagocytes are found in the yolk sac, spleen, 
bursa, gut, thymus, and in the liver; and reticulum cells are present in the spleen and 
liver (Janse and Jeurissen, 1991). After ED15 the B cell repertory begins to expand 
and by ED18 the chick embryo is fully immunocompetent (Ribatti et al., 2001).  
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1.3.2 Advantages and limitations of using the CAM model for the study of 
ovarian cancer 
 
 
Since the lymphoid system in the chick is not fully developed until the late stages of 
incubation, the chick embryo serves as a naturally immunodeficient host which can 
tolerate inoculation of a variety of tumours without specific or non-specific immune 
responses or species-specific restrictions (Armstrong et al., 1982, Murphy, 1913, 
Ossowski and Reich, 1980). It therefore avoids the problem of lack of tumour 
establishment often encountered in ip xenografts in mice. This lack of establishment 
is thought to be attributed to variable immunocompetence of the recipient mice 
(Elkas et al., 2002) and also to the absence of a structural support and interactions 
with extracellular matrices for the cells.  The CAM model provides a unique 
supportive environment for primary tumour formation and cells seeded onto the 
CAM are able to rapidly develop into vascularised micro-tumours with organoid 
structures within several days following cell grafting. This is due to the rich supply of 
blood vessels and capillaries present in the CAM. As the CAM is connected to the 
embryo through a continuous circulatory system, it is also an ideal model to study 
cancer cell metastasis.   
 
Another limitation of mouse xenograft models is the location of the tumour and their 
ability to mimic the human disease. Microarray studies have shown that the gene 
expression profiles of cancer cells vary significantly depending on tumour location 
(Hao et al., 2004, Margalit et al., 2003, Yanagawa et al., 2001). The microenvironment 
of the ovary influences cell behaviour and it is therefore important to use a model 
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that is representative to the human disease to accurately study the cellular and 
molecular changes associated with the initiation and progression of human ovarian 
cancer. Subcutaneous or ip xenografts do not mimic the ovarian microenvironment, 
however, orthotopic injection of cancerous cells do. This procedure involves an 
injection of cancer cells into the rodents ovarian bursa, the sac surrounding the 
ovaries. This more accurately represents human disease as this is where ovarian 
cancer normally progresses, providing an ovarian microenvironment, however this 
procedure is less commonly used. The ECM constitution of the CAM, consisting of 
fibronectin, laminin, collagen type I and integrin ανβ3 (Giannopoulou et al., 2001), is 
similar to the peritoneum which is the membrane that surrounds the ovaries. This 
has allowed the CAM model to be successfully used to transplant newborn mouse 
ovaries (Gigli et al., 2005) and foetal bovine ovarian cortical tissue (Gigli et al., 2005, 
Cushman et al., 2002).  In addition, the CAM assay has high reproducibility and is cost 
effective, making it more favourable than subcutaneous xenografts. For the use in 
cancer research the CAM model provides convenient exposure of the implantation 
site with low invasiveness, and allows continuous visualisation of the implantation 
site.  
 
However, the CAM model does harbour some limitations. Due to the limited 
experimental window, the tumours have a maximum of 12 days of growth and in 
some cases the size of the tumour upon excision is less than 5mm in diameter. 
Therefore the type and number of sequential investigations that can be performed 
may be limited. The lack of an immune system until the late stages of development 
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(fully immunocompetent by day 18) prevents investigations of tumour-host immune 
system interactions, which is an important feature needed to mimic a true ovarian 
microenvironment seen in ovarian cancer patients, however, many mouse models 
used in cancer research are immunocompromised. In addition, as the mice model is 
considered the ‘gold standard’ for in vivo biological studies, chicken specific 
antibodies are limited and this can hinder experimental design potential.  
 
 1.3.3 Applications of the CAM in cancer research 
 
Since the use of the CAM model to study the behaviour of mammalian tumours by 
Murphy almost a century ago, the model has been used to monitor the growth and 
metastatic properties of various cancer cell lines (Armstrong et al., 1982, Ossowski 
and Reich, 1980). It is an excellent model to study the molecular mechanisms involved 
in the metastatic process as in vitro and in vivo experimental models cannot 
completely reproduce and characterize each step. In addition the model has been 
used as a rapid and efficient in vivo system for the evaluation of compounds designed 
to inhibit tumour growth. These have included tumours grown from human 
melanoma, breast cancer and leukaemia cell lines (Brooks et al., 1994, Chen et al., 
2007a).  
 
1.3.3.1 The CAM model of ovarian cancer 
 
The CAM assay has previously been used to study tumour angiogenesis and invasion 
in bowel cancer (Cecilia Subauste et al., 2009, Demir et al., 2009), glioma (Strojnik et 
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al., 2010, Balciuniene et al., 2009, Hagedorn et al., 2005), prostate cancer (Kobayashi 
et al., 1998, Wittig-Blaich et al., 2011, Conn et al., 2009), leukaemia (Taizi et al., 2006) 
and osteosarcoma (Balke et al., 2010), however there has only been two studies have 
used the CAM assay to assess ovarian cancer invasion and metastasis (Chang et al., 
2011, Lokman et al., 2012).  
 
 
1.3.4.2 Anti-cancer drug testing 
 
The advantage of rapid and effective tumour growth along with easy access to the 
tumour site makes the CAM an ideal model to test anti-cancer properties of novel 
drugs. The CAM assay is a closed system, and this makes the half-life of many 
experimental molecules such as small peptides much longer in comparison to animal 
models, allowing experimental study of potential compounds that are only available 
in small quantities (Tufan and Satiroglu-Tufan, 2005, Cimpean et al., 2008). Test 
reagents can be applied topically, injected intratumourally (IT) or intravenously (IV) 
and the effect on tumour growth and angiogenesis can be easily observed and 
measured. For example, the model was used to evaluate the effect of doxorubicin on 
tumours grown from a leukaemia cell line on the CAM and resulted in significant 
tumour regression following a single administration of doxorubicin (Taizi et al., 2006). 
The experimentation of novel drugs to induce cell death of ovarian cancer cells have 
not been performed previously.  
 
 
89 
 
Aims of this project 
 
The hypothesis of this project is that HOX genes and their products are potential 
therapeutic targets in ovarian cancer.  
The project will evaluate HOX gene expression in a number of ovarian cancer cell lines 
of different histological subtypes including HGS, endometrioid and clear cell as well 
as in normal ovarian and fallopian tube epithelial. HOX gene expression will also be 
examined in a large series of primary epithelial ovarian and primary peritoneal 
tumours and their correlation with clinical characteristics will be explored. The next 
part of the project will look into targeting the HOX/PBX dimer as a potential 
treatment for ovarian cancer using cell lines, platinum –sensitive and platinum –
resistant and cells cultured from the ascites of ovarian cancer patients.  The potential 
synergy between HXR9 and standard chemotherapy agent cisplatin will also be 
studied. The chick CAM assay will be explored as an alternative model of ovarian 
cancer to grow tumours derived from established cell lines and from ovarian cancer 
cells cultured from ascites samples of ovarian cancer patients. These ovarian CAM 
tumours will be used to assess the efficacy of HXR9 treatment in vivo.  
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CHAPTER 2. 
 
Materials and Methods. 
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2.1 Clinical data 
A cohort of 99 ovarian cancer patients with corresponding age, tumour stage, time 
to progression (TTP), overall survival (OS), tumour histology and chemotherapy 
information was used in the analysis of primary ovarian tumours. Fresh biopsy tissue 
specimens or ascites samples were obtained during surgery from human subjects 
with ovarian cancer or other gynaecological conditions from the Royal Surrey County 
Hospital, Guildford following informed consent and ethical approval. Tissue samples 
were immediately stored in RNAlater® and stored at -20oC for later use. Each biopsy 
was confirmed by a pathologist to be either cancerous of ovarian origin or normal 
ovarian tissue or fallopian tube. OS and TTP were measured from the date of 
diagnosis. The duration of OS was measured up to the date of death or, for patients 
still alive the 1st October 2012, when statistical analysis was performed. The duration 
of TTP was the minimum amount of time until clinical progression, or death. Only 
cases where causes of death were due to disease were used to calculate OS. All 
sample and data collection received an ethical approval by the institutional ethics 
committee (MREC-09/H1103/50). 
 
2.2 Cell and tissue culture 
 2.2.1 Ovarian cancer cell lines  
 
Human ovarian adenocarcinoma-derived cell line SKOV-3, clear cell carcinoma 
derived cell line TOV-21G and the endometrioid carcinoma derived cell line TOV-
112D were obtained from the American Type Culture Collection (LGC Promochem, 
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Teddington, UK). SKOV-3 cells were cultured in McCoys’s 5A modified medium 
(Sigma, Poole, UK) supplemented with 10% (v/v) heat-inactivated foetal bovine 
serum (FBS) (Invitrogen Ltd, Paisley, UK). TOV-112D and TOV-21G cells were cultured 
in 1:1 mixture of Medium 199 (Invitrogen) and MCDB 105 medium (Sigma) 
supplemented with 1.5g/L sodium bicarbonate, with 15% FBS (Invitrogen). The 
epithelial serous carcinoma cell line derived from peritoneal ascites, COV-318, PEO1, 
PEO4, PEO14, PEO23 cells were obtained from The HPA Cell Culture Collection (HPA, 
Salisbury, UK). These cells were cultured in DMEM medium (Sigma) with 10% heat 
inactivated FBS (Invitrogen) and 2mmol/L of L- glutamine (Sigma). PEA1 and PEA2 
cells were a gift from Euan Stronach (Imperial College London, UK). These cells have 
been authenticated by STR profiling by DDC Medical (London, UK). Cells were 
cultured in DMEM medium (Sigma) with 10% heat inactivated FBS (Invitrogen) and 
2mmol/L of L- glutamine (Sigma).  Each medium was supplemented with 1% penicillin 
(10,000 U/ml)/ streptomycin (10 mg/ml) (Sigma). The cell cultures were maintained 
at 37oC in a humidified, 5% CO2 incubator.   
 
 2.2.2 Culturing cells from ovarian tumour samples  
 
For the isolation of single cell suspensions of primary human ovarian cancer cells from 
patient ovarian tumour tissue; samples were washed in PBS and 0.2g of tumour was 
cut into small pieces and transferred to gentleMACS C tube containing 5mL of serum-
free RMPI with 1% Collagenase/Dispase (0.1U/mL) (Roche, Burgess Hill, UK). The C 
tube was attached to the gentleMACS Dissociator and the program “h_tumor_01”, 
then “h_tumor_02”, and then “h_tumor_03” was run. The tube was incubated for 30 
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min at 37°C with automated rotation before returning to the gentleMACS dissociator 
for a repeat of the three programs. The C tube was detached and left to allow debris 
to settle. The suspension was then strained through a cell strainer attached to a 50mL 
tube and washed through with 1mL of PBS. The 50mL tube was then centrifuged for 
5 minutes at 200g. The pellet was re-suspended in 1mL of serum-free Hanks media 
and transferred to 2mL eppendorf and microcentrifuged for 10 minutes at 200g. The 
supernatant was then discarded and pellet re suspend in 10% RMPI.  
 
 2.2.3 Culturing cells from ascites of ovarian cancer patients  
 
For the isolation of primary human ovarian cancer cells from patient ascites samples, 
20mL of ascetic fluid was mixed with 20mL of growth medium (RPMI supplemented 
with 20% FBS (Invitrogen) with 2mmol/L L-Glutamine (Sigma) and 1% penicillin 
(10,000 U/ml)/ streptomycin (10 mg/ml) (Sigma). Cell suspension was then plated in 
a T75 flask. Red blood cells present in the ascetic fluid did not interfere with cell 
plating. After 3-4 days, when adherent cells are apparent, supernatant was removed 
and fresh growth medium was added. All experiments using primary ovarian cancer 
cells were performed at culture passages 1-8. 
 
2.3 Synthesis of HXR9 and CXR9 peptides  
 
HXR9 is an eighteen amino acid peptide consisting of the previously identified 
hexapeptide sequence that can bind to PBX and nine C-terminal arginine residues 
(R9) that facilitate cell entry (Morgan et al., 2007). The N-terminal and C-terminal 
94 
 
amino bonds are in the D-isomer conformation, which has previously been shown to 
extend the half-life of the peptide to 12 hours in human serum (Morgan et al., 2007). 
CXR9 is a control peptide that lacks a functional hexapeptide sequence but still 
includes the R9 sequence. All peptides were synthesized using conventional column 
based chemistry and purified to at least 80 % (Biosynthesis Inc., USA). 
 
2.4 MTS assay 
 
Cell viability was measured via the MTS assay (Promega, Southampton, UK) according 
to the manufacturer’s instructions. For example, SKOV-3 cells were plated at a 
concentration of 2x104 cells per well in flat bottomed 96-well plates and incubated 
for 24 hours until 70% confluent. For HXR9 treatment cells were then treated for 2 
hours with the active peptide HXR9 or the control peptide CXR9 at a range of dilutions 
then returned to a 37oC, 5% CO2 incubator for 2 hours.  For cisplatin treatment, cells 
were treated with cisplatin (Hospira, Warwickshire, UK) for 72 hours. After exposure 
time, media was removed and CellTiter 96® Aqueous One Solution Reagent 
(Promega, Southampton, UK) was added to each well according to the 
manufacturer’s instructions. Plate was returned to the incubator for 1 hour. Cell 
viability was determined by measuring the absorbance at 492nm using the Beckman 
Coulter DTX Multimode Detector plate reader. The IC50 was determined by plotting a 
dose-response curve. 
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2.5 Analysis of cell death 
 2.5.1 Flow cytometry 
To detect changes consistent with apoptosis the Annexin V-PE apoptosis detection 
kit (BD Biosciences, Oxford, UK) was used according to manufacturer’s instructions. 
Briefly, cells were plated at 2x105 cells per well in a 24-well plate and incubated 
overnight to reach 70% confluency. Cells were then treated for 2 hours with 2% FBS 
media, the control peptide CXR9 or the active peptide HXR9 at the IC50 and double 
the IC50. Cells were then harvested by adding 0.25% (w/v) Trypsin (Sigma) and 
incubating at 37oC, 5% CO2 until detached and dissociated and stained with Annexin 
V-PE and 7-Amino-Actinomycin (7-AAD) Viability Staining Solution. Viable cells with 
intact membranes exclude 7-AAD, whereas the membranes of dead and damaged 
cells are permeable to 7-AAD. Cells that stain positive for Annexin V-PE and negative 
for 7-AAD are in the stages of early apoptosis. Cells staining positive for both Annexin 
V-PE and 7-AAD are either in the end stage of apoptosis, are undergoing necrosis, or 
are already dead. Cells that stain negative for both Annexin V-PE and 7-AAD are alive 
and not undergoing measurable apoptosis. Apoptotic cells were identified using a 
Beckman Coulter Epics XL flow cytometer (argon laser, excitation wavelength 488 
nm, FL-2 and FL-4 detectors). Gating was set up for the following cell populations: a) 
Live cells: Annexin V-PE negative/7AAD negative, b) Early apoptotic cells: Annexin V-
PE positive/7-AAD negative c) Late apoptotic cells: Annexin V-PE positive/7-AAD 
positive and d) Annexin V negative/7-AAD positive.  
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 2.5.2 Caspase-3 assay 
The further confirm the induction of apoptosis, detection of caspase-3 activity was 
carried out using the EnzChek® Caspase-3 Assay Kit#2 (Invitrogen) according to 
manufacturer’s instructions. Briefly, cells were plated at 1x106cells per well in a 6-
well plate and incubated at 37oC, 5% CO2 overnight until 70% confluency was 
reached. Cells were then treated for 2 hours with 2% FBS media, HXR9 at the IC50 or 
equivalent CXR9 concentration. Cells were then harvested by incubating in 0.25% 
trypsin-EDTA (Sigma) at 37oC until detached and dissociated. 1mL of PBS was then 
added to each well and the contents of 2 wells were then transferred to an eppendorf 
tube and microcentrifuged for 5 minutes at 200g. Cell pellets were then re-suspended 
in 1x cell lysis buffer and placed on ice for 30 minutes, disrupting cells every 5 
minutes. Lysed cells were then microcentrifuged at 200g for 5 minutes and 50µL of 
each supernatant was transferred to a well of a 96-well black plate. 50µL of 2x 
working solution was added to each sample and the plate was covered and incubated 
for 30 minutes at RT. The fluorescence was then measured at 492 nm using the 
Beckman Coulter DTX Multimode Detector plate reader.  
 
2.6 Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-
PCR)  
Total RNA from normal human ovarian tissue, catalogue number: CR561072 and 
CR561228, and normal fallopian tube tissue, CR559552 and CR559553, were 
purchased from OriGene (Cambridge, UK). RNA was isolated from SKOV-3, COV-318, 
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PEO1, PEO4, PEO14, PEO23, PEA1, PEA2, TOV-112D and TOG-21G cells and using the 
RNeasy® Plus Mini Kit (Qiagen Ltd, Crawley, UK) following the manufacturer’s 
instructions. Total RNA extracted from ovarian tumour tissue stored in RNAlater® 
(Sigma) was isolated using the gentleMACS dissociator followed by RNA extraction 
using the RNeasy® Plus Mini Kit (Qiagen). 20-30mg of tumour tissue was placed in a 
gentleMACS M Tube (Miltenyi Biotech) containing 600µL of RLT lysis buffer with 1% 
mercaptoethanol and the “RNA_01” programme was selected to run. The tube was 
then centrifuged at 200g for 5 minutes. Supernatant was transferred to a 1.5mL 
eppendorf and microcentrifuged at 200g for 3 minutes. This step is then repeated 
before continuing with the RNeasy® Plus Mini Kit (Qiagen) extraction method. RNA 
purity was verified by the 260nm/280nm absorbance ratio, measured using the 
Nanodrop (Thermo Fisher, MA). Ratios of 1.9-2.0 were considered ‘pure’ RNA as 
described by manufacturer. cDNA was synthesised from RNA using the Cloned AMV 
First Strand Synthesis Kit (Invitrogen) following the manufacturers protocol.  
QRT-PCR was performed using the Stratagene MX3005P Real-Time PCR machine 
(Agilent Technologies UK Ltd, Stockport, UK) and SYBR® Green JumpStart™ Taq 
ReadyMix™ (Sigma). Oligonucleotide primers were designed to facilitate the unique 
amplification of β-actin, and each HOX gene. Relative expression was calculated using 
the Livak comparative Ct method (Heid et al., 1996), normalising HOX gene 
expression to house-keeping gene β-actin to correct for sample to sample variations 
in qRT-PCR efficiency and errors in sample quantification.  β-actin, a cytoskeletal 
protein, was chosen as house-keeping gene on the basis of being a commonly used 
reference gene in RT-PCR in general and in particular ovarian cancer studies (Huggett 
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et al., 2005, Sun et al., 2012). Over or under expression of HOX genes in cancerous 
samples were determined by comparison to ‘normal’ ovarian tissue or ‘normal’ 
fallopian tube deemed non-cancerous by a pathologist at the Royal Surrey Hospital 
or purchased from Origene (Cambridge). Ovarian tissue and fallopian tube were 
chosen as comparative samples as these are considered tissues of origin of ovarian 
cancer.  cDNA samples containing little β-actin shown by a CT value of over 30 were 
not included in analysis as this suggests a poor quality of cDNA.  
 
 
2.7 Chicken embryo chorioallantoic membrane (CAM) assay preparation and 
grafting procedure 
 
Fertilized chicken eggs were purchased from Henry Stewart & Co. Ltd (Fakenham, UK) 
washed and incubated at 37oC with 60% relative humidity on embryonic day (ED) 1, 
for implantation on ED4. The method for the preparation of the CAM was a 
modification of a previously described technique (Ausprunk et al., 1975). Under 
sterile conditions, eggs were washed in 70% ethanol. A small hole was pierced 
through the pointed pole of the shell using a 19G needle and a 2cm diameter window 
of shell was removed to expose the CAM. The membrane was carefully removed with 
sterile forceps to expose the embryo and blood vessels. This window was covered 
with a sterile 10mm tissue culture dish. Between ED7 and ED10 of incubation the 
membranes are ready for grafting. The graft was prepared by suspending cells 
obtained from cell line on ice in Matrigel (BD Biosciences) at a final concentration of 
4 x 106 /25µL.  Cell suspensions of fresh ovarian tumour tissue were obtained at 
different stages of the ‘preparation of single-cell suspension from tumour tissue’ 
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protocol, these being from the strained cell suspension, supernatant of pellet and 
directly from the cell pellet. A large blood vessel was then bruised using a sterile 
cotton bud and 25 µl of the prepared graft, containing 4x106 cells, were then 
inoculated onto this area. After inoculation, the window was then recovered and 
placed back in the incubator. Tumour growth and viability of the embryo was checked 
daily. Diameter of tumour was measured using Dino-Lite digital microscope 
AM413MT with DinoCapture 2.0 software (Dino-Lite, CA, USA). Any dead or 
contaminated eggs were terminated according to schedule I by refrigeration >4 
hours. Between ED17 and ED19 eggs are terminated by refrigeration for >4 hours. 
Tumours were excised and either placed in RNAlater®(Sigma) for RNA extraction and 
qRTPCR or in 4% formaldehyde for 24 hours and embedded in paraffin. Paraffin-
embedded samples were cut into 4µm sections using a Leica RM2125RT microtome 
(Leica, Milton Keynes, UK). Sections were mounted onto flex-coated microscope 
slides and stained with haematoxylin and eosin (H&E) (BD Biosciences). Sections were 
observed under an Olympus photomicroscope (Olympus, Tokyo, Japan) equipped 
with a CCD camera (Princeton Scientific Instruments, Monmouth Junction, NJ). The 
images were analysed using Tricson software (Olympus Italia, Rozzano, Italy). 
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2.8 Immunohistochemistry  
 
 2.8.1 Immunohistochemistry of paraffin embedded tissue 
 
Monoclonal primary antibodies against these gene products were used: Anti-c-Fos at 
dilution of 1:40 (Sigma, #F7799), Cleaved Caspase-3 (Asp175) (5A1), dilution 1:150 
(Cell Signaling Technology, MA, US, #9664L), Anti-human Epithelial Membrane 
Antigen (EMA), dilution 1:100 (Dako, Ely, UK, #IR629), Anti-human Cytokeratin 7 (CK-
7), dilution 1:150 (Dako, #M7018), Anti-human p53 (DO-7) 1:40 (Leica, Newcastle, 
UK, # NCL-L-p53-DO7) and Anti-human Wilms Tumour-1 (WT-1), dilution 1:10 (Leica, 
# NCL-L-WT1-562).  
 
Immunohistochemical staining was performed on 4μm thick, formalin-fixed, paraffin 
embedded tissue sections. Tissue sections were dewaxed with xylene and ethanol. 
The endogenous peroxidase activity of the sections was quenched with 0.3% H2O2 in 
methanol. Antigen retrieval was performed using pH9.0 Tris/EDTA buffer (Dako) and 
heating in a microwave for 12 minutes. Each tissue sample was blocked with horse 
serum (Vectastain Elite ABC kit R.T.U, Vector Laboratories, Peterborough, UK) for 15 
minutes. Avidin solution (Vectastain Avidin/Biotin blocking kit, Vector Laboratories) 
is added to each section for 15mins, after which Biotin solution is added (Vectastain 
Avidin/Biotin blocking kit) for a further 15 minutes. Sections were incubated 
overnight at room temperature with primary antibodies at optimal dilutions. 1%BSA 
PBS was used as a negative control. Positive controls were used as follows: Kidney 
tissue: EMA and WT-1, Tonsil, Cleaved-caspase-3 and CK-7, Breast tissue: P53, and 
Placenta: c-Fos. Subsequently, the tissues sections were incubated sequentially with 
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Universal Biotinylated Anti-Mouse/Rabbit IgG secondary antibody (Vectastain Elite 
ABC kit R.T.U) for 30 minutes, followed by A.B.C reagent (Vectastain Elite ABC kit 
R.T.U) for 30 minutes at room temperature. Immunoreactivity was detected using 
diaminobenzidine/H2O2 (DAB substrate kit, Vector Laboratories). The sections were 
counterstained with 10% haematoxylin (Sigma), dehydrated and coversliped.  
 
 2.8.2 Immunohistochemistry for cells cultured from ascites  
For immunohistochemistry of cells cultured from ascites, 500µl of cell suspension in 
media was added to each well of the BD Falcon™ Chamber slide (BD Biosciences) and 
incubated at 37oC with 5% CO2 until 100% confluency. Cell were then washed in PBS 
and fixed in 4% paraformaldehyde (PFA) for 1 hour at 4oC. PFA was removed and 
500µl of 0.3% H2O2 in methanol was added to each well for 20 minutes. Horse serum 
block (Vectastain Elite ABC kit R.T.U, Vector Laboratories) was added to each well for 
30 minutes. Block was removed and antibody dilution was added to each well and 
incubated overnight at 4oC. Antibody dilutions were made in 1% BSA PBS and 1% BSA 
PBS was also used as a negative control. Antibodies were used at the following 
dilutions: EMA 1:100 (Dako), CK-7 1:150 (Dako), P53 1:40 (Leica) and WT-1 1:10 
(Leica). The SKOV-3 cell line was used as a positive control for EMA, CK-7 and WT-1 
staining. MDA-MB231 was used as a positive control for P53 staining. Subsequently, 
the tissues sections were incubated sequentially with Universal Biotinylated Anti-
Mouse/Rabbit IgG secondary antibody (Vectastain Elite ABC kit R.T.U) for 30 minutes, 
followed by A.B.C reagent (Vectastain Elite ABC kit R.T.U) for 30 minutes at room 
temperature. Immunoreactivity was detected using diaminobenzidine/H2O2 (DAB 
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substrate kit, Vector Laboratories). The sections were counterstained with 10% 
haematoxylin (Sigma), dehydrated and coversliped.  
 
2.9 In vivo mouse model 
 
All experiments were conducted in accordance with the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) guidelines for the Welfare of 
Animals in Experimental Neoplasia (Workman P, 1998) and were approved by the 
University of Surrey Ethics Committee. The mice were kept in positive pressure 
isolators in 12 hour light/dark cycles and food and water were available ad libitum. 
Six-eight week old female balb/C NUDE mice (Charles River Laboratories, Kent, UK) 
were inoculated subcutaneously with a suspension 100µL Hanks media (Sigma) 
containing 106 SKOV-3 cells in 50% matrigel (BD Biosciences).  Once tumours reached 
a volume of approximately 100mm3, mice were randomised into 4 treatment groups, 
each containing 10 mice: PBS alone, Cisplatin alone, HXR9 alone, Cisplatin and HXR9 
in combination. Mice in the HXR9 group received an initial dose of 100mg/kg HXR9 
intra-tumorally (IT), with subsequent dosing of 10 mg/kg twice weekly. The cisplatin 
treatment group received a weekly dose of 3mg/kg via intra-peritoneal injection (IP). 
PBS was used as a control. The mice were monitored carefully for signs of distress, 
including behavioural changes and weight loss.  
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2.10 Statistical analysis 
 
 2.10.1 Cell lines  
 
All experiments were set up in triplicate and the results are expressed as the mean ± 
SEM of at least 3 independent experiments. Original values (Figure 2.1a) showed 
extreme skew and kurtosis. Therefore, a Log2 transformation was applied (Figure 
2.1b) to original values after relative expression to the house keeping gene β-actin 
was calculated to impose a distribution closer to normal across the dataset. Zero 
values were set to ¼ of the minimum value. In this form, qRT-PCR data appropriately 
lends itself to correct parametric, t-test and/or box-plot statistical analyses.  
Significant effects were determined by 2-tailed unpaired t-tests with Welch’s 
correction (p<0.05). The data was analysed using GraphPad PRISM Version 5.0 
(GraphPad Software) and Statistical Package for the Social Sciences (SPSS) for 
Windows Version 20.0 (SPSS, Chicago, IL, USA). The Benjamini and Hochberg 
correction was applied to account for multiple testing.  
 
2.10.2 Ovarian tumours  
All data analysis and manipulation of primary ovarian tumours were performed using 
R (an integrated set of software tools for data manipulation, calculation and graphical 
display). Original HOX gene expression values (Figure 2.1 c) were log2 transformed 
(Figure 2.1 d) after relative expression to housekeeping gene β-actin was calculated 
and zero values were set to ¼ of the minimum value in that dataset. In this form, 
qPCR data appropriately lends itself to correct parametric, t-test and/or box-plot 
statistical analyses. Statistical tests used for analysis included the t-test, Mann-
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Whitney, One-way ANOVA and Kruskal-Wallis. The Benjamini and Hochberg and the 
Bonferroni correction was applied to cell line data and ovarian tumour data, 
respectively, to account for multiple testing. Principle component analysis (PCA) was 
performed and the first two principle components are plotted. The heatmaps include 
row Z-score transformation (genes), and are plotted in red–blue colour scale with red 
indicating high expression and blue indicating low expression. Analysis of OS was 
calculated using the Kaplan-Meier method using GraphPad PRISM Version 5.0 
(GraphPad Software). Hazard ratio (HR) and confidence intervals (CI) were calculated 
using the Log rank model.  
 
 2.10.3 Calculating synergy 
 
To measure synergy between HXR9 and the Cisplatin, cells were plated in a 96-well 
plate and treated with either HXR9 alone, cisplatin alone or in combination at 
concentrations of the drugs IC50 and ± 2-, 4- and 8- fold this concentration. Cell 
viability was then measured by the MTS assay and the presence of synergy was 
assessed by using the computer program CalcuSyn, version 2.0 software (Biosoft, 
Stapleford, UK) based on the median effect principle (Chou, 1991). Combination 
indices (CI) < 1 indicate synergism, CI = 1 shows an additive effect and CI>1 shows 
antagonism between drugs.  
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Figure 2.1. Log2 transformation of original HOX expression data for cell lines and ovarian tumours. HOX gene expression in cell lines and 
ovarian tumours were determined by real-time quantitative reverse transcription PCR (qRT-PCR). Gene expression was normalised to house-
keeping gene β-actin. Log2 transformation of gene expression was calculated to impose a distribution closer to normal across the dataset. 
Zero values were set to ¼ of the minimum value. a) Original cell line HOX gene expression values. b) Log2 of cell line HOX gene expression 
values. c) Original HOX gene expression values for tumour samples. d) Log2 HOX gene expression values for tumour samples.  
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CHAPTER 3. 
 
HOX gene expression and targeting in ovarian cancer 
cell lines. 
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3.1 Introduction 
 
The expression of HOX genes in ovarian cancer has been explored in several studies 
as described in chapter 1.2.4.2. However, these studies have focused on the 
expression of specific HOX genes and their individual role in ovarian oncogenesis. The 
work presented in this chapter provides a more detailed and comprehensive analysis 
of all 39 HOX genes in a panel of established ovarian cancer cell lines of HGS, 
endometrioid and clear cell carcinoma histotypes. The HOX profiles of normal ovary 
and normal fallopian tube was included to determine which HOX genes are 
statistically upregulated in cancerous tissue, suggesting a tumour promoting role in 
ovarian oncogenesis. Equally to determine the genes statistically downregulated 
which indicate tumour suppressor roles in normal tissue. Normal fallopian tube tissue 
was included in the analysis as it has been increasingly argued that the fallopian tube 
is the site of ovarian cancer origin. Comparison of the full HOX profile between 
histotypes was compared which has not been performed before.  
The latter part of this chapter explores the therapeutic potential of targeting HOX 
genes in ovarian cancer. There is generally a high level of functional redundancy 
among the HOX genes (Di-Poi et al., 2010, Lappin et al., 2006), and a similar oncogenic 
function can be common for a number of HOX genes (Lappin et al., 2006, Morgan et 
al., 2007). Their function is largely dependent on the interaction of HOX proteins with 
a common set of co-factors, PBX and MEIS, which modify HOX function by enhancing 
DNA binding specificity and are therefore crucial for target gene regulation (Laurent 
et al., 2008, Moens and Selleri, 2006). Targeting these co-factors has been shown to 
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impair some oncogenic features resulting from HOX gene dysregulation (Morgan et 
al., 2007, Shears et al., 2008, Morgan et al., 2010, Morgan et al., 2012). Targeting the 
HOX-PBX interaction with the HXR9 peptide has shown to induced apoptosis in the 
ovarian HGS cancer cell line SKOV-3 (Morgan et al., 2010), therefore the effectiveness 
of HXR9 in inducing cell death, and the mechanism by which this occurs, in a range of 
other ovarian cancer cell lines was evaluated.   
 
3.2 HOX gene expression in ovarian cancer cell lines and normal ovarian and 
fallopian tube tissue 
In order to evaluate the changes in HOX gene expression in EOC, the relative 
expression of HOX genes in normal ovarian and normal fallopian tube tissue was 
compared to a number of established ovarian cancer cell lines. The panel of ovarian 
cancer cell lines consisted of eight HGS, one endometrioid and one clear cell 
carcinoma. These were compared with ten normal ovarian and three normal fallopian 
tube tissue samples. A highly dysregulated pattern of HOX gene expression was found 
in the EOC cell lines whereas normal tissue showed very little or no HOX gene 
expression (Figure 3.1).  
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Figure 3.1. HOX expression in ovarian cancer cell lines and normal ovarian and 
fallopian tube tissue. Heat map showing differential HOX expression between eight 
HGS ovarian cancer cell lines, one endometrioid cancer cell line, one clear cell 
carcinoma cell line, and ten normal ovarian and three normal fallopian tube tissue 
samples. Expression of each gene was determined by real-time quantitative reverse 
transcription PCR (qRT-PCR) from three independent experiments. Expression is 
relative to housekeeping gene β-actin. Each row represents a cell line/tissue and each 
column represents a gene. Column-wise z-score transformation (genes) was used in 
order to easily visualise ‘high’ and ‘low’ HOX gene expression using a colour scale of 
red-blue. White designates the average level of expression of a particular gene across 
all cell line and samples, red designates a higher than average level of expression and 
blue designates a lower than average level of expression.  
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Table 3.1. Results of t-tests between HOX gene expression of all ovarian cancer cell 
lines and normal ovarian and fallopian tube tissue 
 Ovarian cancer cell lines 
HOXA-B 
SK
O
V
-3
 
C
O
V
-3
1
8
 
P
EO
1
 
P
EO
4
 
P
EO
1
4
 
P
EO
2
3
 
P
EA
1
 
P
EA
2
 
TO
V
-1
1
2
 
TO
V
-2
1
G
 
A1 .967 .004 .000 .004 .000 .000 .000 .000 .000 .005 
A2 .096 .748 .006 .556 .002 .005 .032 .002 .000 .311 
A3 .001 .067 .000 .055 .000 .000 .001 .000 .007 .069 
A4 .001 .876 .751 .490 .000 .000 .041 .004 .000 .603 
A5 .422 .119 .009 .018 .001 .000 .001 .000 .000 .006 
A6 .689 .055 .004 .000 .000 .001 .048 .008 .000 .001 
A7 .186 .945 .001 .000 .000 .000 .007 .001 .000 .003 
A9 .754 .004 .000 .468 .000 .000 .004 .000 .000 .000 
A10 .334 .072 .000 .034 .000 .000 .001 .000 .000 .001 
A11 .186 .393 .000 .000 .005 .024 .588 .166 .454 .492 
A13 .002 .264 .001 .618 .000 .000 .707 .950 .000 .127 
B1 .363 .021 .021 .002 .021 .021 .021 .021 .791 .021 
B2 .290 .020 .337 .479 .337 .337 .337 .527 .481 .337 
B3 .831 .215 .000 .000 .613 .001 .000 .000 .530 .002 
B4 .543 .256 .000 .000 .015 .000 .000 .001 .000 .000 
B5 .008 .009 .001 .000 .041 .280 .001 .663 .000 .135 
B6 .978 .034 .028 .016 .000 .612 .155 .006 .000 .958 
B7 .969 .975 .000 .000 .007 .001 .001 .000 .000 .352 
B8 .358 .651 .622 .612 .204 .946 .336 .120 .652 .398 
B9 .000 .036 .000 .000 .001 .000 .000 .000 .000 .001 
B13 .000 .645 .044 .815 .000 .000 .779 .000 .000 .000 
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Table 1. (Continued) 
 Ovarian cancer cell lines 
HOXC-D 
SK
O
V
-3
 
C
O
V
-3
1
8
 
P
EO
1
 
P
EO
4
 
P
EO
1
4
 
P
EO
2
3
 
P
EA
1
 
P
EA
2
 
TO
V
-1
1
2
 
TO
V
-2
1
G
 
C4 .080 .000 .002 .000 .002 .046 .437 .000 .002 .000 
C5 .000 .019 .004 .004 .088 .291 .641 .011 .022 .004 
C6 .000 .013 .132 .512 .009 .015 .290 .016 .114 .014 
C8 .006 .017 .001 .000 .006 .024 .130 .474 .000 .107 
C9 .001 .006 .000 .157 .000 .000 .523 .102 .000 .059 
C10 .070 .000 .000 .001 .013 .137 .121 .004 .092 .000 
C11 .184 .422 .422 .251 .391 .423 .423 .223 .251 .251 
C12 .584 .316 .000 .009 .041 .010 .133 .307 .000 .000 
C13 .591 .065 .000 .047 .000 .000 .245 .009 .000 .524 
D1 .799 .001 .587 .826 .004 .090 .495 .765 .344 .002 
D3 .867 .127 .004 .004 .585 .004 .004 .770 .000 .457 
D4 .006 .107 .147 .000 .002 .188 .109 .000 .022 .000 
D8 .672 .136 .002 .547 .578 .166 .000 .011 .116 .003 
D9 .600 .201 .216 .659 .056 .019 .387 .173 .610 .010 
D10 .019 .010 .000 .000 .035 .254 .089 .065 .773 .001 
D11 .038 .837 .008 .009 .459 .468 .009 .490 .454 .036 
D12 .593 .480 .337 .337 .337 .337 .337 .207 .337 .337 
D13 .005 .715 .457 .458 .006 .187 .760 .309 .009 .358 
 
Note: Values show p-values determined by the t-test with Welches correction. 
Significant upregulation denoted in red and downregulation denoted in blue. 
Benjamini and Hochberg correction for multiple testing was used.  
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Table 3.2. Statistical difference between high grade serous ovarian cancer cell lines 
and normal ovarian and fallopian tube tissue 
HOXA-B All Serous vs. Normal HOXC-D All Serous vs. Normal 
A1 .0004*** C4 .9974 
A2 .1684 C5 .1935 
A3 .0003*** C6 .0719 
A4 .3444 C8 .0886 
A5 .0062** C9 .6246 
A6 .0049** C10 .1817 
A7 .0098** C11 .0021a 
A9 .0001*** C12 .1150 
A10 .0014** C13 .0180* 
A11 .3447 D1 .7449 
A13 .1561 D3 .1439 
B1 .1833 D4 .0000**** 
B2 .1787 D8 .0327 
B3 .0015** D9 .0635 
B4 .0108* D10 .0000**** 
B5 .4720 D11 .4784 
B6 .7777 D12 .3285 
B7 .0033** D13 .7160 
B8 .1586   
B9 .0000****   
B13 .0084**   
Note: Values show p-values determined by the t-test with Welches correction. 
Significant upregulation denoted in red and downregulation denoted in blue. 
Benjamini and Hochberg correction for multiple testing was used. aHOXC11 was 
severely skewed after log2 transformation due to 71% of cell lines not expressing 
this gene and therefore there is not enough variance for a valid analysis. *p< .05, **p 
< .01, ***p <.001 and ****p <.0001. 
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The most commonly overexpressed genes among the cancer cell lines compared to 
normal tissue were HOXA1, HOXA7, HOXA9 and HOXB9 (Table 1).  One-way ANOVA 
identified HOXB9 and D10, as being expressed at a significantly different level 
between cell lines. A number of genes from the HOXC and HOXD clusters showed 
statistically significant downregulation compared to normal tissue (Table 1). 
 
The histological variants clear cell, endometrioid and HGS carcinoma are known to 
have very different molecular backgrounds (described in chapter 1.1.2). This is also 
reflected in the HOX gene expression profiles, with the endometrioid cell line, TOV-
112D, showing the highest level of HOX gene expression and 25 HOX genes were 
expressed at statistically different levels when compared to normal tissue (Table 3.1; 
Figure 3.2).   
 
HGS ovarian cancers are very genetically heterogeneous, and this is reflected in the 
differences seen between the eight HGS cell lines included in this study (Figure 3.1). 
The COV-318 cell line showed only six HOX genes being significantly dysregulated 
compared to normal tissue, whilst the PEO14 cell line showed twenty-six HOX genes 
(Table 3.1). The eight HGS cell lines were grouped together and their average 
expression was then compared to normal ovarian and fallopian tube tissue. Thirteen 
HOX genes were upregulated, which included most of the HOXA and HOXB clusters 
with the most significant upregulated gene being HOXB9 followed by HOXA9 with p-
values of 2.5x10-5 and 1x10-4, respectively (Table 3.2).  
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Figure 3.2. Heat map showing differential HOX expression between histological 
subtypes. HOX expression data from cell lines of the same histological subtype were 
grouped together to produce a heatmap to display differential HOX expression. 
Expression of each gene was determined by real time quantitative reverse 
transcription PCR (qRT-PCR) and is shown relative to the house keeping gene β-actin. 
Column-wise z-score transformation (genes) was used in order to easily visualise 
‘high’ and ‘low’ HOX gene expression using a colour scale of red-blue. White 
designates the average level of expression of a particular gene across all histotypes 
and normal tissue, red designates a higher than average level of expression and blue 
designates a lower than average level of expression.  
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The clear cell carcinoma cell line shows the largest number of downregulated HOX 
genes when compared to normal tissue. The endometrioid cell line TOV-112D on the 
other hand shows the largest level of significant HOX gene upregulation (Table 1a). 
This is more so apparent when HOX gene expressions between histotypes are 
displayed using a heat map, as the endometrioid cell line shows the highest 
expression of the majority of HOX genes (Figure 3.2). One-way ANOVA analysis 
reveals that nineteen genes were expressed at significantly different levels between 
histotypes; HOXA5, B3, B4 and B7 were the most significant with p-values < 0.001. 
 
3.3 Targeting HOX/PBX dimers in ovarian cancer cells 
By virtue of their marked difference and dysregulation when compared to normal 
cells, the HOX genes comprise a promising set of targets for therapeutic intervention. 
Previous studies have shown that HXR9 (that selectively inhibits HOX-PBX interaction) 
is cytotoxic in melanoma (Morgan et al., 2007), renal cancer (Shears et al., 2008), 
small-cell lung cancer (Plowright et al., 2009) and breast cancer cell lines (Morgan et 
al., 2012) but is not toxic in normal cells (Morgan et al., 2007, Shears et al., 2008). 
However, HXR9 treatment has only been investigated in one ovarian cancer cell line, 
SKOV-3 (Morgan et al., 2010), which is now known to be a poor model for ovarian 
cancer  (Domcke et al., 2013). Therefore, the effectiveness of HXR9 as a cytotoxic 
agent in ovarian cancer cells was investigated further to include a number of HGS cell 
lines, as well as an endometrioid and a clear cell carcinoma cell line.  
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3.3.1 MTS assay of ovarian cancer cell lines 
In order to determine the effect of HXR9 on ovarian cancer cell viability, the MTS 
assay was used with varying concentrations of the peptide. The IC50 values 
(concentration of drug required to kill 50% of cells) of HXR9 for PEA1, SKOV-3, PEO4, 
PEA2, PEO1, PEO23, TOV-112D, COV-318 and TOV-21G cells, were 14.6, 20, 24.5, 25, 
27.3, 28, 28, 37.5, 50 and 91µM, respectively (Table 3.3; Figure 3.3 a-j). The most 
sensitive cell lines were of the HGS subtype and the most resistant cell line was the 
clear cell carcinoma cell line, TOV-21G. A second peptide, CXR9 which has an identical 
polyarginine cell penetrating sequence to HXR9 but has a single alanine substitution 
in its hexapeptide sequence that renders it inactive was used as a control (Morgan et 
al., 2014). None of the cell lines were sensitive to CXR9 (IC50> 100µM). 
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Table 3.3 IC50 (the concentration of drug to kill 50% of cells) for ovarian cancer cells 
treated with HXR9 
Cell line Histology IC50 (µM) 
PEA1 Serous 15 
PEO14 Serous 20 
SKOV-3 Serous 25 
PEO4 Serous 25 
PEA2 Serous 27 
PEO1 Serous 28 
PEO23 Serous 28 
TOV-112D Endometrioid 38 
COV-318 Serous 50 
TOV-21G Clear cell 91 
Note: The MTS assay was performed to determine IC50 values for each ovarian 
cancer cell line. CalcuSyn version 2.0 software was used to accurately calculate 
values. The negative control, CXR9, was not toxic at any of the concentrations tested 
for any of the cell lines (i.e., the IC50 > 100µM).  
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Figure 3.3. MTS assay for the determination of HXR9 toxicity in ovarian cancer cells. 
a) SKOV-3, b) COV-318, c) TOV-112D, d) TOV-21G, e) PEO1, f) PEO4, g) PEO14, h) 
PEO23, i) PEA1 and j) PEA2 cells were plated in 96-well plates overnight then treated 
with varying concentrations of HXR9 or CXR9 for 2 hours. A sample of the same cell 
suspension was used as a ‘cell only’ control. The values shown are the average of at 
least 3 independent experiments and error bars show the SEM. The red line indicates 
50% cell survival.  
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3.3.1.1 Correlation regression analysis between HXR9 IC50 and HOX gene 
expression in ovarian cancer cell lines  
Pearson’s correlation was used to determine whether there is a relationship between 
HOX gene expression and sensitivity to HXR9. Five HOX genes were found to be 
negatively correlated with IC50 values: HOXB3, B4, C10, C12 and D1 (Table 3.4).  
 
3.3.2 HXR9 induces apoptosis in ovarian cancer cells 
The two major routes leading to cell death are known as apoptosis and necrosis. The 
apoptotic program is characterized by distinguishable morphologic features such as 
condensation of the cytoplasm and nucleus, internucleosomal cleavage of DNA and 
the formation of apoptotic bodies. The process distinctly differs to necrosis which 
involves mitochondrial swelling, plasma membrane breakdown resulting in the 
release of cellular contents (Bonfoco et al., 1995, Hengartner, 2000). Previous studies 
have shown that HXR9 induces apoptosis in cancer cells (Morgan et al., 2007, Shears 
et al., 2008, Plowright et al., 2009, Morgan et al., 2010, Morgan et al., 2012), 
therefore, flow cytometric analysis (FACs), caspase-3 assay and cFos detection via RT-
qPCR was used to investigate the mode of cell death of ovarian cancer cells induced 
by HXR9.  
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Table 3.4. Correlation regression analysis between IC50 values for HXR9 and HOX 
gene expression in ovarian cancer cell lines 
HOXA-B PC P-value HOXC-D PC P-value 
A1 -0.141 0.475 C4 -0.186 0.343 
A2 -0.048 0.808 C5 -0.247 0.206 
A3 -0.231 0.236 C6 -0.236 0.227 
A4 -0.1 0.613 C8 0.059 0.767 
A5 0.004 0.985 C9 -0.029 0.884 
A6 0.192 0.328 C10 -.691* 0.000 
A7 -0.025 0.898 C11 -0.242 0.215 
A9 0.115 0.561 C12 -.495* 0.007 
A10 -0.004 0.984 C13 -0.087 0.659 
A11 -0.139 0.48 D1 -.651* 0.000 
A13 -0.016 0.937 D3 0.107 0.589 
B1 -0.109 0.582 D4 0.102 0.606 
B2 -0.056 0.776 D8 -0.303 0.116 
B3 -.544* 0.003 D9 -0.015 0.941 
B4 -0.453 0.015 D10 0.317 0.101 
B5 -0.01 0.959 D11 0.365 0.056 
B6 0.079 0.689 D12 -0.093 0.639 
B7 -0.37 0.053 D13 0.018 0.929 
B8 0.084 0.671    
B9 -0.217 0.268    
B13 0.078 0.692    
Note: Pearson’s correlation (PC) and 2-tailed t-test was used to determine 
significant relationships between HXR9 IC50 values and individual HOX gene 
expression. Expression of each gene was determined by quantitative PCR (qRT-
PCR) from three independent experiments and normalised to the house keeping 
gene β-actin. The MTS assay was performed to determine the IC50 of HXR9 for each 
cell line. Red highlighted genes indicate significant correlation at the 0.02 level (2-
tailed). Correlation significant at the 0.01 level (2-tailed) is denoted as *. 
PC = Pearson correlation. 
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3.3.2.1. Flow cytometry analysis (FACS) of apoptotic cells 
Changes of the plasma membrane are among the earliest features of apoptosis, 
where the membrane phospholipid phosphatidylserine (PS) is translocated from the 
inner to the outer leaflet of the plasma membrane, exposing PS to the external 
cellular environment. Annexin V is a phospholipid-binding protein which has a high 
affinity for PS and when conjugated to fluorochromes such as phycoerythrin (PE) can 
act as a sensitive probe for flow cytometric analysis (FACs) of cells that are 
undergoing apoptosis (Koopman et al., 1994, Vermes et al., 1995, Martin et al., 1995). 
This method identifies apoptosis at an earlier stage than assays based on nuclear 
changes such as DNA fragmentation, and therefore used for the indentification of 
apoptotic cells after HXR9 treatment. Firstly, SKOV-3, COV-318, PEO1, PEO4, TOV-
112D and TOV-21G cells were either treated with HXR9 at their calculated IC50 (Table 
3.2) and double their IC50 or with the equivalent dose of CXR9 control for 2 hours. 
Cells were then stained with annexin V conjugated to PE followed by counterstaining 
with the vital dye 7-amino-actinomycin (7-AAD) which is permeable to necrotic cells. 
FACs analysis identified all cell lines treated with HXR9 showed a significant increase 
in the number of cells in late apoptosis compared to untreated cells (Figure 3.6). A 
significant increase in the number of cells in early apoptosis was also seen for all 
except the endometriod cell line, TOV-112D. CXR9 treatment did not cause apoptosis. 
These results show that HXR9 caused cell death predominately through apoptosis 
after 2 hours of treatment. 
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Figure 3.4. HXR9 induces apoptosis in ovarian cancer cell lines. Cells were assessed 
for apoptosis or necrosis through annexin/propidium iodine staining after HXR9 
treatment. a) The bar graphs show the percentage of cells in early apoptosis, late 
apoptosis, and necrosis, as well as viable cells, when untreated, treated at the HXR9 
IC50 dose or double the IC50 dose for each cell line or equivalent CXR9 dose. Error bars 
show the SEM. P-values <0.05 are denoted as *, <0.005 ** and < 0.001 as *** with 
respect to untreated cells. Example plots for each treatment using SKOV-3 cells b) 
untreated; c) CXR9 25 µM; d) CXR9 50 µM; e) HXR9 25 µM and f) HXR9 50 µM.  
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3.3.2.2 Caspase-3 assay 
 
Caspase activation plays a central role in the execution of apoptosis. Caspase-3 is 
activated in the mitochondrial-initiated pathways by its upstream regulator caspase-
9 (Budihardjo et al., 1999). Using the activation of caspase-3 as a biomarker is a well-
established method for assessing apoptosis and understanding the mechanism of 
apoptosis induction. The caspase-3 activity assay was used to detect the levels of 
caspse-3 after HXR9 treatment. Significant increases in caspase-3 activity were seen 
after 2 hours of HXR9 treatment in all cell lines tested (Figure7).  Cells were not 
affected by the same concentration of CXR9. This supports apoptosis as being the 
mode of cell death induced by HXR9.  
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Figure 3.5. Caspase-3 activity in ovarian cancer cell lines. Cell lines were treated with 
their IC50 for HXR9 or equivalent CXR9 concentration for 2 hours. A background signal 
was established using a caspase inhibitor and subtracted from the treated cell line 
signals. Bars show the average from 3 independent experiments and the error bars 
show the SEM. P-values <0.05 are denoted as * and those <0.005 as ** with respect 
to untreated cells.  
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3.3.2.3 cFos upregulation 
 
Fos proteins are members of the bZIP superfamily of transcription factors, which are 
characterized by a basic DNA-binding domain combined with a leucine zipper region 
(Hess et al., 2004). They bind to Jun or other bZIP proteins to create the AP-1 dimer 
complex, which regulates gene expression. cFos is a well-established proto-oncogene 
considered to play a critical role in tumourgenesis, proliferation and transformation, 
angiogenesis, tumour invasion and metastasis (Wagner and Eferl, 2005). Therefore, 
cFos has been considered an anti-apoptotic molecule, however a pro-apoptotic role 
has also been observed.  
 
This pro-apoptotic function was first suggested by the observation that cFos 
expression preceded apoptosis (Smeyne et al., 1993) and this has also been found in 
other studies where an increase in cFos expression triggered apoptosis (Eichhorst et 
al., 2000, Kasibhatla et al., 1998b, Kolbus et al., 2000, Le-Niculescu et al., 1999, Matsui 
et al., 2000, Grimm et al., 2001, Rich et al., 1997). cFos has also been shown to act as 
a pro-apoptotic protein through repression of the anti-apoptotic gene, c-FLIP(L), by 
direct binding to its promoter (Zhang et al., 2007). The tumour-suppressive activity 
of cFos is also reflected in its ability to inhibit cell cycle progression when over-
expressed, and to stimulate murine hepatocyte cell death and strongly suppress 
tumour formation in vivo (Mikula et al., 2003).  
 
HOX genes have been shown to prevent apoptosis, at least in part, through the 
blocking of cFos expression, and therefore after treatment with HXR9 treatment 
cancer cells show an increased cFos expression and mediated apoptosis (Morgan et 
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al., 2007). In particular, the HOXB7/PBX2 complex has been reported to 
transcriptionally activate micro RNAs (miRs) miR-221 and miR-222, which are the 
most deregulated miRs implicated in cancer and highly upregulated in a variety of 
solid tumours (Garofalo et al., 2012). miRs are small non-coding RNA that regulate 
gene transcription post-transnationally (Sassen et al., 2008). Abrogation of the 
functional HOXB7/PBX complex by HXR9 lead to reduced miR-221 and miR-222 
transcription which consequently resulted in direct upregulation of cFos (Errico et al., 
2013). When ovarian cancer cells were treated with HXR9 for 2 hours, cFos expression 
increased compared to untreated cells, as detected by RT-QPCR (Figure 3.6). The 
most significant change was observed in the endometrioid cell line, TOV-112D. This 
shows that the upregulation of cFos is a key event in HXR9-mediated apoptosis in 
ovarian cancer cells.  
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Figure 3.6.  qRTPCR of cFos in HXR9 treated ovarian cancer cell lines. RNA was 
extracted from cells cultured in vitro and treated with the IC50 of HXR9 for 2 hours. 
Results are expressed as a ratio to the housekeeping gene β-actin for each cell line, 
and show the average of 3 independent experiments. Error bars show the SEM. P-
values <0.05 are denoted as * and those <0.005 as ** with respect to untreated cells. 
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3.4 Discussion  
HOX gene dysregulation was found in ovarian cancer cells lines with little to no 
expression being found in normal ovarian and fallopian tube tissue. The majority of 
overexpression among cell lines was found within the HOXA and HOXB clusters, and 
some downregulation of HOXC and HOXD genes was apparent.  
Although the function of the HOX genes in cancer remains unclear, there have been 
reports that they can act as tumour suppressors or oncogenes. In ovarian cancer both 
HOXB7 and B13 expression has been linked to the invasive characteristics of ovarian 
cancer cells (Yamashita et al., 2006). HOXB7 has also been shown to be a regulator of 
bFGF- a potent mitogenic and angiogenic factor (Naora et al., 2001b) and involved in 
double strand break repair (Rubin et al., 2007), whereas HOXB13 has been shown to 
promote cell proliferation (Miao et al., 2007b).  
Cheng et al. have previously shown that the overexpression of specific HOX genes 
determines the histological subtype, HOXA9 being overexpressed in HGS subtypes, 
HOXA10 in endometrioid and HOXA11 in mucinous (Cheng et al., 2005). Interestingly, 
in this study HOXA9 was found to be overexpressed in only 3 of the 8 HGS cell lines, 
but was also present in the clear cell and endometrioid cell lines. Results from one-
way ANOVA on the cell line data revealed that HOXA5, B3, B4 and B7 expression 
showed the most significant differences between histotypes. However, the 
differences in HOXB genes may just be a reflection of the aggressiveness of each cell 
line rather than histological subtype. HOXB7 has previously been shown to be 
overexpressed in ovarian cancer cell lines (Naora et al., 2001b, Yamashita et al., 
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2006), and HOXB3 has been shown to epigenetically silence the RAS association 
domain family protein 1a gene (RASSF1A), a tumour suppressor gene silenced in a 
variety of cancers, including approximately 50% of ovarian tumours (Donninger et al., 
2007, van der Weyden and Adams, 2007, Hesson et al., 2007, Agathanggelou et al., 
2005). In non-small cell lung cancer cell lines, HOXB3 was shown to bind to the DNA 
methyltransferase DNMT3B gene resulting in an increase of its expression. DNMT3B 
is then recruited to the RASSF1A promoter, resulting in hypermethylation and 
silencing of RASSF1A expression (Palakurthy et al., 2009). This oncogenic role of 
HOXB3 may account for its upregulation in ovarian cancer. Another way in which 
HOXB3 could be acting as an oncogene is through the upregulation of the cell division 
cycle associated 3 (CDCA3) gene which is commonly overexpressed in ovarian cancer. 
HOXB3 is upregulated in prostate cancer and associated with poor clinical outcome, 
it has been shown in prostate cancer cells that HOXB3 directly binds to the promoter 
region of CDCA3 to upregulate its expression, which in turn enhances cellular 
proliferation with prevention of G1 phase arrest (Chen et al., 2013). A similar 
mechanism may occur in ovarian cancer cells.  
Among all cells lines, HOXA1, A7, A9 and B9 were the most common significantly 
overexpressed genes. HOXA1 has been reported as an oncogene in breast cancer as 
it stimulates the transcription of a number of pro-oncogenic molecules, including 
cyclinD1 and B-cell leukaemia/lymphoma-2 (Bcl-2), permitting increased 
proliferation and survival of mammary carcinoma cells. The transcriptional activity of 
HOXA1 was found to be increased due to human growth hormone (hGH) which has 
an increased expression in neoplastic mammary epithelial cells. Forced expression of 
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HOXA1 also enhances anchorage-independent cell proliferation and causes 
oncogenic transformation of the cells, rendering them capable of aggressive tumour 
formation (Zhang et al., 2003). Following from this study, it has been demonstrated 
that HOXA1 is a downstream effector of E-cadherin-directed signalling through Rac1 
in mammary carcinoma cells, which is required for anchorage-independent cell 
proliferation (Zhang et al., 2006b). E-cadherin expression is known to be highly 
expressed in ovarian cancer cells compared to normal ovarian cells (MainesBandiera 
and Auersperg, 1997, Dong et al., 2012) and has been implicated in tumour 
progression by protecting cells from anoikis, a form of apoptosis which normally 
prevents epithelial cells that have lost anchorage with the basement membrane from 
surviving, reattaching and proliferating outside the appropriate tissue context (Frisch 
and Francis, 1994, Meredith et al., 1996). Therefore, E-cadherin mediated cell-cell 
adhesion allows cancer cells to survive in the absence of matrix attachment forming 
three-dimensional tumour nests which can metastasize, and a large proportion of 
ovarian cancer cell exist like this as multicellular aggregates in ascites.  
Microarray analysis identified that oncogenicity stimulated by HOXA1 in human 
mammary carcinoma cells was mediated by selective upregulation of components of 
the p44/42 MAPK pathway (Mohankumar et al., 2007). MAPK pathways have been 
implicated in the pathogenesis of cancer and this particular pathway is a well-
characterized intracellular signalling pathway, transducing signals from the cell 
surface to the nucleus to activate transcription (Seger and Krebs, 1995). p44/42 
MAPK has roles in various cellular processes, including cell proliferation, 
differentiation, apoptosis and oncogenic transformation. Activation of this signalling 
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cascade has been reported in the oncogenic transformation of various cell lines, and 
increased p44/42 MAPK activity has been implicated in the metastatic potential of 
human cancer (Mansour et al., 1994). The highly significant upregulation of HOXA1 
found among the ovarian cancer cell lines suggest that this gene also plays a role in 
ovarian carcinogenesis but further investigation would be needed to identify whether 
this is via the p44/42 MAPK pathway.  
Cell line data shows a downregulation of a number of HOXC and HOXD genes, the 
most significant of which are HOXC4, C5, D4 and D10. This downregulation has not 
been previously reported; however this may suggest these genes play a role in 
tumour suppression and in maintaining the normal structure and function of the 
adult ovary. Oestrogen in a known regulator of HOX gene expression and is essential 
for the determination of the posterior axis during embryogenesis, and is a regulator 
of the reproductive cycle in adults (Korach, 1994, Hewitt et al., 2005), with HOX genes 
mediating the function of sex steroids during each cycle. HOXC4 transcription is 
activated by oestrogen response elements (EREs) within the promoter that are bound 
by oestrogen-oestrogen receptor complexes (Mai et al., 2010). In human breast 
cancer MCF-7 cells, oestrogen rapidly and effectively induces HOXC4 together with 
the neighbouring HOXC5 and HOXC6 genes (Frasor et al., 2003). HOXC4 has been 
found to be a critical activator of the activation-induced cytosine deaminase (AID) 
gene promoter (Park et al., 2009, Delker et al., 2009). AID is critical for antibody class 
switch DNA recombination (CSR) and somatic hypermutation (SHM), needed for the 
maturation of antibody response to foreign antigens and self-antigens (Di Noia and 
Neuberger, 2007, Stavnezer et al., 2008, Maizels, 2005, Teng and Papavasiliou, 2007, 
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Odegard and Schatz, 2006). It is known that females have better antibody responses 
to microbial antigens, as presented in vaccines or as natural infections, than males 
(Fish, 2008), and this can be explained through the indirect upregulation of AID 
expression by oestrogen through HOXC4 activation. Therefore, the expression of 
these HOXC genes may be due to the normal functioning of the ovary in response to 
oestrogen stimulation, and in ovarian cancer, expression decreases due to 
mechanisms in place for the cancer cell to avoid immune responses. Interestingly, 
HOXC5 expression was found at lower levels in cancerous breast tissue with mutated 
p53 compared to normal breast tissue and cancerous samples with wild-type p53 
(Makiyama et al., 2005). This may suggest that HOXC5 acts as a tumour suppressor 
and is a downstream target of p53. My work shows HOXC5 expression is decreased 
in 4 cell lines, 2 of which have deleted Tp53 expression, one has an unknown p53 
status, and the TOV-21G cell line has wild-type p53. Other cell lines which have 
mutated p53 do not show a decrease in HOXC5.   
A decrease in HOXD10 expression was also found among the cell lines and 
interestingly, HOXD10 has previously been implicated in the suppression of tumour 
cell migration and invasion. HOXD10 expression has been shown to be significantly 
downregulated in prostate cancer (Ramachandran et al., 2005) and progressively lost 
in breast cancer with increasing degrees of malignancy. When HOXD10 expression 
was restored in MDA-MB-231 breast cancer cells, migration and invasion was 
impaired in vitro and tumour formation was inhibited (Carrio et al., 2005) suggesting 
a tumour suppressive function, and as HOXD10 expression is lost in ovarian cancer 
cells, a suppressive role in ovarian epithelial cells as well.  
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Targeting the HOX/PBX dimer by treating cells with HXR9 is cytotoxic in ovarian 
cancer with the HGS histological subtype showing sensitivity to this treatment. The 
clear carcinoma cell line was HXR9 resistant with an IC50 value of 90 µM. This could 
be explained by the large number of downregulated HOX genes in this cell line, 
suggesting this histological subtype is not driven by HOX overexpression. A 
relationship between HOX expression and HXR9 sensitivity was investigated using 
Pearson’s correlation regression and 5 HOX genes were found to be negatively 
correlated with IC50 values: HOXB3, B4, C10, C12 and D1. Cell lines with high 
expression of these genes had a lower IC50 value, therefore needing less HXR9 to kill 
the same number of cancer cells as a cell line harbouring a lower level of expression. 
This suggests that these genes have an oncogenic function that is prevented by HXR9 
treatment. A previous study investigating HXR9 use in breast cancer cell lines found 
a positive relationship between increasing HXR9 toxicity and the mean HOXB1 
through to HOXB9 expression (paralogue groups targeted by HXR9). The clear cell 
carcinoma cell line has the lowest HOXB1-9 expression which follows this pattern as 
it is the least sensitive cell line. The most sensitive cell lines had a higher level of HOX 
dysregulation, apart from the SKOV-3 cell line. Therefore, HXR9 can be used as a drug 
to target cancer cells with highly dysregulated HOX gene expression. 
As HOXA1 was one of the HOX genes found to be most significantly upregulated 
among the cell lines, it is interesting to find a study demonstrating the importance of 
the HOX-PBX interaction for the oncogenic activity of HOXA1. Various HOXA1 
mutants, which had substituted residues in the hexapeptide region, lost contact 
inhibition and the ability of anchorage-independent cell growth and to stimulate cell 
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proliferation (Delval et al., 2011). This supports the notion that the HOX-PBX 
interaction is a therapeutic target for cancer treatment. Sensitivity to HXR9 is not 
dependent on the level of HOXA1 alone, therefore the interaction between PBX and 
HOX proteins must be important for the oncogenic potential of other HOX proteins 
with the hexapeptide region.  
In vitro work carried out on ovarian cancer cell lines establishes there is dysregulated 
HOX gene expression in ovarian cancer, with the upregulation and downregulation of 
genes compared to normal ovarian and fallopian tube tissue, which have little to no 
HOX gene expression, suggesting that HOX genes have oncogenic and suppressive 
roles in tumour progression. Of particular interest is the overexpression of HOXA1 
which has not been reported before in ovarian cancer, but has a role in breast cancer. 
It therefore may have a similar role in ovarian oncogenesis. The difference between 
cancerous and normal ovarian and fallopian tube tissue can be used therapeutically 
by targeting the products of these upregulated genes with the novel peptide, HXR9. 
HXR9 treatment in these ovarian cancer cells was shown to induce cell death via 
apoptosis. Evidence for this is an increase in apoptotic cells, increased caspase-3 
activity and cFos upregulation after HXR9 treatment for 2 hours. Therefore, 
dysregulated HOX gene expression in ovarian cancer is a potential therapeutic target.  
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CHAPTER 4. 
 
Platinum resistance in ovarian cancer. 
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4.1 Introduction. 
Ovarian cancer is often referred to as a ‘silent killer’ because at the point of diagnosis 
the disease has usually metastasised to the peritoneum (Ozols et al., 2004), and at 
this advanced stage the 5-year survival rate is less than 30% (Siegel et al., 2012). 
Standard treatment for ovarian cancer patients with advanced stage disease (FIGO 
stage IC-IV) is initial debulking surgery followed by 3 weekly carboplatin-paclitaxel 
combination chemotherapy, which is known as adjuvant chemotherapy. The 
intention is to kill remaining tumour cells after surgery to prevent a relapse. In cases 
where the disease is deemed too extensive to allow surgery, upfront-neo-adjuvant 
regimes can also be used. This entails giving cytostatic drugs prior to cytoreductive 
surgery in order to shrink the tumour sufficiently to enable its complete removal 
(Trope and Kaern, 2007). The platinum compounds cisplatin and carboplatin are 
among the most effective anticancer drugs available and initially show excellent 
clinical results. However, approximately 70% of advanced stage patients will relapse 
and develop recurrent disease predominantly due to the emergence of platinum 
resistance, a key obstacle in the management of ovarian cancer (Ledermann et al., 
2013). Platinum resistance is defined as tumour progression during or within six 
months after completion of platinum therapy and is common in recurrent disease 
(Markman et al., 1991, Gore et al., 1990). A small fraction (around 14%) of patients 
will have progressive disease during initial treatment, and are classified as having 
platinum-refractory disease (Cooke and Brenton, 2011). Nevertheless, platinum-
based chemotherapy remains the mainstay for treatment of recurrent disease.  
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IV administered cisplatin is initially inactive and only becomes active inside the cell. 
The chloride ligands of cisplatin are replaced by water molecules to generate a 
positively charged aquated species that reacts with nucleophilic sites on intracellular 
macromolecules to form protein, RNA and DNA adducts. The adduct formation 
causes intra- or inter-stand cross-links disrupting the structure of the DNA molecule 
and leading to steric changes in the helix. This leads to replicative and transcriptional 
blockage resulting in the activation of signalling pathways that induce cell cycle arrest 
and apoptosis (Rabik and Dolan, 2007). The molecular mechanism of platinum 
resistance in ovarian cancer cells is multifactorial and poorly understood. In vitro 
models have identified several factors that cause  platinum resistance, which include 
a reduced net uptake of drug into cells, increased drug export, trapping of cisplatin 
in intracellular complexes and changes in the expression of genes involved in cell 
death pathways, such as p53, Bcl2 and Akt/mTOR (Vasey, 2003). Due to the 
heterogeneous nature of ovarian cancers, more than one mechanism may be present 
in a particular tumour. One mechanism which is widely accepted as an important 
indicator of a tumour’s sensitivity to an anti-cancer drug is the inhibition of apoptosis 
and the apoptotic response of cancer cells to chemotherapeutic drugs (Hajra et al., 
2008, Fraser et al., 2003). Tumour cells have intrinsic differences in DNA repair 
mechanisms compared to normal cells and DNA damaged caused by cisplatin can be 
repaired resulting in the continued viability of the cell  and consequently platinum 
resistance. One such DNA repair pathway which has been implicated in cisplatin 
resistance is the error-prone non-homologous end-joining (NHEJ) pathway.  
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NHEJ involves the DNA end-binding heterodimer Ku70/Ku80, the DNA-dependent 
kinase (DNA-PK), the XRCC gene product and DNA ligase IV. The Ku antigen binds 
DNA-strand breaks and recruits DNA-PK which becomes activated and enables DNA 
repair. HOXC4 and HOXD4 have been shown to interact with the C- terminus of Ku 
antigens, promoting their recruitment to DNA end breaks and phosphorylation by 
DNA-PK (Schild-Poulter et al., 2001). HOXB7 has been shown to have a role in DNA 
repair through NHEJ by interactions with Ku70, Ku80, the catalytic subunit of DNA-PK 
(DNA-PKcs) and PARP. HOXB7 overexpression enhances NHEJ and DNA repair, and 
can confer a transformed phenotype and resistance to ionizing radiation in cultures 
of human mammary epithelial cells, MCF10A (Rubin et al., 2007). Interestingly, DNA-
PK activity in platinum resistant ovarian cancer cells inhibits cisplatin-mediated 
apoptosis, through the activation of the Akt/mTOR pathway (Stronach et al., 2011a), 
which in turn plays essential roles in cellular functions, including proliferation, growth 
and metabolism (Hay, 2005, Plastaras et al., 2008), and dysregulation of this pathway 
has been implicated in tumourgenesis (Vivanco and Sawyers, 2002). 
Phosphatidylinositol 3-kinase (PI3K) is activated upon growth factor stimulation 
which in turn converts phosphatidylinositol 4,5-diphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3). AKT is subsequently recruited to the 
cell surface through interaction with PIP3 and is activated by phosphorylation at 
residues serine 473 (S473), and threonine 308 (T308) (Hay, 2005). The Akt/mTOR 
pathway is thought to be a key mediator of platinum resistance in ovarian cancer 
(Stronach et al., 2011b). Increased activation of this survival pathway has been shown 
to occur in ovarian cancer cells in response to cisplatin treatment (Peng et al., 2010). 
148 
 
Inhibition of this pathway increases cisplatin-induced apoptosis (Peng et al., 2010), 
however, AKT also plays a role in fundamental biological processes such as insulin 
signalling and normal growth control (Crouthamel et al., 2009), and thus targeting 
AKT therapeutically could lead to many metabolic abnormalities.  In a study using a 
series of matched clinically platinum sensitive/resistant paired HGS ovarian cancer 
cell lines (Langdon et al., 1988) -the same cell lines used in this chapter- DNA-PKcs 
was found to be highly expressed and, in response to cisplatin-induced DNA damage, 
phosphorylates AKT at serine 473 in clinically platinum resistant cells but not in the 
matched platinum sensitive cells (Stronach et al., 2011a). This occurs through a 
separate mechanism to cell-surface mediated AKT activation described above, as 
binding of DNA-PKcs to AKT was shown in the nucleus of platinum resistant ovarian 
cancer cells. Inhibition of DNA-PK prevented AKT activation and enhanced cisplatin 
sensitivity in clinically platinum resistant ovarian cancer cells (Stronach et al., 2011a), 
making DNA-PK inhibition a therapeutic strategy for the treatment of platinum 
resistant ovarian cancer.  
A series of cell lines have been established from three cases of serous ovarian cancer 
both before and after acquiring clinical platinum resistance (Langdon et al., 1988). 
Genomic analyses of these cell lines revealed that, as well as sharing genomic 
features, sensitive and resistant tumour cells from the same patient displayed 
mutually exclusive genomic characteristics (Cooke et al., 2010). This indicates that 
platinum sensitive and resistant diseases are not linearly related but share a common 
ancestor at an early stage of tumour development. Hence genetically divergent sub-
clones that are intrinsically resistant to platinum-based treatment may already exist 
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within a tumour at the time of presentation and before treatment begins, opposing 
the previous hypothesis of acquired resistance whereby it is proposed that mutations 
arise in sensitive tumour cells in response to cisplatin treatment. Intrinsically resistant 
sub-clones present in the original tumour supports the CSC hypothesis for 
carcinogenesis, in which cancers are driven by a subset of highly tumorigenic cells 
with stem-cell like properties for sustaining growth from the neoplastic clone. As 
described in chapter 1.2.3.1, one of the properties of CSCs is drug resistance and 
several mechanisms have been reported. Normal stem cells show a high expression 
of efflux transporters from the ABC gene family to protect DNA from chemical 
mutagens, and thus prevent carcinogenesis. It is thought that ovarian CSC may 
acquire this defence system, rendering them resistant to chemical mutagens i.e. 
chemotherapy agents (Kobayashi et al., 2011, Hu et al., 2010). Ovarian CSCs have also 
been shown to resist tumour necrosis factor α (TNFα) mediated apoptosis (Alvero et 
al., 2009). Ovarian cancer cells were found to develop paclitaxel resistance through 
EMT, which allowed them to acquired stem-cell like phenotypes (Kurrey et al., 2009). 
In regards to the cell lines described above, it could be suggested that the original 
platinum sensitive tumour contained a small subset of CSC  resistant to 
chemotherapy treatment, however,  the initial response seen is due to the bulk of 
the tumour responding . The platinum sensitive cell line which derived from this 
tumour would be representative of the platinum sensitive phenotype.  At tumour 
recurrence, the residing subset of CSCs have proliferated to generate a tumour with 
a platinum resistant phenotype. The cell line derived from this tumour is therefore 
platinum resistance.   
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Due to the poor survival of women with platinum resistance, further understanding 
of this phenomenon and improved therapeutic approaches are urgently needed. 
Drug resistance highlights the necessity for anti-cancer agents that have different 
targets to platinum-based drugs, or act on those pathways that induce platinum 
resistance in order to re-sensitise the cells to standard chemotherapy. Thus, further 
work to understand the molecular changes and identify new therapeutic targets for 
ovarian cancer treatment is an important goal. In this chapter, the HOX genes and 
the HOX/PBX interaction are explored as alternative therapeutic targets for the 
treatment of platinum resistant disease. Their involvement in DNA repair and the 
prevention of apoptosis in ovarian cancer cells (Chapter 1.2.4), makes them potential 
candidates. Firstly, HOX gene expression profiles of known platinum sensitive and 
platinum resistant cell lines were compared statistically. The effectiveness of 
targeting HOX genes using the HXR9 peptide that inhibits the HOX/PBX interaction 
was performed to determine whether sensitively to HXR9 was correlated to cisplatin 
sensitivity. Finally, the potential synergy between HXR9 and cisplatin was 
investigated in vitro and in vivo.  
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4.2 Comparison of HOX expression between platinum sensitive and platinum 
resistant paired ovarian cancer cell lines. 
To evaluate differences in HOX expression between platinum sensitive and resistant 
EOC, the PEO/PEA series of ovarian cancer cell lines were analysed.  These  cell lines  
were established as spontaneously immortalized polyclonal lines acquired from three 
separate cases of HGS ovarian cancer (Figure 4.1) (Langdon et al., 1988). The cell line 
pairs PEO14/23 and PEA1/2 were established prior to treatment and at platinum 
resistant relapse seven and six months later, respectively. The PEO1 cell line was 
cultured from relapsed disease 22 months after combination chemotherapy with 
cisplatin. The patient was successfully re-treated with platinum based agents, and 
therefore the tumour was considered to be clinically sensitive to platinum, as a 
relapse more than 12 months after initial treatment is defined as platinum sensitive 
disease (Markman et al., 1991). PEO4 was derived from further progressive disease 
10 months later. The PEO1/4 cell lines arise from a patient with a BRCA2 germline 
mutation (Sakai et al., 2009), although BRCA function has been restored in the PEO4 
cell line (Cooke et al., 2010).  
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Figure 4.1. Cell lines from 3 ovarian cancer patients established at different time 
points through disease progression. All patients received platinum-based 
chemotherapy and developed platinum resistant disease. Pink boxes indicate 
platinum resistant cell lines.  
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HOX expression in PEO1, PEO14 and PEA1 - platinum sensitive cell lines were 
compared with PEO4, PEO23 and PEA2 platinum resistant cell lines, respectively and 
significant differences were found. The PEO4 (platinum resistant cell line) showed a 
significant increase in HOXB4 gene expression compared to its paired sensitive cell 
line, PEO1 (Figure 4.2a). Notably, there was reduced expression of HOXA9, C8, C12 
and C13 in the resistant cell line. Before the Benjamini and Hochberg procedure was 
applied, which accounts for multiple testing, HOXB1 and B3 also showed significant 
upregulation in the PEO4 cell line. The PEO23 (platinum resistant) cell line also has a 
significantly higher expression of HOXB4 in addition to HOXB5, B7 and B9 when 
compared to its platinum sensitive couterpart-PEO14, however, this significance is 
only seen when the Benjamini and Hochberg correction is not applied (Figure 4.2b). 
In the third pair, PEA2 also shows an increase in the expression of HOXB9 which 
remains significant after the Benjamini and Hochberg procedure is applied. HOXA2, 
A4, B6, B7 and C9 show significant upregulation in the PEA2 resistant cell line before 
the Benjamini and Hochberg correction. A significant decrease in the expression level 
of HOXC4 is seen in the PEA2 cell line (Figure 4.2c). Cell line gene expression data was 
pooled according to platinum sensitivity status and the average expression was 
displayed using a heat map. The resistant cell lines show an overall higher HOX 
expression compared to normal and sensitive cell lines. The main difference comes 
from a cluster of genes which have similar levels of expression and were upregulated 
in the platinum resistant cell lines. These being HOXA2, A3, A4, A5, A6, A10, B4, B7, 
B9, C4 and C13 (Figure 4.2d).  
 
154 
 
 
a) 
 
b) 
 
 
c) 
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Figure 4.2. HOX gene expression of paired platinum sensitive and platinum resistant 
ovarian cancer cell lines. The comparison of HOX gene expression profiles between 
patient derived cell lines before (PEO1, PEO14 and PEA1) and after (PEO4, PEO23 and 
PEA2) developing platinum resistance. a) HOX expression profile of the platinum 
sensitive cell line PEO1 and platinum resistant cell line PEO4. b) HOX expression data 
between PEO14 and PEO23 paired cell lines. c) PEA1 and PEA2 comparisons. Data 
points represent the mean log2 gene expression and error bars show the standard 
error of the mean. Log2 transformed expression values had a close-to-normal 
distribution with no obvious bias. Statistical significance in gene expression between 
sensitive and resistant matched paired cell lines were calculated using the t-test with 
Welches correction and p-values <0.05 are denoted as *. Genes showing significant 
difference after the Benjamini and Hochberg procedure was used to correct for 
multiple testing are denoted as **. Significant downregulation is denoted in pink. d) 
Heat map showing differential HOX expression of all cell lines with respect to known 
platinum sensitivity status. HOX expression profiles were determined by qRT-PCR and 
156 
 
gene expression was normalised to housekeeping gene β-actin. Each column  
represents a gene and each row represents the sensitivity group/normal. Rows-wise 
z-score transformation (genes) was used. Red colour for a gene indicates expression 
above the median level of expression across all samples for that gene and blue 
indicates expression below the median.  
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4.3 HXR9 and platinum sensitivity status in ovarian cancer cell lines 
 
To determine whether sensitivity to HXR9 changed after platinum resistance 
developed, the dose-response curves of platinum sensitive cells treated with HXR9 
were compared to that of their resistant counterpart. No statistically significant 
differences were found, showing that HXR9 is effective in platinum resistant and 
platinum sensitive cancer cell lines (Table 4.1).  
 
4.4 Investigation of synergy between HXR9 and cisplatin in platinum resistant cell 
lines.  
 
Due to the increased expression of specific HOX genes after platinum resistance 
developed, HXR9 was used in combination with cisplatin to determine whether this 
would increase the cells sensitivity to cisplatin treatment. In theory, HXR9 could block 
the function of the overexpressed HOX genes of the resistant cell lines which may  
render the cells platinum sensitive.  
 
In order to calculate synergy between two drugs, an IC50 for each drug needs to be 
established. Cells were then treated with this concentration as well as 2- and 4-fold 
this concentration, with each drug individually and in combination. CalcuSyn version 
2.0 software was used to calculate synergy between the two drugs.  
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Table 4.1. IC50 values for HXR9 in paired ovarian cancer cell lines. 
Cell line 
Platinum 
status 
HXR9 IC50 
(µM) 
P-value Standard 
Deviation 
Significance 
PEO1 Serous 27.3 0.62 
 
4.5 
NS 
PEO4 Serous 26.0 4.0 
PEO14 Serous 19.0 0.54 
 
4.3 
NS 
PEO23 Serous 28.3 2.7 
PEA1 Serous 14.6 0.21 9.4 
NS 
PEA2 Serous 27.3 3.8 
Note: The MTS assay was performed to determine IC50 values for HXR9. CalcuSyn 
software was used to accurately calculate values. The negative control peptide CXR9 
was not toxic at any of the concentrations tested for any of the cell lines (i.e. 
IC50>100µM). Values are representative from at least 3 independent experiments. 
NS; No statistical significance. 
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4.4.1 Assessing sensitivity to cisplatin in platinum sensitive and platinum 
resistant paired ovarian cancer cell lines 
 
The MTS assay was used to determine the IC50 values for cisplatin treatment. All 
platinum resistant cell lines, PEO4, PEO23 and PEA2 showed an increase in the IC50 
for cisplatin compared to their platinum sensitive counterparts, PEO1, PEO14 and 
PEA1, respectively, by 50-67% (Table 4.2).  
 
4.4.2 Synergistic effects of cisplatin and HXR9 in ovarian cancer cell lines 
 
The ability of HXR9 to increase cell cytotoxicity when combined with cisplatin 
treatment in ovarian cancer cells was investigated. Cells were treated with either 
HXR9 or cisplatin alone, or in combination at various concentrations. Cell lines were 
derived from platinum- resistant cancer were used: PEO4, PEO23, PEA2 and SKOV-3. 
The platinum sensitive cells lines, PEO1, PEO14 and PEA1 were also used to 
determine whether HXR9 and cisplatin combination treatment was more effective at 
cell killing. The IC50 values were subsequently compared to their platinum resistant 
counterpart to determine whether the combined treatment was just as effective in 
resistant cells. In all cell lines, HXR9 in combination with cisplatin produced a shift in 
the dose-response curve, showing decreased cell survival at lower drug 
concentrations than when either drug was used alone (Figure 4.3a-g). CalucSyn 
version 2.0 software was used to calculate synergy between the two drugs based on 
the median effect principle (Chou, 1991). Combination indices (CI) < 1 indicate 
synergism, CI = 1 shows an additive effect and CI>1 shows antagonism between 
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drugs. Combination effects between HXR9 and cisplatin suggested synergy for all ED 
values for the PEO4, PEO23 and PEA1 cell lines. Synergy at ED50 and strong synergy 
at ED75 and ED90 was observed in the PEO14 and PEA2 cell lines. Strong synergy was 
seen at all ED values in the SKOV-3 cell line (Table 3). The PEO1 cell line displayed an 
antagonistic effect at ED50 with a CI value of 1.26, but not from ED75 through to 
ED90 which show synergy present with CI values of 0.79 and 0.59, respectively (Table 
4.3).  
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Table 4.2. IC50 values for cisplatin treatment in paired ovarian cancer cell lines 
Cell line Platinum status Cisplatin  IC50 (µM) Fold increase 
PEO1 Serous 
23 
2.7 (62%) 
PEO4 Serous 
62 
PEO14 Serous 
13 
2 (50%) 
PEO23 Serous 26 
PEA1 Serous 
15 
3 (67%) 
PEA2 Serous 
46 
Note: The MTS assay was performed to determine IC50 values for cisplatin. CalcuSyn 
software was used to accurately calculate values. The negative control DMF was not 
toxic at any of the concentrations tested for any of the cell lines (i.e., the 
IC50>100µM). Values are representative from at least 3 independent experiments.   
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
 
a) PEO1 
 
 
 
b) PEO4 
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c) PEO14 
 
 
 
d) PEO23 
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e) PEA1 
 
 
 
f) PEA2 
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g) SKOV-3 
 
Figure 4.3. MTS assays for the assessment of synergy between HXR9 and cisplatin 
treatment in ovarian cancer cells. The MTS assay was used to measure the 
cytotoxicity of HXR9 alone, cisplatin alone, and HXR9 and cisplatin in combination for 
a) PEO1 b) PEO4 c) PEO14 d) PEO23 e) PEA1 f) PEA2 and g) SKOV-3 cells. Cisplatin 
exposure was 48 hours and HXR9 exposure was 2 hours. A sample of the same cell 
suspension was used as a ‘cell only’ control. Results are the average of at least 3 
independent experiments and error bars show the SEM. 
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Table 4.3.  Synergy results between HXR9 and cisplatin treated platinum sensitive 
and resistant cell lines 
Cell line Drug 
Parameters 
Combination index 
(CI) values at: 
Significance 
IC50 
(µM) 
r 
ED50 ED75 ED90 
PEO1 
HXR9 42.5 0.93 - - - - 
Cisplatin 20.8 0.96 - - - - 
Comb. 12.7 0.97 1.26 0.79 0.59 Synergy at ED75 and ED90 
PEO4 
HXR9 47.6 0.87 - - - - 
Cisplatin 52.2 0.99 - - - - 
Comb. 15.5 0.96 0.62 0.66 0.72 Synergy at all ED values 
PEO14 
HXR9 20.0 0.98 - - - - 
Cisplatin 21.0 0.41 - - - - 
Comb. 3.7 0.75 0.62 0.23 0.22 Synergy at ED50; Strong 
synergy at ED75 and ED90 
PEO23 
HXR9 46.0 0.95 - - - - 
Cisplatin 23.0 0.98 - - - - 
Comb. 14.0 0.98 0.82 0.73 0.67 Synergy at all ED values 
PEA1 
HXR9 25.6 0.97 - - - - 
Cisplatin 20.4 0.96 - - - - 
Comb. 9.9 0.97 0.91 0.81 0.73 Synergy at all ED values 
PEA2 
HXR9 22.5 0.98 - - - - 
Cisplatin 45.6 0.43 - - - - 
Comb. 7.9 0.79 0.89 0.48 0.47 Synergy at  ED50; Strong 
synergy at ED75 and ED90 
SKOV-3 HXR9 73 0.97 - - - - 
 Cisplatin 57.3 0.60 - - - - 
Comb. 10.0 0.92 0.41 0.30 0.27 Strong synergy at all ED 
values 
Note:  Cells were exposed to increasing concentrations of HXR9 or cisplatin either 
alone or in combination. Cells were treated with cisplatin for a total of 72hr and with 
HXR9 for 2hr. IC50 values were calculated using CalcuSyn version 2.0 software, from 
three experiments each conducted with three replicates. Combination index (CI) 
values at ED50, ED75 and ED90 were generated from the data shown in Figure 2 
with CalcuSyn software to establish the presence of synergy.                           Comb. = 
Combination treatment group. 
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4.4.3 Cisplatin and HXR9 combination treatment in vivo 
 
The effects of combined HXR9 and cisplatin on mice bearing SKOV-3 tumours was 
studied to determine if the synergistic effects observed in vitro between HXR9 and 
cisplatin also occurred in vivo. The combination group showed a significant difference 
in the rate of tumour growth when compared to the control treatment group (p = 
0.0066; Figure 4.4). No statistical significant differences were observed between the 
either treatment group and the control group. Kaplan-Meier survival curves of the 
data show that the combination group has the highest survival rate of 55 days 
compared to either treatment group alone, of which both had a survival of 46 days. 
The control group had a survival of 25 days. Although no significance was found 
between the control and combination treatment groups, the results do propose each 
treatment alone does prolongs survival and this increase is enhanced when both 
treatments are used in combination (Figure 4.5). This study also highlights the 
effectiveness of HXR9 as an anti-cancer treatment, showing the same survival 
outcome as the cisplatin alone treatment group.  
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Figure 4.4. In vivo combination study of HXR9 and cisplatin. Antitumor activity of 
HXR9 and cisplatin alone or in combination against ovarian cancer (SKOV-3) 
xenografts. Nude female mice were inoculated subcutaneously (SC) with 1 x 106 
SKOV-3 cells (Day 0). Treatment was initiated when tumours reached an approximate 
volume of 100m3. An initial dose of HXR9 was given IT at 100 mg/kg, followed by 
twice weekly doses at 10 mg/kg. Cisplatin was administered IP at 3 mg/kg weekly. 
Combinational studies consisted of both treatments; PBS was used as a control. 
Arrows indicates drug administration.  
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Figure 4.5. HXR9 and cisplatin combination treatment prolongs overall survival. 
Kaplan-Meier survival curves of mice bearing SKOV-3 tumours.  The combination 
treatment group shows the highest overall. No significance was found between the 
control or treatment groups. 
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4.5 Discussion 
Our findings show that platinum resistant cell lines have a higher overall HOX 
expression compared to normal cells and platinum sensitive cell lines. The main 
difference comes from a cluster of genes which are expressed at a lower level in both 
platinum sensitive cell lines and normal tissue compared to platinum resistance cells. 
These were HOXA2, A3, A4, A5, A6, A10, B4, B7, B9, C4 and C13 (Figure 4.2d). This 
suggests that these genes may play a role in the development platinum resistance; 
although further work is needed to understand the mechanism behind this. When 
analysing the specific changes in HOX expression profiles between the cell lines 
derived from the same patients who were initially sensitive to platinum treatment 
and subsequently developed resistance, the common finding is the upregulation of 
HOX genes from the HOXB cluster. These include HOXB1, B3, B4, B5, B6, B7 and B9, 
with HOXB4, B7 and B9 being common in at least two paired cell lines. Increased 
HOXB4 and B9 expression in the PEO4 and PEA2 cell lines, respectively, was still 
significant after the Benjamini and Hochberg correction for multiple testing (Figure 
4.2a-c). HOXB4 overexpression in ovarian cancer has been reported before in a 
relatively small study using only four cell lines and seven ovarian cancer tumour 
samples (Hong et al., 2010), but no oncogenic function for this gene has been 
determined. It has been implicated as a cancer-related gene in other malignancies, 
including breast cancer, leukaemia, osteosarcoma and lung cancer (Bodey et al., 
2000b, Zhang et al., 2008, Bodey et al., 2000c, Bodey et al., 2000a). HOXB7  
overexpression has also been previously reported (Naora et al., 2001b, Yamashita et 
al., 2006) to function in  DNA repair (Rubin et al., 2007), whereas HOXB3 has been 
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shown to epigenetically silence the RASSF1A gene, a tumour suppressor that is down-
regulated in a variety of cancers [reviewed in (Donninger et al., 2007, van der Weyden 
and Adams, 2007). The reduced expression of a number of HOXC and HOXD genes 
together with elevated HOXB expression suggests that the latter could have 
oncogenic properties, driving platinum resistance, while members of the HOXC and 
HOXD clusters are acting as tumour suppressors. This tumour promoting function of 
the HOXB genes is supported by the recent TCGA genomic analysis of HGS-OvCa. Four 
subtypes were described based on differences in gene content and one of which was 
named the ‘mesenchymal’ subtype, characterised by the high expression of HOX 
genes and markers suggestive of increased stromal components. The HOX genes 
overexpressed were of the HOXB cluster: HOXB2, B5 and B8. As described above, 
there is evidence that the EMT has a role in the acquisition of a stem-like cell 
phenotype by ovarian cancer cells, which leads in turn to drug resistance (Kurrey et 
al., 2009). It is possible that the HOXB genes support a mesenchymal subtype, and 
thus a stem-like cell phenotype that promotes platinum resistance. 
In chapter 3 the HOX genes were shown to have an anti-apoptotic affect in ovarian 
cancer cells, as inhibiting the function of these genes with the peptide HXR9 induces 
apoptosis. The specific increase in HOX gene expression in platinum resistant cells 
compared to platinum sensitive cells suggests that these may play a role in preventing 
cisplatin-induced apoptosis. As previously described in section 4.1, DNA-PK has been 
shown to play a role in specifically preventing cisplatin-induced apoptosis in platinum 
resistant cells through the phosphorylation of AKT at S473, thus activating the Akt 
survival pathway. The DNA-PKcs is recruited to DNA damage by the DNA binding 
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proteins, Ku70 and Ku80, which detect and bind to DNA double strand breaks, and 
thus initiate NHEJ repair. As HOX proteins have been shown to interact with Ku 
antigens and DNA-PK to promote their recruitment to double strand breaks for DNA 
repair, preventing the function of these HOX proteins through HXR9 treatment may 
be preventing DNA-PK activity. This in turn will prevent the initiation of the NHEJ DNA 
repair pathway and prevent AKT phosphorylation at S473. Prevention of AKT S473 
phosphorylation has already been shown to re-sensitise platinum resistant ovarian 
cancer cells to cisplatin (Stronach et al., 2011a), therefore, HXR9 treatment could also 
reverse the sensitivity of platinum through the indirect inhibition of AKT S473 
phosphorylation. This effect on both the NHEJ DNA repair and Akt/mTOR survival 
pathways could make HXR9 treatment more potent than DNA-PK inhibitors alone.  
In vitro work shows a synergistic relationship between HXR9 and cisplatin for the 
treatment of ovarian cancer. This raises the possibility of using HXR9 in combination 
with cisplatin as an alternative treatment option for platinum resistant ovarian cancer 
patients. To further extend these findings, an in vivo model was set up to investigate 
these synergistic effects between HXR9 and cisplatin. The results show a similar 
relationship between the two drugs, with the greatest inhibition of tumour growth in 
the combination drug treatment group compared to either drug used alone. The 
combination treatment group was the only group to show a statistically significant 
decrease in tumour volume compared to the control treatment group. The benefit of 
this drug combination is evidenced by an increase in overall survival in the 
combination group compared to those treated with HXR9 or cisplatin alone. 
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Combined platinum and HXR9 may thus represent an effective treatment strategy in 
platinum resistant ovarian cancer.  
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CHAPTER 5. 
 
HOX gene expression in primary ovarian cancer. 
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5.1 Introduction 
Unlike other tumour types which exhibit loss of specialised features of the tissue of 
origin, the majority of EOCs display specialised features of non-ovarian lineages. This 
has led researchers to question the origin of EOC. The traditional view has been that 
the EOC derives from the simple monolayerd OSE and that subsequent metaplastic 
changes lead to the development of different cell types: serous, endometrioid and 
mucinous, which morphologically resemble the epithelia of the fallopian tube, 
endometrium and endocervix, respectively. The OSE origin of EOC has been 
supported by several mouse genetic models where introduction of oncogenic 
alterations of the OSE induced tumour formation (Orsulic et al., 2002, Connolly et al., 
2003, Wu et al., 2007).  However, many argue that the OSE is not the precursor cell 
as this epithelium does not contain the constituents of which these tumours 
resemble. The fallopian tubes, endometrium and endocervix share a common 
embryological origin unrelated to that of the ovary. They derive from the embryonic 
structures called Müllerian ducts. They first develop as a pair medial to the 
mesonephric ducts during early foetal development and in females the distal portion 
eventually fuses to become the upper third of the vagina, cervix and the body of the 
uterus. The proximal segments remain unfused to become the fallopian tubes. 
Therefore, it is surprising to find that the EOC resemble the segments of the Müllerian 
tract despite not being embryonically related.   
The differentiation of the Müllerian ducts is controlled by homeobox genes which 
include the tandemly arranged HOXA9, HOXA10, HOXA11 and HOXA13 (Benson et al., 
1996, Zhao and Potter, 2001, Hsiehli et al., 1995). These genes are uniformly 
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expressed along the axis of the Müllerian duct during embryonic development and as 
the ducts differentiate the expression of these genes become restricted to particular 
regions of the reproductive tract, as described in chapter 1.2.2.2. This colinear 
pattern of expression is maintained in adulthood with HOXA9 expression found in the 
fallopian tubes, HOXA10 expression restricted to the uterus, HOXA11 expression 
found in the lower uterine/cervix and HOXA13 expressed in the upper vagina. These 
HOX genes are not expressed in the ovary but their expression is recapitulated in the 
major subtypes of EOC according to the Müllerian-like differentiation they display, 
with HOXA9 expression found in the serous histotype, HOXA10 expression is found in 
the endometrioid and HOXA13 expression in mucinous tumours (Cheng et al., 2005). 
Targeted mutagenesis of these genes results in region-specific defects along the 
reproductive tract, for example, Hoxa10-deficient female mice exhibit homoeotic 
transformation of the anterior segment of the uterus into oviductal-like structures 
(Benson et al., 1996). In another study, the homeobox of Hoxa11 was replaced with 
that of Hoxa13 in mice which resulted in the modified Hoxa11 to assume a Hoxa13 
function as the uterus showed homeotic transformation towards cervix/vaginal-like 
structures (Zhao and Potter, 2001). Ectopic expression of these genes in 
undifferentiated transformed mouse OSE cells which were then propagated in the 
peritoneaum of female mice produced tumours which acquired the features of 
different Müllerian lineages. Mouse OSE cells expressing Hoxa9  formed papillary 
tumours that resembled high-grade serous carcinoma, cells expressing Hoxa10  
produced high-grade endometrioid-like tumours and those expressing Hoxa11 
formed mucinous-like tumours (Cheng et al., 2005). Adult OSE cells have an 
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embryonic-like uncommitted phenotype (Auersperg et al., 2001, Naora, 2007) with 
very little E-cadherin expression -which is highly expressed in EOC and thought to 
promote tumour proliferation (MainesBandiera and Auersperg, 1997, Dong et al., 
2012), and strong expression of stem cell maintenance genes (Bowen et al., 2009). As 
a high level of plasticity is needed for post-ovulatory repair (Auersperg et al., 2001), 
this could explain the capability of OSE to acquire features of different lineages.  
In this chapter, HOX gene expression profiles of a cohort of patients with EOC 
including histotypes HGS, endometrioid and clear cell, were determined and 
statistically analysed against HOX profiles of normal ovary and normal fallopian tube 
tissue.  
 
5.2 HOX expression in HGS ovarian carcinomas compared to normal ovarian and 
fallopian tube tissue 
 
To comprehensively evaluate HOX gene expression profiles in HGS EOC, HOX profiles 
from a cohort of 73 HGS ovarian cancer patients were determined by qRT-PCR and 
compared to ten normal ovarian and three normal fallopian tube tissue samples 
(patient characteristics are summarized in Table 5.1). This is the first comprehensive 
analysis of the expression of all 39 members of the HOX gene family on a large cohort 
of primary ovarian cancer cases along with clinico-pathological comparisons.  
Very little to no HOX expression was found in the 10 normal ovarian tissue samples 
and 2 of the fallopian tube samples (Figure 5.1). One commercially brought fallopian 
tube RNA sample however did show slightly higher levels of HOX expression 
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compared to other fallopian tube tissues. A heatmap was produced to display the 
differential HOX expression between HGS and normal tissue samples. The samples 
are clustered based on the similarity of HOX gene expression between them.  The 
comparison of HGS tumours to normal ovarian and fallopian tube tissue exhibited a 
significant dysregulation in the expression of 30 of the 39 HOX genes (Figure 5.2). The 
strongly overexpressed genes included HOXA9 (p-value = 1.04 x 10-9), previously 
reported to be related to the HGS histotype (Cheng et al., 2005). An even more 
significant increase in expression was exhibited by HOXA3 with a p-value of 2.65 x 10-
11. Other highly significant overexpression was seen by HOXB13 and C10, with p-
values of 8.95 x 10-9 and 1.06 x 10-8, respectively.  
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Table 5.1. Patient characteristics 
Median age at surgery (range)  65 (30-88) 
Histology High grade serous 73 
 Endometrioid 7 
 Clear cell 4 
 MMMT 5 
FIGO stage at diagnosis I 5 
 II 3 
 III 59 
 IV 22 
Grade 1 and 3 4 
 3 and unknown 85 
Note: Tumour samples and patient information was obtained from the Royal Surrey 
Hospital, Guildford following informed consent and ethical approval. 
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Figure 5.1 HOX expression in normal ovarian tissue and normal fallopian tube tissue. RNA extracted from ten normal ovary tissue and three 
fallopian tube tissue samples were used. Expression of each gene was determined by real-time quantitative reverse transcription PCR (qRT-
PCR) from at least three independent experiments and expression is relative to the house keeping gene β-actin. Bars represent the mean of 
and error bars represent the SEM. 
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Figure 5.2. HOX gene expression in high grade serous (HGS) ovarian tumours.        a) 
Heat map showing differentially expressed HOX genes between HGS ovarian tumours 
and normal ovarian and fallopian tube tissue. HOX gene expression data for HGS 
tumours (yellow) were compared to ten normal ovarian and three fallopian tube 
tissue samples (green) and the results showed the upregulation of 33 genes in the 
HGS tumours. HOX expression profiles were determined by qRT-PCR and gene 
expression was normalised to housekeeping gene β-actin. Each row represents a 
gene and each column represents a sample. Rows-wise z-score transformation 
(genes) was used. Red colour for a gene indicates expression above the median level 
of expression across all samples and blue indicates expression below the median. b) 
(i) Principle component analysis (PCA) of high grade serous tumours (yellow) and 
normal ovarian and fallopian tube tissue samples (green). (ii) Bar plot showing the 
proportion of variance explained by each PCA component. 
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5.3 Comparison between HGS and endometrioid ovarian cancers  
 
There were significant differences in HOX expression profiles between the HGS and 
endometrioid histological subtypes (Figure 5.3a). HOXA7, A9, A10, A13, B13, C13 and 
D10 were significantly upregulated in the endometrioid samples, whilst HOXA1 and 
D11 were significantly downregulated. Principle component analysis (PCA), which 
separates samples based on similarities in HOX gene expression, shows a very tight 
clustering of endometrioid samples with a distinct HOX gene profile with very little 
heterogeneity as seen from the HGS samples (Figure 5.3b (i) and (ii)). HOXB2 was the 
only gene to show a significant difference between HGS and clear cell carcinomas, 
although this may be a reflection of the small sample size.  
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Figure 5.3. Comparison of HOX gene expression between high grade serous (HGS) 
and endometrioid ovarian tumours. a) Heat map showing differences in HOX gene 
expression between high grade serous (HGS) and endometrioid tumours. HOX gene 
expression data for HGS tumours (yellow) were compared to 5 endometrioid ovarian 
tumours (green). HOXA7, HOXA9, HOXA10, HOXA13, HOXB13, HOXC13 and HOXD10 
were overexpressed in the endometrioid samples compared to HGS tumours. HOXA1 
and D11 were significantly downregulated in the endometrioid samples compared to 
HGS tumours. HOX expression profiles were determined by qRT-PCR and gene 
expression was normalised to the housekeeping gene β-actin. Each row represents a 
gene and each column represents a sample. Rows-wise z-score transformation 
(genes) was used. Red colour for a gene indicates expression above the median level 
of expression across all samples and blue indicates expression below the median. b) 
(i) PCA of high grade serous tumours (yellow) and endometrioid tumour samples 
(green). (ii) Bar plot showing the proportion of variance explained by each PCA 
component. 
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5.4 HOX expression and clinical features in primary ovarian cancer  
 
The HOX expression profile in HGS EOC was subsequently correlated with clinical 
characteristics including stage, TTP and OS to establish if any particular HOX gene has 
a clinical value.  
 
 5.4.1 Stage 
 
The FIGO staging system was used to stage ovarian tumours and analysis revealed 
that stage IV cancers expressed HOXA9, B5, B13, C8, C9, C13, D9, and D10 at a lower 
level than stage I, II and III cancers (Figure 5.4a). Within the HGS subtype, HOXA9 was 
the only gene found to be expressed significantly lower in stage IV cancers (Figure 
5.4c). The PCA dot plots show that the stage I and II cancers are clustered closely with 
a group of stage III cancers, whereas the stage IV cancers are spread out on the dot 
plot away from stage I and II cases. Other stage III cancers are also closely related to 
stage IV. This shows there is a distinct difference in some cancers of stage I and II to 
stage IV, and that some stage III cancers are either similar to the stage I and II group 
or closer to the stage IV cancers. This could suggest that the stage III cancers plotted 
similarly to stage IV cancer may be close to developing into stage IV cancer, and those 
cancer cases clustered closely to stage I and II may be at an earlier stage in their 
disease progression. However, the current staging system only takes into account the 
anatomical distribution of cancer and does not reflect the molecular characteristics. 
This finding may reflect the more aggressive nature and poor differentiation of stage 
IV EOC tumours. 
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5.4.2 Overall survival and prognostic signature in ovarian cancer  
The HOX expression profile in EOC also correlated with OS. 5 HOX genes: HOXA13, 
B6, C13, D1 and D13 were expressed at a significantly higher level in the HGS tumours 
of patients with poor survival (Figure 5.5a). Each individual gene, analysed by the 
Kaplan-Meier method, showed that patients who had high expression of either of 
these genes had a significantly shorter survival time, with p-values ranging from 
0.0128 to 0.0317 and a HR ranging from 4.5 – 8.3 (Figure 5.5c (i)-(v)).  
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Figure 5.4. Comparison of HOX gene expression between disease stage in ovarian 
tumours. a) Heat map showing differential HOX gene expression between disease 
stages among all histotypes. The expression of 9 HOX genes was found to be 
statistically overexpressed in stage I and II tumours. b) (i) PCA of stage I and II (green), 
stage III (yellow) and stage IV (grey) tumour samples. (ii) Bar plot showing the 
proportion of variance explained by each PCA component. c) Comparison of HOX 
gene expression between disease stage in high grade serous (HGS) ovarian tumours. 
HOXA9 was the only gene found to be expressed at a higher level in earlier disease 
stages compared to stage IV. Staging was determined using the FIGO staging system. 
HOX gene expression was determined by real time quantitative reverse transcription 
PCR (qRT-PCR) and normalised to the housekeeping gene β-actin. Each row 
represents a gene and each column represents a sample. Rows-wise z-score 
transformation (genes) was used. Red colour for a gene indicates expression above 
the median level of expression across all samples and blue indicates expression below 
the median. 
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a)  
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b) (ii) 
 
 
 
 
 
 
 
 
 
c) (i) 
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c) (ii) 
 
c) (iii) 
c) (iv) 
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c) (v) 
 
 
Figure 5.5. Expression of 5 HOX genes correlated with poor overall survival in high 
grade serous (HGS) ovarian cancer. Heat map showing differential HOX gene 
expression between surviving and deceased patients. The expression of 5 HOX genes, 
HOXA13, HOXB6, HOXC13, HOXD1 and HOXD13 were found to be significantly 
overexpressed in patients who died due to their disease. HOX gene expression was 
determined by qRT-PCR and gene expression was normalised to the housekeeping 
gene β-actin. Each row represents a gene and each column represents a sample. 
Rows-wise z-score transformation (genes) was used. Red colour for a gene indicates 
expression above the median level of expression across all samples and blue indicates 
expression below the median. b) (i) PCA of alive (green) and dead (yellow) ovarian 
cancer patients. (ii) Bar plot showing the proportion of variance explained by each 
PCA component. c) Kaplan-Meier survival curves of patients expressing high (≥ upper 
quartile) or low (≤ lower quartile) transcript levels of each of the 5 HOX genes i) 
HOXA13 ii) HOXB6 iii) HOXC13 iv) HOXD1 and v) HOXD13 which were found to be 
associated with poor overall survival in ovarian cancer patients. Statistically 
significant relationships were found between high expression and poor overall 
survival for all 5 genes. Significant values were determined by log-rank test. c) PCA of 
surviving (green) and deceased (yellow) patient tumour samples. ii) Bar plot showing 
the proportion of variance explained by each PCA component.  
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5.4.3 TTP 
 
To determine whether the expression of certain HOX genes could act as a prognostic 
marker for HGS patients, the relationship between HOX gene expression and TTP data 
for each patient was analysed. No HOX gene was found to be significant in relation to 
TTP within the HGS samples only, however, when all cancer samples were included 
in the analysis, the expression of HOXD13 was significantly associated with TTP. The 
expression of HOXD13 was found to be significantly higher in both those patients who 
progressed within and beyond 6 months after chemotherapy compared to the non-
progression group (Figure 5.6). 
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Figure 5.6. Correlation of HOX gene expression with time to progression (TTP) in all 
ovarian cancer tumours. Patients who had received chemotherapy were divided into 
3 groups depending on their TTP: NP (no progression), TTP<6 (progressed within 6 
months of chemotherapy) or TTP> 6 (progressed after 6 months post chemotherapy). 
HOXD13 was the only gene found to be expressed higher in patients who progressed 
(for both groups :<6 months and >6 months compared to the no progression group).  
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5.5 Discussion 
The data analysed in this chapter confirms that HOX genes are highly dysregulated in 
ovarian cancer with 30 of the 39 HOX genes showing significantly increased levels of 
expression in ovarian tumours compared to normal ovarian and fallopian tube tissue. 
Little to no expression was found in normal ovarian tissue and two of the fallopian 
tube tissue samples, however, one fallopian tube sample did show a higher level of 
expression than other normal samples. This was a commercial RNA sample which 
states no cancerous cells were present. The HOX genes which were expressed at a 
higher level may be an indication of genes with tumour suppressor roles as the HOX 
genes showing the highest level of expression, HOXA5 , has been reported previously 
to have tumour suppressor roles in breast cancer (Raman et al., 2000, Chen et al., 
2004b).  
Cheng et al. have previously shown that the overexpression of specific HOX genes 
determines the histological subtype, HOXA9 being overexpressed in serous subtypes, 
HOXA10 in endometrioid and HOXA11 in mucinous (Cheng et al., 2005). In this study 
HOXA9 was significantly overexpressed in the HGSs samples, however HOXA10 and 
HOXA11 were also expressed, which was not previously reported in the Cheng study. 
HOXA7 has been suggested to play a role in the process of differentiation of OSE to 
EOC (Ota et al., 2007). We found that HOXA7 is overexpressed in HGS cancers as well 
as in the endometrioid carcinomas compared to normal ovarian and fallopian tube 
tissue, supporting this role. In addition, HOXA13 is also overexpressed in the HGS and 
endometrioid tumours. This suggests that the HOXA genes play a role in the 
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determination of histological subtypes, but the differences in expression are not as 
clear as previously suggested by Cheng et al.  
 
The highest degree of heterogeneity in HOX expression is displayed in the HGS 
tumours, whereas the endometrioid subtypes show a very distinct HOX expression 
profile. This is illustrated in Figure 5.3 b) (i) showing the PCA plot between 
endometrioid and HGS samples. The tight clustering of endometrioid samples shows 
that these tumour samples express the same genes at similar levels, in particular 
expressing HOXA7, A9, A10, A13, B13 and D10 at significantly higher levels than HGS. 
This may suggest these genes are particularly important in the endometrioid subtype 
of ovarian cancer. This finding therefore suggests the endometrioid subtype of 
ovarian cancer may be very susceptible to a treatment which targets HOX gene 
function. To investigate this further a larger sample size of endometrioid ovarian 
cancers would be needed to firstly demonstrate that high expression of these HOX 
genes are characteristic of the endometrioid subtype. Secondly, isolation of cancer 
cells from these tumours could be used to grow in vitro and in the CAM model in 
order to determine their sensitivity to HXR9, targeting HOX gene function. However, 
this subtype of ovarian cancer is less common than HGS, and therefore this 
experimental plan is determined by time and available resources. 
The HGS samples are distributed throughout the PCA plot with no apparent group 
clustering. The HGS histological subtype is known to be genetically heterogeneous 
and this is likely to explain this variation as the level of gene expression may differ in 
individual tumour samples, however the functional redundancy between HOX genes 
198 
 
may mean the net effect of HOX overexpression is similar even in cells expressing 
different HOX genes (Lappin et al., 2006).  
 
The only significant difference between HGS and clear cell histotypes is HOXB2. 
However, this may reflect the limited number of clear cell samples in the cohort. Clear 
cell carcinomas share characteristic features of both serous and endometrioid 
cancers, with glycogen filled clear cells arranged in papillary configurations mixed 
with endometrioid patterns, which may account for the lack of difference between 
the subtypes. Clear cell carcinomas have however a very different molecular profile 
and should not be classed in the same group as HGS and endometrioid cancers.  
 
Although the function of the HOX genes in cancer has still not been fully elucidated, 
there have been reports that they act as tumour suppressors or oncogenes, described 
in chapter 1.2.4. In ovarian cancer both HOXB7 and B13 expression has been linked 
to the invasion characteristics of ovarian cancer cells (Yamashita et al., 2006), and 
HOXB7 has been shown to be a regulator of bFGF- a potent mitogenic and angiogenic 
factor (Naora et al., 2001b), and to be involved in double strand break repair (Rubin 
et al., 2007). HOXB13 has been shown to promotes cell proliferation (Miao et al., 
2007b). HOXB7 is also a potential oncogene for other cancers as well. In melanoma, 
HOXB7 overexpression leads to increased cellular proliferation via direct 
transactivation of the bFGF gene (Caré et al., 1996) and in breast cancer HOXB7 
promotes EMT through activation of the RHO/RAC pathway (Wu et al., 2006). ER+ 
breast cancer cells were shown to overexpress HOXB7 causing resistance to 
tamoxifen through increased EGF receptor (EGFR) expression and signalling (Jin et al., 
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2012). Further evidence for a functional role of the HOXB cluster in cell proliferation 
is the rapid wave of expression of the HOXB genes from 3’ to 5’ direction, e.g. HOXB1-
HOXB9, induced in mitogen activated peripheral T lymphocytes (Care et al., 1994), 
and the data presented in this chapter supports this with seven out of the ten HOXB 
genes upregulated in ovarian cancer: HOXB1, B2, B4, B5, B6, B7 and B13.  
 
HOXB4 overexpression in ovarian cancer has been reported before in a relatively 
small study using only four cell lines and seven ovarian cancer tumours samples (Hong 
et al., 2010), but no oncogenic function for this gene has been determined. It has 
been implicated as a cancer-related gene in other malignancies, including breast 
cancer, leukaemia, osteosarcoma and lung cancer (Bodey et al., 2000b, Zhang et al., 
2008, Bodey et al., 2000c, Bodey et al., 2000a). A role in cell proliferation is implied 
as it has been shown to be a strong positive regulator of HSC self-renewal. Retroviral 
overexpression of HOXB4 significantly enhanced in vivo HSC regeneration (Antonchuk 
et al., 2001, Thorsteinsdottir et al., 1997, Sauvageau et al., 1995) and HOXB4-
transduction leads to HSC expansion ex vivo (Antonchuk et al., 2002).  Furthermore, 
when mice were injected with Rat-1 cells (a rat fibroblast cell line) overexpressing 
HOXB4 they developed well vascularized tumours (Krosl et al., 1998). The recent 
genomic analysis of HGS-OvCa by the TCGA researchers detected numerous somatic 
copy number alterations and three members of the HOXB family, HOXB2, B5 and B8 
were among these focally amplified regions. The group divided HGS ovarian cancer 
into four expression subtypes ‘immunoreactive’, ‘differentiated’, ‘proliferative’ and 
‘mesenchymal’ on the basis of gene content, and high expression of HOX genes were 
characteristic of the mesenchymal subtype (TCGA, 2011). HOXB2 and B5 were among 
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those found overexpressed in HGS tumour samples in this study, supporting an 
oncogenic role of HOXB genes in ovarian cancer. The function of HOXB1, B2, B5 and 
B6 in ovarian cancer has not been previously identified and results from this chapter 
suggest further investigation into their roles is needed. 
  
Correlation between HOX expression and clinical characteristics including FIGO stage, 
TTP and OS were investigated. Interestingly stage IV cancers expressed HOXA9, B5, 
B13, C8, C9, C13, D9, D10 and D13 at a lower level than stage I, II and III tumours 
(Figure 5.4a). The FIGO staging system is traditionally based on clinical examination 
and on the anatomical extent of the disease, some of the early stage cancers may in 
fact be inadequately staged and the correlation with specific gene expression profile 
may be misleading.  However, one explanation for the difference between the more 
advanced and earlier stages of cancer may be the role these genes play in the early 
events of ovarian tumourgenesis and the dedifferentiation of the more aggressive 
and subsequently very advanced cancers. The unique characteristic of EOC is the 
ability of the OSE to differentiate into a committed phenotype resembling epithelial 
of the Müllerian duct (Auersperg et al., 2001). HOX genes induce haematopoietic 
progenitor cells to differentiate along specific lineages (Magli et al., 1997) and 
aberrant expression of HOX genes in the OSE could be the early step in epithelial 
ovarian neoplasia to induce epithelial differentiation. The HOX genes found to be 
expressed in the early disease stages may be involved in this differentiation process 
for the development of the OSE into EOC resembling the specialised epithelia of the 
reproductive tract. It is only in the late disease stages that the specialised epithelial 
features of EOC diminish, displaying a less epithelial-like morphology 
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(MainesBandiera and Auersperg, 1997) which would account for the loss of 
expression of these specific HOX genes; HOXA9, B5, B13, C8, C9, C13, D9 and D10. As 
previously discussed, Cheng et al. show that the HOX genes involved in the 
development of the Müllerian duct are expressed in ovarian cancer determining 
histotype (Cheng et al., 2005). Interestingly, HOXA9 is the only gene found to show 
significance between early and late stage disease in the serous EOC patients (Figure 
5.4c). Expression of this gene is usually restricted to the fallopian tube in the 
reproductive tract, which is the epithelium that serous cancers resemble, further 
supporting a role for HOXA9 in the differentiation of OSE into EOC. Thus, it is possible 
that, in addition to HOXA9, these other genes are needed to drive the differentiation 
of OSE into EOC and their expression is lost as the cancer cells loses differentiation in 
the most advanced stages.  
 
Survival analysis in the context of HOX gene overexpression showed that a cluster of 
5 HOX genes: HOXA13, B6, C13, D1 and D13, were highly correlated with poor OS in 
HGS patients. HOXA13 is usually expressed in the upper vagina (Taylor et al., 1997) 
playing a role in Müllerian duct differentiation during development, but has been 
reported to be overexpressed in ovarian cancer cell lines (Yamashita et al., 2006). 
HOXA13 is also expressed abnormally in oesophageal cancerous tissues but not in 
non-cancerous tissues counterparts (Chen et al., 2005). It was linked to poor OS in 
oesophageal squamous cell carcinoma patients, and the same study found that its 
expression in cell lines enhanced tumour growth in vitro and in vivo (Gu et al., 2009). 
HOXA13 has been linked to leukaemogenesis as well (Taketani et al., 2002, Su et al., 
2006). High-throughput microarray analysis of gastric cancer patients revealed 
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HOXA10 and A13 over-expression  with HOXA13 upregulation significantly associated 
with an aggressive phenotype, and a prognostic marker for poor OS (Han et al., 2013). 
Large-scale deregulation of the HOXA cluster has been found in hepatocellular 
carcinoma (HCC), in particular HOXA13 (Cillo et al., 2011). Cillo et al. found it to be 
the only HOX gene to be consistently overexpressed, independent of stage and 
expression, and that its expression was associated with a poor prognosis (Cillo et al., 
2011). It was shown HOXA13 strongly interacts with the initiation factor of protein 
synthesis, eIF4E, a protein overexpressed  in human cancers and a strong promoter 
of tumour growth and angiogenesis (De Benedetti and Graff, 2004). HOXA13-eIF4E 
complexes were found abundantly in actively proliferating HCC cells suggesting 
HOXA13 plays a role in the proliferation of tumour cells, regulating gene expression 
at a post-transcriptional level. It is thought to act in a similar way to HOXA9, which 
interacts with eIF4E to facilitate the export of nuclear mRNAs and promote cell 
proliferation (Topisirovic et al., 2005).  
 
Upregulation of HOXB6 has been reported in ovarian cancer before in addition to 
HOXB7 with the highest levels of expression observed in early-stage tumours (Stone 
et al., 2003). The oncogenic roles of HOXB genes have been demonstrated in mouse 
studies where overexpression caused hematopoietic cells to transform with high 
frequency. This was due to HOXB3 and HOXB4 heterodimerisation with PBX or Meis 
proteins which resulted in the blocking of normal differentiation of haematopoietic 
lineages (Thorsteinsdottir et al., 2001, Krosl et al., 1998). Data from this study and 
previous reports of high HOXB expression in ovarian cancer suggests that the HOXB 
gene products play a role in ovarian tumourgenesis.  
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HOXC13 is known to play a fundamental role in skin homeostasis in the adult, being 
an important regulator of the hair keratin gene cluster (Jave-Suarez et al., 2002). 
Overexpression of HOXC13 in transgenic mice led to the development of alopecia, 
accompanied by a progressive pathological skin condition (Tkatchenko et al., 2001). 
In addition to this developmental role, a recent study has shown HOXC13 is a member 
of human DNA complex involved in DNA replication (Comelli et al., 2009) supporting 
an oncogenic function. A role in human cancer has also been reported with 
overexpression found in metastatic melanoma (Cantile et al., 2012) and fusion with 
NUP98 has been associated with AML (Panagopoulos et al., 2003). HOXC13 has also 
been shown to be transcriptionally regulated by the steroid hormone oestrogen (17 
beta-estradiol; E2) and the mixed lineage leukaemia (MLL) family of histone 
methylases, in an E2 dependent manner (Ansari et al., 2009). This prompted a study 
of the role of HOXC13 in tumourgenesis, revealing it to be essential for cell viability 
and cell cycle progression. Furthermore, its overexpression induced three-
dimensional (3D) colony formation in soft agar media (Kasiri et al., 2013). Regulation 
by oestradiol may explain its involvement in ovarian cancer and its association with 
poor survival.  
 
In one study, HOXD1 was among 28 HOX genes which were upregulated in the 25 
HCCs analysed compared to the 19 non-cancerous liver tissues (Kanai et al., 2010). 
Increased HOXD1 expression was found after inducing human neuroblastoma (NB) 
cells to differentiate with retinoic acid (Manohar et al., 1996). A genome-wide 
association study of single nucleotide polymorphisms (SNPs) in ovarian cancer 
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patients found the ovarian cancer risk-associated SNP rs2072590 lies in non-coding 
DNA downstream of HOXD3 and upstream of HOXD1 (Goode et al., 2010). By 
comparing HOXD1 and HOXD3 expression between normal primary OSE cells and 
ovarian cancer cells, they found differences in HOXD1 gene expression only, 
concluding HOXD1 has a gain-of-function role in ovarian cancer development (Goode 
et al., 2010). The data in this chapter supports this role of HOXD1 in ovarian cancer. 
 
In normal morphogenesis, HOXD13 is involved in the determination of the terminal 
digestive and urogenital tracts.(Warot et al., 1997, Podlasek et al., 1997, Huang et al., 
2007). HOXD13 deregulation has been shown in breast and cervical cancer, 
melanoma and astrocytomas (Makiyama et al., 2005, Lopez et al., 2006, Maeda et al., 
2005, Abdel-Fattah et al., 2006), and plays a role in the neuro-endocrine 
differentiation of advanced prostate cancers (Cantile et al., 2005). Cantile and 
colleagues conducted a large analysis of HOXD13 expression in 79 different tumour 
types (Cantile et al., 2009). HOXD13 homeoprotein expression in more than 4000 
normal and neoplastic tissue samples were detected using microarray technology. 
Validation at the RNA level was also performed on selected tumour types. When 
comparing multi-normal and multi-tumour array staining, differential HOXD13 gene 
expression was found in 19 tissues and a significant increase in mRNA levels were 
found in the cancerous tissues of the brain, colon, breast, endometrium, lung and 
skin compared to the normal tissue. A significant increase in the homeoprotein 
expression was also found in ovarian serous adenocarcinoma and endometrioid 
carcinomas. The deregulated HOXD13 expression in these adenocarcinomas 
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reported from the study’s multi-tumour tissue microarray (MT-TMA), suggests that 
this gene may be involved in the neoplastic transformation of glandular epithelia.  
 
HOXD13 was found to be correlated to TTP when including all tumour samples in the 
analysis, with significantly higher expression found in patients whose cancer had 
progressed after chemotherapy. Therefore, high HOXD13 expression may act as a 
marker for poor prognosis in all ovarian cancer histology’s. Interestingly, high 
expression of HOXD13 also correlated with poor OS, therefore HOXD13 is a good 
candidate for a prognostic marker in ovarian cancer patients.  
 
 
This comprehensive analysis of HOX gene expression in primary ovarian tumours 
demonstrates that they are profoundly dysregulated compared to normal ovary and 
fallopian tube tissue. A high level of heterogeneity was found in HGS tumours, 
whereas endometrioid tumours show a distinct HOX profile, expressing genes at a 
much higher level than other histotypes. The results strongly suggest that the HOXB 
genes play an important role in ovarian tumourgenesis. The clinical relevance of this 
dysregulated HOX expression was further supported by a 5 HOX gene-signature that 
predicts poor outcome: HOXA13, B6, C13, D1 and D13 in EOC patients. Eight HOX 
genes: HOXA9, B5, B13, C8, C9, C13, D9 and D10, were expressed at a lower level in 
late disease stages, suggesting a role in cellular differentiation during the early events 
of ovarian tumourgenesis. These HOX gene signatures have a prognostic significance 
and HOX gene dysregulation may represent a novel therapeutic target.   
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CHAPTER 6. 
 
The chorioallantoic membrane (CAM) model of 
ovarian cancer 
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6.1 Introduction 
 
The majority of animal model systems to study cancer progression involve the use of 
immunocompromised mice and rats for hetero- or orthotopic transplantations of 
human tumour cells. Currently, the most commonly used animal model to study 
ovarian cancer is subcutaneous or IP injection of tumour cells into nude mice. 
However, these models have their limitations, including high cost, a long 
experimental time frame and the need for a large number of animals. A less 
commonly used model for the study of cancers is the CAM model. This model was 
first introduced by Murphy (Murphy, 1913) and involves the grafting of cancer cells 
on to the CAM of a fertilized chick egg for short-term investigations. The model 
represents an intermediate state between in vivo and in vitro systems and addresses 
some of the limitations faced with previously used animal models. The chick embryo 
is a naturally immune-deficient host which can tolerate inoculation of a variety of 
tumours (Armstrong et al., 1982, Murphy, 1913, Ossowski and Reich, 1980) without 
specific or non-specific immune responses. It therefore avoids the problem of lack of 
tumour establishment, often encountered in IP xenografts in mice. This lack of 
establishment is thought to be attributed to variable immunocompetence of the 
recipient mice (Elkas et al., 2002) and also to the absence of a structural support and 
interactions with ECM’s for the cells. The CAM model provides a unique supportive 
environment for primary tumour formation and cells seeded onto the CAM are able 
to rapidly develop into vascularised micro-tumours with organoid structures within 
days following cell grafting. This is due to the rich supply of blood vessels and 
capillaries present in the CAM. As the CAM is connected to the embryo through a 
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continuous circulatory system, it is also an ideal model to study angiogenesis, tumour 
cell invasion and metastasis, and has been widely used to do so (Richardson and 
Singh, 2003, Deryugina and Quigley, 2008, Tufan and Satiroglu-Tufan, 2005, Ossowski 
and Reich, 1980, Zhai et al., 2007).  
 
Another limitation of mouse xenograft models is the location of the tumour and their 
inability to mimic the human disease. Microarray studies have shown that the gene 
expression profiles of cancer cells vary significantly depending on tumour location 
(Hao et al., 2004, Margalit et al., 2003, Yanagawa et al., 2001). The microenvironment 
of the ovary influences cell behaviour and it is therefore important to use a model 
that is representative to the human disease to accurately study the cellular and 
molecular changes associated with the initiation and progression of human ovarian 
cancer. Subcutaneous or IP xenografts do not mimic the ovarian microenvironment, 
however, orthotopic injection of cancer cells do. This procedure involves an injection 
of cancer cells into the  ovarian bursa of rodents, the sac surrounding the ovaries, 
and more accurately represents human disease as this is where ovarian cancer 
normally progresses, providing an ovarian microenvironment, however this 
procedure is less commonly used and has a number of disadvantages. The surgery is 
complex, and therefore low numbers of mice per study are used. The model is costly 
and tumor growth and response are difficult to follow and therefore often the only 
end point used is survival.  
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The ECM constitution of the CAM is similar to that of the peritoneum which is the 
membrane that surrounds the ovaries. This has allowed the CAM model to be 
successfully used to transplant newborn mouse ovaries (Gigli et al., 2005) and foetal 
bovine ovarian cortical tissue (Gigli et al., 2005, Cushman et al., 2002).  A study by 
Cushman et al (Cushman et al., 2002) who investigated the process involved in the 
activation of the growth of primordial follicles by grafting ovarian cortical pieces to 
the CAM reported that the chick membrane forms a bursa-like structure around 
vascularised ovarian cortical pieces which results in a microenvironment similar to 
that of the ovary. In addition, ECM proteins such as fibronectin, laminin, collagen type 
I and integrin ανβз (Giannopoulou et al., 2001) are present in the CAM, mimicking a 
physiological cancer cell environment. This makes the CAM model more favourable 
than subcutaneous xenografts.  
 
The difficulty in monitoring IP disease formation and progression in vivo is another 
criticism of xenograft models. Visual assessment of tumours is only possible using 
magnetic resonance imaging (Gossmann et al., 2000) or with cells that stably express 
green fluorescent proteins (Chaudhuri et al., 2001), however these techniques are 
costly and the repeated transportation of immunodeficient animals can be 
problematic. These problems are overcome by using the CAM model as real-time in 
vivo observations can be made using simple microscopy, allowing easy assessment of 
tumour formation and progression. 
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The CAM assay is a well-established model for the study of angiogenesis and invasion 
of cancer cells in other malignancies such as bowel cancer (Cecilia Subauste et al., 
2009, Demir et al., 2009), prostate cancer (Kobayashi et al., 1998, Wittig-Blaich et al., 
2011, Conn et al., 2009), glioma (Strojnik et al., 2010, Balciuniene et al., 2009, 
Hagedorn et al., 2005), leukaemia (Taizi et al., 2006) and osteosarcoma (Balke et al., 
2010), however there has only been two studies which have used the CAM assay to 
assess ovarian cancer invasion and metastasis (Chang et al., 2011, Lokman et al., 
2012), one of which used this model to study the effect of novel therapeutic 
molecules on cancer cell invasion (Lokman et al., 2012). The advantage of using the 
CAM model to study the effect of such drugs is that the CAM is a closed system, and 
therefore the half-life of many experimental molecules such as small peptides tends 
to be much longer in comparison to animal models. This allows experimental study 
of potential anti-cancer compounds that are only available in small quantities (Tufan 
and Satiroglu-Tufan, 2005, Cimpean et al., 2008). 
 
The aim of research presented in this chapter was to evaluate CAM as a model to 
grow ovarian cancer tumours and assess its potential to test novel agents in tumour 
tissues. The CAM assay was used to grow ovarian tumours derived from HGS cell lines 
and cells cultured from the ascites of ovarian cancer patients, and as a model to 
investigate the efficacy of the peptide HXR9 in the treatment of ovarian cancer. CAM 
tumours were then paraffin embedded and subsequently stained to show tumour 
structure and to investigate the mechanism of cell death by HXR9. 
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The work presented in this chapter is the first to demonstrate the use of the CAM as 
an alternative three-dimensional model to xenografts to represent primary human 
ovarian tumours as an in ovo test system for drug toxicity, leading to the novel use of 
a screening method for drug sensitivity for individual patients. This work adds to the 
very limited research using this model of ovarian cancer (Chang et al., 2011, Lokman 
et al., 2012).  
 
6.2 Using the CAM assay as a model of ovarian cancer 
 
The CAM is an extra-embryonic organ responsible for gas exchange during embryonic 
life (Figure 6.1). Formation of the CAM occurs between embryonic day (ED) 4 and 5, 
when the mesodermal lining of the chorion fuses with the vascularised outer 
mesodermal layer of the allantois (Romanoff, 1960). The CAM does not fully envelope 
the embryo until ED12, although the central portion of the CAM is fully developed by 
ED7 to 10 whereupon it is capable of sustaining tissue grafts. The CAM is a very thin 
structure (<100 μm thick) consisting of all three germ layers, the ectoderm, 
mesoderm and endoderm. The ectoderm is attached to the shell membrane and 
overlays the capillary plexus. The capillary plexus is fully developed by ED10 and 
appears as a honeycomb of tiny capillaries connecting the arterial and venous blood 
vessel networks (Melkonian et al., 2002).  The mesoderm is a collagen-rich embryonic 
connective tissue enriched by blood vessels belonging to the arteriolar and venous 
systems. It overlays a thin endoderm layer, which separates the CAM from the 
allantoic cavity (Romanoff, 1960).  
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For the in ovo method, eggs were incubated at 37 oC with 60% relative humidity on 
ED1. On ED4, the CAM is exposed by puncturing the portion of the shell above the air 
space with a 19ga needle and removing the shell with forceps to make a small window 
(Figure 6.2a). The membrane is carefully removed with sterile forceps to expose the 
embryo and blood vessels and the eggs are then returned to 37°C to recover (Figure 
6.2b). On ED7 ovarian cancer cells (4x106 cells) were grafted onto the CAM by causing 
a micro-bleed in a blood vessel (Figure 6.2c) and adding cells suspended in 30μl of 
matrigel (Figure 6.2d). Test reagent may be applied topically, IT or IV on ED14-18. On 
or before ED20 embryos are terminated by refrigeration at 4°C for at least 4 hours, 
shells are broken and the tumour is dissected out. Detailed methodology is described 
in chapter 2. The CAM tumour can then be stored appropriately for subsequent 
analysis.  
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Figure 6.1. Schematic cross-section of a chicken embryo on embryonic day (ED) 15.  
The chick embryo is entirely surrounded by the chorioallantoic membrane (CAM) 
(shown in red). The CAM is comprised of an upper chorionic epithelium, intervening 
mesenchyme, and lower allantoic epithelium and is a very vascular structure which 
allows gas exchange during embryonic life.   
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a)   
 
 
 
b) 
 
 
 
c)      
 
 
 
 
d) 
 
 
 
Figure 6.2. Chick chorioallantoic membrane (CAM) preparation and grafting 
procedure. Demonstration of tumour grafting onto the CAM. a) Shell is carefully 
removed to expose the CAM on embryonic day (ED) 4, b) eggs are returned to the 
incubator to recover until ED7, c) induction of a micro-bleed using a sterile cotton 
swab on a major blood vessel on ED7 for the inoculation of tumour cells, d) showing 
tumour formation of ED12. 
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The CAM was used to successfully grow human tumours using the HGS cell lines 
SKOV-3, COV-318, PEO1 and PEO4. The incidence of tumour formation was 100% 
after inoculation on ED7 without the need of growth supplementation. By ED10 a 
monolayer of grafted cells was visible and by ED12 the formation of three-
dimensional tumours could be observed, with an average diameter of 3mm (Figure 
6.3). The increased number of capillaries in the seeding area is further evidence of 
successful tumour grafting. As tumour development progressed, a more spherical 
and solid tumour became visible, whereas the initial graft appeared to consist of a 
monolayer of cells (Figure 6.4 a-c). Tumours were measured using the Dino-Lite 
digital microscope AM413MT and DinoCapture 2.0 software. Due to the nature of 
tumour formation on the CAM, accurate tumour growth rates were difficult to 
calculate as measurements could only be taken from aerial view and the majority of 
the tumour was not visible. Therefore growth curves do not depict true tumour 
growth. The infection rate of eggs was low with an average of 11% of embryos dying 
before ED20.  
 
Tumours were paraffin embedded and subsequently sectioned and stained with 
haemolysin and eosin (H&E). H&E slides of established cell line derived CAM tumours 
were shown to a pathologist at Royal Surrey Hospital who confirmed they 
represented HGS ovarian cancer. Staining shows poorly differentiated 
adenocarcinoma with homogeneous cell shape and large cell nuclei, resembling 
sections from primary ovarian tumours as shown on Figure 6.5. HGS carcinomas are 
architecturally heterogeneous multiloculated, partially cystic, partially solid tumours 
and this is depicted in the CAM tumours. Cells are atypical with pleomorphic nuclei 
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and hyperchromasia. A characteristic of papillary carcinomas is the presence of 
psammoma bodies. These are concentric lamellated calcified structures commonly 
found in papillary thyroid carcinoma, meningioma, and papillary serous 
cystadenocarcinoma of ovary, but rarely in any other neoplasm. Psmomma bodies 
were present in the majority of slides (Figure 6.5 a) (ii) and b) (ii).   
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a)   
 
 
 
 
 
 
b)  
 
 
 
 
 
 
Figure 6.3. COV-318 cell derived chorioallantoic membrane (CAM) tumour 
development from embryonic day (ED) 10 to 12. 4 x 106 COV-318 cells suspended in 
30 µL of matrigel were grafted onto the CAM on ED7. a) COV-318 and matrigel graft 
on the CAM on ED10 shows an opaque area of cells at site of inoculation, b) same 
CAM tumour on ED12 showing formation of a three-dimensional structure.   
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a)  
 
 
 
 
b) 
 
 
 
 
 
c) 
 
 
 
 
 
Figure 6.4. SKOV-3 cell line derived tumour development on the chick 
chorioallantoic membrane (CAM). 4 x 106 SKOV-3 cells were suspended in 30 µL of 
matrigel and grafted onto the CAM on embryonic day (ED) 7. a) SKOV-3 cells and 
matrigel graft on the CAM on ED11, b) same CAM tumour on ED17 and c) same CAM 
tumour ED18 showing more spherical tumours and increased capillary formation.  
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a) (i) 
 
 
a) (ii) 
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a) (iii)  
 
 
 
b) (i) 
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b) (ii) 
 
 
c) (i) 
 
 
 
 
222 
 
c) (ii) 
 
 
 
Figure 6.5. Histology of chick chorioallantoic membrane (CAM) tumours H&E 
staining to show typical HGS tumours. a) H&E staining of SKOV-3 derived CAM 
tumour. (i) Magnification x 4; (ii) magnification x10 showing psammoma body 
characteristic for serous papillary ovarian cancer (black arrowhead) and (iii) enlarged 
image of cells; magnification x 40. b) H&E staining of COV-318 derived CAM tumour. 
(i) magnification x 10; (ii) magnification x20, showing psammoma bodies (black 
arrowhead) and c) H&E staining of PEO1 derived CAM tumour. i) Magnification x 10; 
(ii) magnification x20.  Examples of nuclear pleomorphism (red arrowhead); 
prominent nucleoli with irregular chromatin patterns (green arrow), and mitotic activity 
(yellow arrow).  
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6.3 Establishment of CAM tumours from cells derived from ascites of ovarian cancer 
patients 
 
The disadvantage of using commercial cell lines for the in vivo study of ovarian cancer 
is the lack of true representation of human tumours. These cell lines do not 
recapitulate the heterogeneity of ovarian tumours. To study tumour behaviour it 
would be best to use cancer cells derived from ovarian cancer patients to grow 
tumours. In addition, an ideal anti-cancer chemo-sensitivity test should be designed 
for each patient since human tumours have different growth potentials and drug 
sensitivities. Chemo-sensitivity tests can be performed in vitro using cells cultures 
from primary tumours or ascites, however, in vivo techniques have the advantage of 
evaluating the net response of solid tumours composed of heterogeneous cell 
populations. Therefore, the potential of using the CAM model to do so was assessed.  
 
Firstly, cells from primary ovarian tumours and ascites of ovarian cancer patients 
were cultured in vitro. To determine that the cells cultured were of ovarian origin and 
cancerous, cells were stained for ovarian cancer markers (Table 6.1). These markers 
were chosen on the basis that they are routinely used by hospital pathologists to 
characterise and diagnosis EOC from biopsies. Epithelial membrane antigen (EMA), 
also known as MUC-1, is a glycoprotein and a marker of epithelial differentiation that 
is highly expressed on the surface of ovarian cancer cells. It is also thought to have an 
oncogenic role through its function in signal transduction (Feng et al., 2002). 
Cytokeratin 7 (CK-7) is a basic cytokeratin expressed in the epithelial cells of ovary, 
lung and breast and is also present in ovarian adenomas and carcinomas (Chu et al., 
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2000, Cathro and Stoler, 2002). Wilms tumour gene product (WT-1), originally 
defined as a tumour suppressor, is now thought to have an oncogenic function 
(Sugiyama et al., 2000) and is a specific marker of EOC (Bruening et al., 1993, Shimizu 
et al., 2000, Hwang et al., 2004). The gene TP53 that encodes the tumour suppressor 
protein p53 is amongst the most commonly mutated gene in human cancer (Brosh 
and Rotter, 2009). Genetic analysis of HGS ovarian cancer shows that 96% of all 
tumours carry TP53 mutations (TCGA, 2011) and detection of a this mutation is 
important in clinical practice in terms of clinical outcome and response to 
chemotherapy. It has been generally accepted that wild-type p53 protein is relatively 
unstable and has a short half-life, which makes it undetectable by 
immunohistochemistry (Rogel et al., 1985). In contrast, mutant p53 has a much 
longer half-life, and therefore, accumulates in the nucleus creating a stable target for 
immunohistochemical detection (Finlay et al., 1988, Kraiss et al., 1991), which is why 
immunohistochemical analysis of p53 expression is commonly used (Marks et al., 
1991).   
 
Immunohistochemistry shows all ascites cells are positive for CK-7 and WT-1, 
supporting a human epithelial ovarian carcinoma origin. The CAM tumour derived 
from ascites 1 has lost EMA expression. This may be a reflection of the control of gene 
expression in due to the change of microenvironment.   
Cell cultured from ascites of ovarian cancer patients were grafted onto the CAM on 
ED7. Histological sections show of H&E staining show poorly differentiated 
adenocarcinoma with heterogeneous carcinoma structure with large cell nuclei 
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consistent with HGS ovarian cancer (Figure 7a). Psammona bodies, which were 
present in the ovarian cancer cell line derived CAM tumours were also observed in 
CAM tumour derived from ascites, further supporting an ovarian cancer origin (Figure 
6.6).  
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Table 6.1. Immunohistochemistry of ovarian cancer markers on cells cultured from ascites of ovarian cancer patients 
Antibody 
Ascites samples  
Ascites 1 Ascites 2 Ascites 4 Positive control 
EMA 
x20 mag x20 mag x40 mag 
 
x10 mag 
CK-7 
x20 mag x20 mag x40 mag 
 
x10 mag 
WT-1 
x40 mag x20 mag x40 mag 
 
x20 mag 
P53 
x20 mag x20 mag x40 mag 
 
x10 mag 
Note:  Ascites 1: - EMA, + CK-7, + WT-1 and weakly positive for p53, Ascites 2: + EMA, + CK-7, weakly positive for WT-1, - 
p53, Ascites 4: + EMA, + CK-7, + WT-1 and weakly positive p53. Primary antibody concentrations were as follows: EMA 
1:100, CK-7 1:150, WT-1 1:10 and P53 1:100. Magnification (mag) denoted under image. 
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a) (i) 
 
 
a) (ii) 
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b) 
 
c) 
 
Figure 6.6. Haemolysin and Eosin (H&E) staining of chick chorioallantoic membrane 
(CAM) tumours derived from ascites. a) Ascites 1 showing psmomma bodies (red 
arrowhead) surrounded by malignant stroma at (i) x10 magnification and (ii) x40 
magnification of green boxed area. b) Ascites 2 staining showing a large epithelial-
like cystic structure (black arrowhead) and psammoma bodies (red arrowhead), 
magnification x20. c) Ascites 4 showing a heterogeneous structure with glandular 
areas, magnification x4. 
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6.4 Effects of HXR9 on established human ovarian cancer cells using the CAM model  
To demonstrate the use of the CAM as a model to test drug efficacy, SKOV-3 and COV-
318 cell lines derived CAM tumours were treated with HXR9. CAM tumours were 
grafted on ED7 and were treated on ED17 with either HXR9 or control peptide CXR9. 
Tumour volume was calculated as a measurement of tumour growth to establish 
growth curve data (Figure 6.7a & b). Two perpendicular diameter measurements 
were taken of each tumour and the average was used for further tumour volume 
calculations. Tumour volume was estimated using the formula for calculating the 
volume of a hemisphere = (2/3) π x r 3. This formula was used on the basis that we 
could not assume the tumour was equally distributed above and below the CAM. 
Differences in tumour growth between the control CXR9 and HXR9 treated tumours 
were compared by plotting a tumour growth curve, using tumour volume as a 
determinant of growth. Examples of the physical changes in the tumours before and 
after treatment are shown in Table 6.2. There is an obvious decrease in tumour size 
following HXR9 treatment, with minimal effect to surrounding tissue apart from some 
discolouration. CXR9 treated CAM tumours show no tumour shrinkage compared to 
HXR9 treated tumours, or visual necrosis. There is an increase in tumour volume of 
CXR9 treated tumours compared to untreated tumours which can be explained by 
the volume of drug added intratumourally. 
230 
 
a)  
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b) 
 
 
 
 
 
 
 
 
 
Figure 6.7. Growth curves of ovarian chick chorioallantoic membrane (CAM) tumours with HXR9 treatment. a) SKOV-3 and b) COV-318 
cells were grafted onto the CAM on ED 7. CAM tumours were treated with either HXR9 or control peptide CXR9 on ED17 and excised on 
ED19. Measurements were taken using the Dino-Lite digital microscope AM413MT microscope and DinoCapture software. Tumour volume 
was calculated using the formula = (2/3) π x r 3. Data represents at least 3 independent experiments.
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Table 6.2. Example of SKOV-3 cell line derived chorioallantoic membrane (CAM) 
tumour appearance before and after treatment with HXR9. 
Treatment 
Embryonic day (ED) 
ED16 ED18 
CXR9 
 
 
 
 
 
 
 
 
 
 
 
HXR9 
 
 
 
 
 
 
 
 
 
 
HXR9 
  
 
HXR9 
  
 
 
 
 
 
 
 
 
Note: 4x106 ovarian cancer cells were suspended in 30 µL of matrigel and grafted 
onto the CAM on embryonic day (ED) 7. Table shows four individual SKOV-3 cell 
derived CAM tumours on ED 16 one day before treatment with HXR9/CXR9 and ED 
18 one day after HXR9/CXR9 treatment. Visible reductions in tumour size are 
apparent in HXR9 treated CAM tumours, with only a minimal effect on surrounding 
normal tissue. Magnification x20.  
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As discussed in chapter 3, caspases are key mediators of apoptosis, and caspase -3 in 
particular is necessary for the cleavage of a large number of proteins, apoptosis-
associated chromatin margination, DNA fragmentation and nuclear collapse during 
apoptosis (Slee et al., 2001). Therefore, the detection of activated caspase-3 is 
valuable and specific for identifying apoptosis, even at early stages before 
morphological features of apoptosis occur. As described in chapter 3.3.2.3, HOX 
genes have shown to prevent apoptosis in part through blocking cFos expression. It 
has previously been shown that HXR9 treatment results in an up-regulation of cFos 
leading to apoptosis (Morgan et al., 2007). Therefore to specifically detect if HXR9 
treatment has induced apoptosis through this mechanism, detection of cFos in the 
CAM tumours after HXR9 treatment was also assessed (Table 6.3).  
 
Immunohistochemistry shows a marked increase in caspase-3 activity after HXR9 
treatment, showing similar amounts of caspase-3 positive staining as the CAM 
tumours treated with cisplatin, a chemotherapeutic drug known to induce apoptosis. 
cFos expression also increased after HXR9 treatment, compared to untreated and 
CXR9 treated controls. The CXR9 treated PEO1 derived CAM tumour however, shows 
a moderate amount of cFos expression. 
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Table 6.3 Immunohistochemistry of ovarian cancer  chorioallantoic membrane (CAM) tumours for the detection of 
apoptosis after HXR9 treatment 
 Caspase-3 
Cell line Untreated CXR9 HXR9 Cisplatin 
SKOV-3 
x10 mag 
 
x10 mag 
 
x10 mag 
 
x10 mag 
COV-318 
x10 mag 
 
x10 mag 
 
x10 mag 
 
x20 mag 
PEO1 
 
x10 mag 
 
x10 mag 
 
X4 mag 
 
x4 mag 
    Table 6.3 continued. 
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Table 6.3. (Continued).  
 Caspase-3 
Cell line Untreated CXR9 HXR9 Cisplatin 
PEO4 
x10 mag x10 mag 
 
x10 mag x10 mag 
 cFos 
SKOV-3 
x10 mag x10 mag x10 mag 
x 
COV-318 
x10 mag x10 mag x10 mag 
x 
Table 6.3 continued.  
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Table 6.3. (Continued).  
 cFos 
Cell line Untreated CXR9 HXR9 Cisplatin 
PEO1 
x10 mag x10 mag x4 mag 
x 
PEO4 
x10 mag x10 mag x10 mag 
x 
Note:  SKOV-3, COV-318, PEO1 and PEO4 ovarian cancer cells were grafted onto the chick chorioallantoic membrane 
(CAM) on embryonic day (ED) 7. Tumours were treated with either HXR9 at a dose of 2x the IC50 for that cell line or 
equivalent CXR9 concentration on ED17. Tumours were excised on ED20 and paraffin embedded. CAM paraffin 
sections (4μm) were immunostained for markers of apoptosis: cleaved capsase-3 and cFos. Caspase-3 antibody was 
used at a 1:100 dilution and tonsil was used as a positive control tissue. cFos antibody was used at a 1:40 dilution, 
and skin was used as a positive control. Cisplatin treatment was used as a positive control for apoptosis by caspase-
3 activation. Magnification ×10.  
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6.4.1 Effects of HXR9 on human ovarian cancer patient’s ascites derived 
chorioallantoic membrane (CAM) tumours  
 
Firstly, the MTS assay was used to determine whether HXR9 is effective at killing 
ovarian cancer cells of primary origin (Figure 6.8). The cells most sensitive to HXR9 
treatment were those cultured from a primary ovarian tumour sample, Ov-Tu-8, with 
an IC50 of 19 µM. The ascites cells show varying degrees of sensitivity to HXR9 ranging 
from 35 to 58 µM, and one sample, Ascites 4, appears to be HXR9 resistant with and 
IC50 of 110 µM (Table 6.4). CXR9 was used as a control and none of the cells were 
sensitive (IC50 > 120 µM).  
Likewise to the established cell lines, cells cultured from patients ascites samples 
were grafted onto the CAM. This was to explore whether these cells would proliferate 
in the CAM environment, creating a novel model to test drug efficacy on patient 
derived tumours. 
Although not as successful as grafting to the CAM as established cell lines, three of 
the four ascites samples did grow to form micro-tumours. Two of these were treated 
with either HXR9 or the control CXR9 on ED17, and excised on ED19. These tumours 
were paraffin embedded and stained for caspase-3 and cFos to determine apoptosis 
induction by HXR9 treatment (Table 6.5). 
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Figure 6.8. Cytotoxic effect of HXR9 on cells cultured from ascites of ovarian cancer patients and an ovarian tumour. The MTS assay was 
carried out on cells cultured from ascites of ovarian cancer patients (Ascites 1-4) and cells cultured from an ovarian tumour, using HXR9 or 
CXR9.  
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Table 6.4. IC50 of HXR9 treatment on cells cultured from ascites of ovarian cancer 
patients and from a primary ovarian tumour 
Ascites/ tumour sample Histology IC50 (µM) 
Ascites 1 High grade serous 58 
Ascites 2 High grade serous 35 
Ascites 3 High grade serous 35 
Ascites 4 High grade serous 110 
Ov-Tu -8 High grade serous 19 
Note:  The MTS assay was used to determine an IC50 for HXR9. Cells were treated 
with varying concentration of HXR9 or control peptide CXR9 for 2 hours. A sample 
of the same cell suspension was used as a ‘cell only’ control. Results presented are 
an average from at least 2 independent experiments. 
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Table 6.5. Immunological staining for apoptotic markers in ascites derived 
chorioallantoic membrane (CAM) tumours treated with HXR9. 
Original 
cells 
Caspase-3 
Untreated CXR9 HXR9 
Ascites 1 
   
Ascites 2 
 
 
 
Original 
cells 
cFos 
Untreated CXR9 HXR9 
Ascites 1 
  
 
 
Ascites 2 
 
 
 
Note: Ascites derived cells were grafted onto the CAM on embryonic day (ED) 7. 
Tumours were left untreated or treated with either HXR9 or control peptide CXR9 on 
ED17. On ED20 CAM tumours were excised and paraffin embedded. CAM paraffin 
sections (4μm) were immunostained with cleaved caspase-3 and cFos antibody to 
show apoptosis induction at dilutions of 1:100 and 1:40, respectively. Magnification 
x10. 
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Immunohistochemistry of ascites derived CAM tumours treated with HXR9 both 
show caspase-3 activity which is not seen in the CXR9 treated tumours. However, 
ascites one does show some positive staining in the untreated tumour. Ascites 2 
shows a large amount of cFos expression after HXR9 treatment however, although 
this is not seen to this extent in the CXR9 treated tumour, the untreated tumour is 
showing background staining. Very little cFos expression is shown in the ascites 1 
derived CAM tumour. Due to the limited number of CAM tumours grown form this 
ascites sample, repeats could not be performed.  
 
6.5 Discussion 
The CAM model shows successful tumour grafting due to the immature immune 
system of the chick embryo, with a typical successful grafting rate of 100% and short 
tumour development time. A xenograft model was used in chapter 4 as it is a widely 
accepted in vivo model, however a number of problems were encountered using this 
method. The PEO4 and PEA2 cell line failed to grow in the xenograft model. The 
SKOV-3 xenograft model is commonly used to study ovarian tumours in vivo, and this 
cell line grafted but tumour growth was very slow with tumours visible only after 22 
days. However, in the recent publication by (Domcke et al., 2013), based on genetic 
similarity to HGS ovarian tumours the SKOV-3 cell line is not a good representation 
of HGS ovarian cancer, and therefore using this cell line was not ideal. The CAM model 
avoids these problems and in addition is simple, cheap and efficient, producing rapid 
results. It is therefore an attractive alternative over the commonly used xenograft 
models.  
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It has been argued that the standard xenograft approach using commercial tumour 
cell lines does not fully recapitulate the true biology of human cancers. The use of an 
animal model which spontaneously develops tumours naturally is the preferred 
option. However, for the study of ovarian cancer there are few animal models which 
spontaneously develop ovarian cancer. Hens which are maintained under intensive 
egg-laying conditions develop ovarian adenocarcinomas however, this is 
uncommonly seen in hens less than 2 years old (Fredrickson, 1987). In some strains 
of mice 2 and Wistar and Sprague-Dawley rats, ovarian tumours of various histologic 
subtypes have spontaneously arisen with age (Walsh and Poteracki, 1994, Gregson 
et al., 1984), though the low incidence and length of time until tumours appear makes 
these models impractical for experimental studies of ovarian cancer. The work 
described in this chapter has shown the promising potential of the CAM model to 
overcome this problem, with the rapid growth of tumours derived from cells cultured 
from ovarian cancer patients, and the recapitulation of the true tumour biology. The 
study demonstrates the application of the model for the use in drug screening with 
the successful treatment of the CAM tumours with the novel drug HXR9. CAM 
tumours treated with HXR9 induced a visible and measureable decrease in tumour 
size compared to untreated and the control CXR9 treated tumours (Figure 6.7). The 
CXR9 treated tumours show an increase in tumour size compared to untreated 
tumours due to the intratumoural injection of a solution. This shows that the injection 
of fluid intratumourally is not detrimental to the tumour. Immunohistochemistry 
performed confirmed in vitro data (Chapter 3) showing the induction of apoptosis in 
both cell line and ascites derived tumours. Further work to include larger samples 
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numbers needs to be performed using ascites or patient derived cells to grow CAM 
tumours to advance this model for potential use for personalised drug screening, as 
only a small number of ascites samples were obtained for this use in this study. 
However, the study does demonstrate this potential application. The ability to culture 
ovarian cancer cells from ascites offers an important experimental system that 
resembles the patient situation more closely, providing a better tool to develop 
potential interventions with higher therapeutic applicability. In vitro these cells are 
short lived, limiting the amount of in vitro investigations which can be performed. Yet 
due to the microenvironment of the CAM, these ascites cells are able to proliferate 
into structured micro-tumours. This therefore presents a novel use for the CAM 
model to grow human tumours for personalised drug testing, and for the evaluation 
of novel chemotherapeutic drugs.  
 
In conclusion, this chapter shows that the CAM model is a promising alternative 
model to use for the in vivo study of ovarian cancer. This model is advantageous over 
existing mouse models as it is a reliable and robust model as well as being cost 
effective and less labour intensive.  It is an especially beneficial model for the testing 
of novel drugs. The development of new anticancer therapies requires the in vivo 
study of novel targets and molecules. However, commonly used murine models are 
costly and require a large number of animals as well as a long experimental time 
frame. The low cost and the rapid development of tumours makes the CAM assay an 
attractive alternative. In addition, the CAM model can be used to grow ovarian 
tumours derived from ascites samples of ovarian cancer patient’s for the screening 
of potential drugs, enabling a personalized therapeutic approach.  
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Discussion 
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7.1 Discussion 
The work presented confirms that HOX genes are highly dysregulated in ovarian 
cancer, with little or no expression in normal ovarian and fallopian tube tissue. This 
is true for both established ovarian cancer cell lines and primary ovarian tumours. 
The HGS carcinoma subtype shows the highest degree of heterogeneity of HOX 
expression for both cell lines and primary tumours, whereas endometrioid subtypes 
show a very distinct HOX expression profile. HGS tumours are known to be genetically 
heterogeneous and this is likely to explain this variation, however the functional 
redundancy between HOX genes may mean the net effect of HOX overexpression is 
similar even in cells expressing different HOX gene paralogues (Lappin et al., 2006). 
The majority of significant upregulation among ovarian cancer cell lines and primary 
tumours was seen within the HOXA and HOXB cluster. Of particular interest is the 
highly significant overexpression of HOXA1 which has not been reported before in 
ovarian cancer but a role in breast cancer has been investigated. It may therefore 
have a similar role in ovarian oncogenesis. Seven out of the ten HOXB genes were 
upregulated in primary ovarian tumours: HOXB1, B2, B4, B5, B6, B7 and B13. Only 
HOXB7 and B13 have previously been shown to have an oncogenic role in ovarian 
cancer (Yamashita et al., 2006, Naora et al., 2001b, Rubin et al., 2007, Miao et al., 
2007a). HOXB4 has been implicated as a cancer associated gene in other malignancies 
(Bodey et al., 2000b, Zhang et al., 2008, Bodey et al., 2000c, Bodey et al., 2000a). 
However, the roles of the HOXB1, B2, B4, B5 and B6 in ovarian cancer have not been 
investigated and the data presented in chapter 3 and 5 strongly warrants further 
investigation.  
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This dysregulated HOX gene expression in cancerous cells compared to normal tissue 
therefore comprises a set of possible targets for therapeutic intervention. The novel 
peptide HXR9 has been designed to target the products of these genes. Work 
presented in chapter 2 has shown that HXR9 causes cell death by inducing apoptosis 
in ovarian cancer cell lines. This has been shown by an increase in the number of 
apoptotic cells after 2 hours of HXR9 treatment using FACs analysis, along with 
increased caspse-3 activity and cFos expression. HXR9 was also shown to be effective 
at killing cells derived from primary ovarian tumours.  
As platinum resistance is a major obstacle in the treatment of ovarian cancer, 
understanding the molecular mechanisms behind its development is important in the 
search of novel drugs to manage recurrent disease. Work presented in chapter 4 
shows that overall there is higher HOX gene expression in platinum resistant cell lines 
compared to sensitive cell lines and normal tissue. The main difference is observed 
in a cluster of genes which are expressed at a lower level in both platinum sensitive 
cell lines and normal tissue compared to platinum resistance cells. These were 
HOXA2, A3, A4, A5, A6, A10, B4, B7, B9, C4 and C13. When comparing specific changes 
in HOX gene expression between the cell lines derived from the same patients who 
were initially sensitive to platinum treatment and subsequently developed 
resistance, the common finding is the upregulation of HOX genes from the HOXB 
cluster. This is particularly interesting when put together with data from chapter 3 
showing that the majority of significant HOX gene dysregulation is due to upregulated 
expression of genes from the HOXA and HOXB clusters. When considered together 
with data from previous reports showing an oncogenic role for HOXB7 and HOXB13 
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in ovarian cancer (Yamashita et al., 2006, Naora et al., 2001b, Rubin et al., 2007, Miao 
et al., 2007a), and the recent publication by TCGA showing a distinct subset of HGS 
ovarian cancer being characterised by  overexpression of members of the HOXB 
family (TCGA, 2011), the role of the HOXB genes in promoting ovarian oncogenesis in 
particular is evident and more importantly suggests their possible role in promoting 
recurrent disease and platinum resistance. TCGA described the subtype of HGS 
ovarian cancer as the ‘mesenchymal’ subtype due to the increased markers for 
stromal components. An association between chemo-resistance and the acquisition 
of EMT and CSC-like phenotypes in cancer has been demonstrated previously (Hollier 
et al., 2009, Latifi et al., 2011, Ahmed et al., 2010). Chemo-resistant recurrent ovarian 
tumours are found to be enriched in CSCs and stem cell pathway mediators, 
suggesting that CSCs may contribute to recurrent disease (Latifi et al., 2012, Steg et 
al., 2012). With the finding of increased HOX gene expression in the platinum 
resistant cell lines, it can be suggested these are playing a role in supporting a 
mesenchymal stem-like cell phenotype which is driving the development of platinum 
resistance. However, further work is needed to determine the role of these HOX 
genes, but from the findings presented in chapter 4, targeting the HOX genes with 
the HXR9 peptide increased the sensitivity of platinum resistant cells to cisplatin. 
Treatment of HXR9 in combination with cisplatin was synergistic for the killing of 
platinum resistant cells. Therefore, HXR9 could potentially be a drug that can be used 
in combination with existing chemotherapy regimens to treat platinum resistant 
disease. 
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From the analysis of HOX gene expression in primary ovarian tumours with clinico-
pathological data, it was revealed that a number of HOX genes were expressed at a 
lower level in the later stage cancers compared to early stage disease. It is known 
that HOX genes play a role in determining tissue identity during embryogenesis and 
a unique characteristic of EOC is the ability of the OSE to differentiate into more 
specialised epithelia resembling that of the reproductive tract (Auersperg et al., 
2001). Therefore, the findings suggest that these particular HOX genes are needed to 
induce epithelial differentiation in the early stages of ovarian oncogenesis. As the 
tumour becomes more advanced, the epithelium loses this differentiation which may 
in turn account for the loss of HOX gene expression. However, there is difficulty in 
interpreting this data as the FIGO staging system was used to stage these tumours, 
which is based on the anatomical extent of disease spread, rather than the TNM 
classification of malignant tumours – which is commonly used for other cancers. 
Using the FIGO staging system, early stage cancer can actually be a locally  advanced 
and large but has yet to spread beyond the ovary and therefore is classified as stage 
I cancer.  
 
We found that a specific HOX gene signature was strongly associated with poor 
overall survival in HGS patients. This signature consisted of five HOX genes, HOXA13, 
B6, C13, D1 and D13. High HOXA13 expression has been linked to poor OS in 
oesophageal squamous cell carcinoma, hepatocellular carcinoma and gastric cancer 
patients (Gu et al., 2009, Cillo et al., 2011, Han et al., 2013). HOXD13 was the only 
HOX gene to correlate with TTP with high expression found in patients who had 
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suffered disease progression after chemotherapy. Therefore, HOXD13 may be an 
excellent prognostic marker candidate in ovarian cancer.  
The final results chapter shows an alternative model for the in vivo study of ovarian 
cancer, demonstrating the CAM model is a reliable, robust, cost effective method to 
grow ovarian tumours and to evaluate the in vivo response to the novel peptide, 
HXR9. Subsequently, immunohistochemistry was used to identify cellular changes 
from drug action. Therefore, this model is a simple and cost effective method for 
testing drug toxicities of new anti-cancer therapies. A novel aspect for the use of this 
model is the ability to grow tumours directly from ovarian cancer ascites samples. 
This shows the potential of using this model for future personalised screening of 
potential novel drugs.  
 
7.2 Conclusion 
This comprehensive analysis of HOX gene expression in ovarian cancer cell lines and 
primary ovarian tumours demonstrates that these genes are profoundly 
dysregulated compared to normal ovary and fallopian tube tissue. A high level of 
heterogeneity was found within HGS tumours, whereas endometrioid tumours show 
a distinct HOX profile, expressing genes at a much higher level than other histotypes. 
The results show that HOXB genes play an important role in ovarian tumourgenesis 
and in the development of platinum resistance. The clinical relevance of this 
dysregulated HOX expression was further supported by a five HOX gene signature 
that predicts poor outcome in EOC patients: HOXA13, B6, C13, D1 and D13. Nine HOX 
genes: HOXA9, B5, B13, C8, C9, C13, D9, D10 and D13, were expressed at a lower level 
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in late disease stage, suggesting a possible role in cellular differentiation during the 
early events of ovarian tumourgenesis. The CAM model was shown to be a simple 
and cheap method for the study of ovarian cancer in vivo and has the potential to be 
used as a model for screening novel anticancer drugs for personalised treatment.  
 
7.3 Outlook and future directions 
To follow on from the work presented, investigation into fully understanding the 
mechanism of cell death elicited by HXR9 would be beneficial to establish a patient 
group who would clinically benefit from HXR9 treatment. One way this could be 
explored is by performing a reverse phase protein assay (RPPA) on ovarian cancer cell 
lines treated with HXR9. This assay provides a quantitative analysis of the differential 
expression of active (usually phosphorylated or cleaved) and parental proteins. The 
activation state/functionality of a given protein or of an entire pathway (e.g. a signal 
transduction pathway) can be assessed through the configuration of total proteins 
and their corresponding phosphoprotein. By comparing results to untreated/CXR9 
treated cells, this assay will determine which downstream pathway are being 
effected by HXR9. In addition to identifying a subgroup of patients who are likely to 
benefit from HXR9 treatment, understanding the pathways which 
activated/deactivated after HXR9 treatments allows the exploration of combinational 
studies with drugs to either target the same pathways or survival pathways which are 
not effected in order to maximise treatment efficiency. The findings can also be 
extended to compare platinum sensitive to resistant cell lines in terms of the changes 
in the signalling pathways elicited by HXR9. Following from these finding, 
 251 
 
combinational study work with other pathway inhibitors could be explored to 
increase cell death potential in platinum resistant cells. The synergistic effect of HXR9 
and cisplatin should also be explored further and this could also continue from the 
RPPA results. By determining the pathways by which HXR9 effects could explain the 
synergy seen. In addition, taking the combination treatment further through 
repeated in vivo work, testing on cells derived from human ovarian tumours, and 
using these in the CAM model for testing drug efficacy, is needed to potentially 
develop this combinational treatment for clinical trials.  
Chapter 4 demonstrates the upregulation of a subset of HOX genes in resistant cell 
lines, with HOXB4, B7 and B9 being the most common between platinum resistant 
cell lines. To further validate a role for these genes in platinum resistance, knockdown 
studies of these genes should be performed, starting with the commonly expressed 
genes in these. After individual knock down of HOXB4, B7 and B9 in the platinum 
resistance cell lines PEO4, PEO23 and PEA2 using siRNA or shRNA, cells would be 
treated with cisplatin and a proliferation assay performed to determine whether re-
sensitisation to cisplatin has occurred.  
To further fine tune of use the CAM model to grow human ovarian cancer samples 
direct from patients would be extremely beneficial in expanding the use of the model 
for translation and clinical investigative research. The successful application of this 
would provide a platform for a variety of analyses, importantly drug screening, to 
quickly determine an optimum treatment strategy for patients. Changes such as the 
addition of antibiotics to samples upon grafting, or the addition of hormones for 
tumour growth in ovo could be explored.  
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In addition to the immunochemistry performed on excised CAM tumour, imaging in 
ovo could be used to monitor the drug effects and tumour responses in real-time. For 
example, by fluorescently labelling cancer cells prior to grafting onto the CAM the 
tumour growth or cell death from drug application could be monitored through a 
series of fluorescence microscopy images.  
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